IntechOpen Book Series will also publish a program of research-driven Thematic Edited Volumes that focus on specific areas and allow for a more in-depth overview of a particular subject.
\\n\\n
IntechOpen Book Series will be launching regularly to offer our authors and editors exciting opportunities to publish their research Open Access. We will begin by relaunching some of our existing Book Series in this innovative book format, and will expand in 2022 into rapidly growing research fields that are driving and advancing society.
With the desire to make book publishing more relevant for the digital age and offer innovative Open Access publishing options, we are thrilled to announce the launch of our new publishing format: IntechOpen Book Series.
\n\n
Designed to cover fast-moving research fields in rapidly expanding areas, our Book Series feature a Topic structure allowing us to present the most relevant sub-disciplines. Book Series are headed by Series Editors, and a team of Topic Editors supported by international Editorial Board members. Topics are always open for submissions, with an Annual Volume published each calendar year.
\n\n
After a robust peer-review process, accepted works are published quickly, thanks to Online First, ensuring research is made available to the scientific community without delay.
\n\n
Our innovative Book Series format brings you:
\n\n
\n\t
Topic Focused Publications - Each topic showcases high impact subject areas
\n\t
Renowned Editorial Expertise - Series Editors, Topic Editors, and a team of international Board Members that permanently support each Book Series
\n\t
Fast Publishing - quick turnaround which is unique for book publishing
\n\t
The benefit of ISSN and ISBN for increased citation and indexing possibilities
\n
\n\n\n\n
IntechOpen Book Series will also publish a program of research-driven Thematic Edited Volumes that focus on specific areas and allow for a more in-depth overview of a particular subject.
\n\n
IntechOpen Book Series will be launching regularly to offer our authors and editors exciting opportunities to publish their research Open Access. We will begin by relaunching some of our existing Book Series in this innovative book format, and will expand in 2022 into rapidly growing research fields that are driving and advancing society.
We invite you to explore our IntechOpen Book Series, find the right publishing program for you and reach your desired audience in record time.
\n\n
Note: Edited in October 2021
\n'}],latestNews:[{slug:"step-in-the-right-direction-intechopen-launches-a-portfolio-of-open-science-journals-20220414",title:"Step in the Right Direction: IntechOpen Launches a Portfolio of Open Science Journals"},{slug:"let-s-meet-at-london-book-fair-5-7-april-2022-olympia-london-20220321",title:"Let’s meet at London Book Fair, 5-7 April 2022, Olympia London"},{slug:"50-books-published-as-part-of-intechopen-and-knowledge-unlatched-ku-collaboration-20220316",title:"50 Books published as part of IntechOpen and Knowledge Unlatched (KU) Collaboration"},{slug:"intechopen-joins-the-united-nations-sustainable-development-goals-publishers-compact-20221702",title:"IntechOpen joins the United Nations Sustainable Development Goals Publishers Compact"},{slug:"intechopen-signs-exclusive-representation-agreement-with-lsr-libros-servicios-y-representaciones-s-a-de-c-v-20211123",title:"IntechOpen Signs Exclusive Representation Agreement with LSR Libros Servicios y Representaciones S.A. de C.V"},{slug:"intechopen-expands-partnership-with-research4life-20211110",title:"IntechOpen Expands Partnership with Research4Life"},{slug:"introducing-intechopen-book-series-a-new-publishing-format-for-oa-books-20210915",title:"Introducing IntechOpen Book Series - A New Publishing Format for OA Books"},{slug:"intechopen-identified-as-one-of-the-most-significant-contributor-to-oa-book-growth-in-doab-20210809",title:"IntechOpen Identified as One of the Most Significant Contributors to OA Book Growth in DOAB"}]},book:{item:{type:"book",id:"3600",leadTitle:null,fullTitle:"Frontiers in Evolutionary Robotics",title:"Frontiers in Evolutionary Robotics",subtitle:null,reviewType:"peer-reviewed",abstract:"This book presented techniques and experimental results which have been pursued for the purpose of evolutionary robotics. Evolutionary robotics is a new method for the automatic creation of autonomous robots. When executing tasks by autonomous robots, we can make the robot learn what to do so as to complete the task from interactions with its environment, but not manually pre-program for all situations. Many researchers have been studying the techniques for evolutionary robotics by using Evolutionary Computation (EC), such as Genetic Algorithms (GA) or Genetic Programming (GP). Their goal is to clarify the applicability of the evolutionary approach to the real-robot learning, especially, in view of the adaptive robot behavior as well as the robustness to noisy and dynamic environments. For this purpose, authors in this book explain a variety of real robots in different fields.\r\nFor instance, in a multi-robot system, several robots simultaneously work to achieve a common goal via interaction; their behaviors can only emerge as a result of evolution and interaction. How to learn such behaviors is a central issue of Distributed Artificial Intelligence (DAI), which has recently attracted much attention. This book addresses the issue in the context of a multi-robot system, in which multiple robots are evolved using EC to solve a cooperative task. Since directly using EC to generate a program of complex behaviors is often very difficult, a number of extensions to basic EC are proposed in this book so as to solve these control problems of the robot.",isbn:null,printIsbn:"978-3-902613-19-6",pdfIsbn:"978-953-51-5829-5",doi:"10.5772/62",price:159,priceEur:175,priceUsd:205,slug:"frontiers_in_evolutionary_robotics",numberOfPages:598,isOpenForSubmission:!1,isInWos:1,isInBkci:!1,hash:null,bookSignature:"Hitoshi Iba",publishedDate:"April 1st 2008",coverURL:"https://cdn.intechopen.com/books/images_new/3600.jpg",numberOfDownloads:74138,numberOfWosCitations:54,numberOfCrossrefCitations:19,numberOfCrossrefCitationsByBook:4,numberOfDimensionsCitations:76,numberOfDimensionsCitationsByBook:4,hasAltmetrics:0,numberOfTotalCitations:149,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:null,dateEndSecondStepPublish:null,dateEndThirdStepPublish:null,dateEndFourthStepPublish:null,dateEndFifthStepPublish:null,currentStepOfPublishingProcess:1,indexedIn:"1,2,3,4,5,6,7",editedByType:"Edited by",kuFlag:!1,featuredMarkup:null,editors:[{id:"123552",title:"Prof.",name:"Hitoshi",middleName:null,surname:"Iba",slug:"hitoshi-iba",fullName:"Hitoshi Iba",profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"0",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"University of Tokyo",institutionURL:null,country:{name:"Japan"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"1283",title:"Autonomous Robot",slug:"evolutionary-robotics-autonomous-robot"}],chapters:[{id:"843",title:"A Comparative Evaluation of Methods for Evolving a Cooperative Team",doi:"10.5772/5445",slug:"a_comparative_evaluation_of_methods_for_evolving_a_cooperative_team",totalDownloads:2066,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Takaya Arita and Yasuyuki Suzuki",downloadPdfUrl:"/chapter/pdf-download/843",previewPdfUrl:"/chapter/pdf-preview/843",authors:[null],corrections:null},{id:"844",title:"An Adaptive Penalty Method for Genetic Algorithms in Constrained Optimization Problems",doi:"10.5772/5446",slug:"an_adaptive_penalty_method_for_genetic_algorithms_in_constrained_optimization_problems",totalDownloads:4056,totalCrossrefCites:6,totalDimensionsCites:41,hasAltmetrics:0,abstract:null,signatures:"Helio J. C. Barbosa and Afonso C. C. Lemonge",downloadPdfUrl:"/chapter/pdf-download/844",previewPdfUrl:"/chapter/pdf-preview/844",authors:[null],corrections:null},{id:"845",title:"Evolutionary-Based Control Approaches for Multirobot Systems",doi:"10.5772/5447",slug:"evolutionary-based_control_approaches_for_multirobot_systems",totalDownloads:2140,totalCrossrefCites:1,totalDimensionsCites:1,hasAltmetrics:0,abstract:null,signatures:"Jekanthan Thangavelautham, Timothy D. Barfoot and Gabriele M.T. D'Eleuterio",downloadPdfUrl:"/chapter/pdf-download/845",previewPdfUrl:"/chapter/pdf-preview/845",authors:[null],corrections:null},{id:"846",title:"Learning by Experience and by Imitation in Multi-Robot Systems",doi:"10.5772/5448",slug:"learning_by_experience_and_by_imitation_in_multi-robot_systems",totalDownloads:2149,totalCrossrefCites:2,totalDimensionsCites:2,hasAltmetrics:0,abstract:null,signatures:"Dennis Barrios-Aranibar, Luiz M. G. Goncalves and Pablo Javier Alsina",downloadPdfUrl:"/chapter/pdf-download/846",previewPdfUrl:"/chapter/pdf-preview/846",authors:[null],corrections:null},{id:"847",title:"Cellular Non-Linear Networks as a New Paradigm for Evolutionary Robotics",doi:"10.5772/5449",slug:"cellular_non-linear_networks_as_a_new_paradigm_for_evolutionary_robotics",totalDownloads:2493,totalCrossrefCites:2,totalDimensionsCites:5,hasAltmetrics:0,abstract:null,signatures:"Eleonora Bilotta and Pietro Pantano",downloadPdfUrl:"/chapter/pdf-download/847",previewPdfUrl:"/chapter/pdf-preview/847",authors:[null],corrections:null},{id:"848",title:"Optimal Design of Mechanisms for Robot Hands",doi:"10.5772/5450",slug:"optimal_design_of_mechanisms_for_robot_hands",totalDownloads:4206,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"J.A. Cabrera, F. Nadal and A. Simon",downloadPdfUrl:"/chapter/pdf-download/848",previewPdfUrl:"/chapter/pdf-preview/848",authors:[null],corrections:null},{id:"849",title:"Evolving Humanoids: Using Artificial Evolution as an Aid in the Design of Humanoid Robots",doi:"10.5772/5451",slug:"evolving_humanoids__using_artificial_evolution_as_an_aid_in_the_design_of_humanoid_robots",totalDownloads:3237,totalCrossrefCites:3,totalDimensionsCites:3,hasAltmetrics:0,abstract:null,signatures:"Malachy Eaton",downloadPdfUrl:"/chapter/pdf-download/849",previewPdfUrl:"/chapter/pdf-preview/849",authors:[null],corrections:null},{id:"850",title:"Real-Time Evolutionary Algorithms for Constrained Predictive Control",doi:"10.5772/5452",slug:"real-time_evolutionary_algorithms_for_constrained_predictive_control",totalDownloads:2324,totalCrossrefCites:0,totalDimensionsCites:5,hasAltmetrics:0,abstract:null,signatures:"Mario Luca Fravolini, Antonio Ficola and Michele La Cava",downloadPdfUrl:"/chapter/pdf-download/850",previewPdfUrl:"/chapter/pdf-preview/850",authors:[null],corrections:null},{id:"851",title:"Applying Real-Time Survivability Considerations in Evolutionary Behavior Learning by a Mobile Robot",doi:"10.5772/5453",slug:"applying_real-time_survivability_considerations_in_evolutionary_behavior_learning_by_a_mobile_robot",totalDownloads:2245,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Wolfgang Freund, Tomas Arredondo V. and Cesar Munoz",downloadPdfUrl:"/chapter/pdf-download/851",previewPdfUrl:"/chapter/pdf-preview/851",authors:[null],corrections:null},{id:"852",title:"An Evolutionary MAP Filter for Mobile Robot Global Localization",doi:"10.5772/5454",slug:"an_evolutionary_map_filter_for_mobile_robot_global_localization",totalDownloads:2e3,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"L. Moreno, S. Garrido, M. L. Munoz and D. Blanco",downloadPdfUrl:"/chapter/pdf-download/852",previewPdfUrl:"/chapter/pdf-preview/852",authors:[null],corrections:null},{id:"853",title:"Learning to Walk with Model Assisted Evolution Strategies",doi:"10.5772/5455",slug:"learning_to_walk_with_model_assisted_evolution_strategies",totalDownloads:1897,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Matthias Hebbel and Walter Nistico",downloadPdfUrl:"/chapter/pdf-download/853",previewPdfUrl:"/chapter/pdf-preview/853",authors:[null],corrections:null},{id:"854",title:"Evolutionary Morphology for Polycube Robots",doi:"10.5772/5456",slug:"evolutionary_morphology_for_polycube_robots",totalDownloads:2099,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Takahiro Tohge and Hitoshi Iba",downloadPdfUrl:"/chapter/pdf-download/854",previewPdfUrl:"/chapter/pdf-preview/854",authors:[null],corrections:null},{id:"855",title:"Mechanism of Emergent Symmetry Properties on Evolutionary Robotic System",doi:"10.5772/5457",slug:"mechanism_of_emergent_symmetry_properties_on_evolutionary_robotic_system",totalDownloads:2181,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Naohide Yasuda, Takuma Kawakami, Hiroaki Iwano, Katsuya Kanai, Koki Kikuchi and Xueshan Gao",downloadPdfUrl:"/chapter/pdf-download/855",previewPdfUrl:"/chapter/pdf-preview/855",authors:[null],corrections:null},{id:"856",title:"A Quantitative Analysis of Memory Usage for Agent Tasks",doi:"10.5772/5458",slug:"a_quantitative_analysis_of_memory_usage_for_agent_tasks",totalDownloads:1912,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"DaeEun Kim",downloadPdfUrl:"/chapter/pdf-download/856",previewPdfUrl:"/chapter/pdf-preview/856",authors:[null],corrections:null},{id:"857",title:"Evolutionary Parametric Identification of Dynamic Systems",doi:"10.5772/5459",slug:"evolutionary_parametric_identification_of_dynamic_systems",totalDownloads:2969,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Dimitris Koulocheris and Vasilis Dertimanis",downloadPdfUrl:"/chapter/pdf-download/857",previewPdfUrl:"/chapter/pdf-preview/857",authors:[null],corrections:null},{id:"858",title:"Evolutionary Computation of Multi-Robot/Agent Systems",doi:"10.5772/5460",slug:"evolutionary_computation_of_multi-robot_agent_systems",totalDownloads:2047,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Philippe Lucidarme",downloadPdfUrl:"/chapter/pdf-download/858",previewPdfUrl:"/chapter/pdf-preview/858",authors:[null],corrections:null},{id:"859",title:"Embodiment of Legged Robots Emerged in Evolutionary Design: Pseudo Passive Dynamic Walkers",doi:"10.5772/5461",slug:"embodiment_of_legged_robots_emerged_in_evolutionary_design__pseudo_passive_dynamic_walkers",totalDownloads:2822,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Kojiro Matsushita and Hiroshi Yokoi",downloadPdfUrl:"/chapter/pdf-download/859",previewPdfUrl:"/chapter/pdf-preview/859",authors:[null],corrections:null},{id:"860",title:"Action Selection and Obstacle Avoidance Using Ultrasonic and Infrared Sensors",doi:"10.5772/5462",slug:"action_selection_and_obstacle_avoidance_using_ultrasonic_and_infrared_sensors",totalDownloads:5769,totalCrossrefCites:0,totalDimensionsCites:1,hasAltmetrics:0,abstract:null,signatures:"Fernando Montes-Gonzalez, Daniel Flandes-Eusebio and Luis Pellegrin- Zazueta",downloadPdfUrl:"/chapter/pdf-download/860",previewPdfUrl:"/chapter/pdf-preview/860",authors:[null],corrections:null},{id:"861",title:"Multi-Legged Robot Control Using GA-Based Q-Learning Method With Neighboring Crossover",doi:"10.5772/5463",slug:"multi-legged_robot_control_using_ga-based_q-learning_method_with_neighboring_crossover",totalDownloads:1956,totalCrossrefCites:1,totalDimensionsCites:3,hasAltmetrics:0,abstract:null,signatures:"Tadahiko Murata and Masatoshi Yamaguchi",downloadPdfUrl:"/chapter/pdf-download/861",previewPdfUrl:"/chapter/pdf-preview/861",authors:[null],corrections:null},{id:"862",title:"Evolved Navigation Control for Unmanned Aerial Vehicles",doi:"10.5772/5464",slug:"evolved_navigation_control_for_unmanned_aerial_vehicles",totalDownloads:2056,totalCrossrefCites:0,totalDimensionsCites:4,hasAltmetrics:0,abstract:null,signatures:"Gregory J. Barlow and Choong K. Oh",downloadPdfUrl:"/chapter/pdf-download/862",previewPdfUrl:"/chapter/pdf-preview/862",authors:[null],corrections:null},{id:"863",title:"Application of Artificial Evolution to Obstacle Detection and Mobile Robot Control",doi:"10.5772/5465",slug:"application_of_artificial_evolution_to_obstacle_detection_and_mobile_robot_control",totalDownloads:2222,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Olivier Pauplin and Arnaud de La Fortelle",downloadPdfUrl:"/chapter/pdf-download/863",previewPdfUrl:"/chapter/pdf-preview/863",authors:[null],corrections:null},{id:"864",title:"Hunting in an Environment Containing Obstacles: A Combinatory Study of Incremental Evolution and Co-Evolutionary Approaches",doi:"10.5772/5466",slug:"hunting_in_an_environment_containing_obstacles__a_combinatory_study_of_incremental_evolution_and_co-",totalDownloads:1788,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Ioannis Mermigkis and Loukas Petrou",downloadPdfUrl:"/chapter/pdf-download/864",previewPdfUrl:"/chapter/pdf-preview/864",authors:[null],corrections:null},{id:"865",title:"Evolving Behavior Coordination for Mobile Robots Using Distributed Finite-State Automata",doi:"10.5772/5467",slug:"evolving_behavior_coordination_for_mobile_robots_using_distributed_finite-state_automata",totalDownloads:2561,totalCrossrefCites:1,totalDimensionsCites:2,hasAltmetrics:0,abstract:null,signatures:"Pavel Petrovic",downloadPdfUrl:"/chapter/pdf-download/865",previewPdfUrl:"/chapter/pdf-preview/865",authors:[null],corrections:null},{id:"866",title:"An Embedded Evolutionary Controller to Navigate a Population of Autonomous Robots",doi:"10.5772/5468",slug:"an_embedded_evolutionary_controller_to_navigate_a_population_of_autonomous_robots",totalDownloads:2119,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Eduardo do Valle Simoes",downloadPdfUrl:"/chapter/pdf-download/866",previewPdfUrl:"/chapter/pdf-preview/866",authors:[null],corrections:null},{id:"867",title:"Optimization of a 2 DOF Micro Parallel Robot Using Genetic Algorithms",doi:"10.5772/5469",slug:"optimization_of_a_2_dof_micro_parallel_robot_using_genetic_algorithms",totalDownloads:3955,totalCrossrefCites:1,totalDimensionsCites:2,hasAltmetrics:0,abstract:null,signatures:"Sergiu-Dan Stan, Vistrian Maties and Radu Balan",downloadPdfUrl:"/chapter/pdf-download/867",previewPdfUrl:"/chapter/pdf-preview/867",authors:[null],corrections:null},{id:"868",title:"Progressive Design through Staged Evolution",doi:"10.5772/5470",slug:"progressive_design_through_staged_evolution",totalDownloads:1933,totalCrossrefCites:0,totalDimensionsCites:2,hasAltmetrics:0,abstract:null,signatures:"Ricardo A. Tellez and Cecilio Angulo",downloadPdfUrl:"/chapter/pdf-download/868",previewPdfUrl:"/chapter/pdf-preview/868",authors:[null],corrections:null},{id:"869",title:"Emotional Intervention on Stigmergy Based Foraging Behaviour of Immune Network Driven Mobile Robots",doi:"10.5772/5471",slug:"emotional_intervention_on_stigmergy_based_foraging_behaviour_of_immune_network_driven_mobile_robots",totalDownloads:2015,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Diana Tsankova",downloadPdfUrl:"/chapter/pdf-download/869",previewPdfUrl:"/chapter/pdf-preview/869",authors:[null],corrections:null},{id:"870",title:"Evolutionary Distributed Control of a Biologically Inspired Modular Robot",doi:"10.5772/5472",slug:"evolutionary_distributed_control_of_a_biologically_inspired_modular_robot",totalDownloads:2415,totalCrossrefCites:0,totalDimensionsCites:1,hasAltmetrics:0,abstract:null,signatures:"Sunil Pranit Lal and Koji Yamada",downloadPdfUrl:"/chapter/pdf-download/870",previewPdfUrl:"/chapter/pdf-preview/870",authors:[null],corrections:null},{id:"871",title:"Evolutionary Motion Design for Humanoid Robots",doi:"10.5772/5473",slug:"evolutionary_motion_design_for_humanoid_robots",totalDownloads:2510,totalCrossrefCites:2,totalDimensionsCites:4,hasAltmetrics:0,abstract:null,signatures:"Toshihiko Yanase and Hitoshi Iba",downloadPdfUrl:"/chapter/pdf-download/871",previewPdfUrl:"/chapter/pdf-preview/871",authors:[null],corrections:null}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},subseries:null,tags:null},relatedBooks:[{type:"book",id:"7270",title:"Agricultural Robots",subtitle:"Fundamentals and Applications",isOpenForSubmission:!1,hash:"404b9128ab371832f2b7f0b6f32b2951",slug:"agricultural-robots-fundamentals-and-applications",bookSignature:"Jun Zhou and Baohua Zhang",coverURL:"https://cdn.intechopen.com/books/images_new/7270.jpg",editedByType:"Edited by",editors:[{id:"242047",title:"Dr.",name:"Jun",surname:"Zhou",slug:"jun-zhou",fullName:"Jun Zhou"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophile",surname:"Theophanides",slug:"theophile-theophanides",fullName:"Theophile Theophanides"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3161",title:"Frontiers in Guided Wave Optics and Optoelectronics",subtitle:null,isOpenForSubmission:!1,hash:"deb44e9c99f82bbce1083abea743146c",slug:"frontiers-in-guided-wave-optics-and-optoelectronics",bookSignature:"Bishnu Pal",coverURL:"https://cdn.intechopen.com/books/images_new/3161.jpg",editedByType:"Edited by",editors:[{id:"4782",title:"Prof.",name:"Bishnu",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"371",title:"Abiotic Stress in Plants",subtitle:"Mechanisms and Adaptations",isOpenForSubmission:!1,hash:"588466f487e307619849d72389178a74",slug:"abiotic-stress-in-plants-mechanisms-and-adaptations",bookSignature:"Arun Shanker and B. Venkateswarlu",coverURL:"https://cdn.intechopen.com/books/images_new/371.jpg",editedByType:"Edited by",editors:[{id:"58592",title:"Dr.",name:"Arun",surname:"Shanker",slug:"arun-shanker",fullName:"Arun Shanker"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"72",title:"Ionic Liquids",subtitle:"Theory, Properties, New Approaches",isOpenForSubmission:!1,hash:"d94ffa3cfa10505e3b1d676d46fcd3f5",slug:"ionic-liquids-theory-properties-new-approaches",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/72.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"314",title:"Regenerative Medicine and Tissue Engineering",subtitle:"Cells and Biomaterials",isOpenForSubmission:!1,hash:"bb67e80e480c86bb8315458012d65686",slug:"regenerative-medicine-and-tissue-engineering-cells-and-biomaterials",bookSignature:"Daniel Eberli",coverURL:"https://cdn.intechopen.com/books/images_new/314.jpg",editedByType:"Edited by",editors:[{id:"6495",title:"Dr.",name:"Daniel",surname:"Eberli",slug:"daniel-eberli",fullName:"Daniel Eberli"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"57",title:"Physics and Applications of Graphene",subtitle:"Experiments",isOpenForSubmission:!1,hash:"0e6622a71cf4f02f45bfdd5691e1189a",slug:"physics-and-applications-of-graphene-experiments",bookSignature:"Sergey Mikhailov",coverURL:"https://cdn.intechopen.com/books/images_new/57.jpg",editedByType:"Edited by",editors:[{id:"16042",title:"Dr.",name:"Sergey",surname:"Mikhailov",slug:"sergey-mikhailov",fullName:"Sergey Mikhailov"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1373",title:"Ionic Liquids",subtitle:"Applications and Perspectives",isOpenForSubmission:!1,hash:"5e9ae5ae9167cde4b344e499a792c41c",slug:"ionic-liquids-applications-and-perspectives",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/1373.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2270",title:"Fourier Transform",subtitle:"Materials Analysis",isOpenForSubmission:!1,hash:"5e094b066da527193e878e160b4772af",slug:"fourier-transform-materials-analysis",bookSignature:"Salih Mohammed Salih",coverURL:"https://cdn.intechopen.com/books/images_new/2270.jpg",editedByType:"Edited by",editors:[{id:"111691",title:"Dr.Ing.",name:"Salih",surname:"Salih",slug:"salih-salih",fullName:"Salih Salih"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],ofsBooks:[]},correction:{item:{id:"81444",slug:"corrigendum-to-the-role-of-ultra-radical-surgery-in-the-management-of-advanced-ovarian-cancer-state-",title:"Corrigendum to: The Role of Ultra-Radical Surgery in the Management of Advanced Ovarian Cancer: State of the Art",doi:null,correctionPDFUrl:"https://cdn.intechopen.com/pdfs/81444.pdf",downloadPdfUrl:"/chapter/pdf-download/81444",previewPdfUrl:"/chapter/pdf-preview/81444",totalDownloads:null,totalCrossrefCites:null,bibtexUrl:"/chapter/bibtex/81444",risUrl:"/chapter/ris/81444",chapter:{id:"78061",slug:"the-role-of-ultra-radical-surgery-in-the-management-of-advanced-ovarian-cancer-state-of-the-art",signatures:"Felicia Elena Buruiana, Lamiese Ismail, Federico Ferrari and Hooman Soleymani Majd",dateSubmitted:"March 15th 2021",dateReviewed:"April 8th 2021",datePrePublished:"August 12th 2021",datePublished:"October 6th 2021",book:{id:"10342",title:"Ovarian Cancer",subtitle:"Updates in Tumour Biology and Therapeutics",fullTitle:"Ovarian Cancer - Updates in Tumour Biology and Therapeutics",slug:"ovarian-cancer-updates-in-tumour-biology-and-therapeutics",publishedDate:"October 6th 2021",bookSignature:"Gwo-Yaw Ho and Kate Webber",coverURL:"https://cdn.intechopen.com/books/images_new/10342.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"297757",title:null,name:"Gwo-Yaw",middleName:null,surname:"Ho",slug:"gwo-yaw-ho",fullName:"Gwo-Yaw Ho"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:[{id:"325727",title:"Dr.",name:"Felicia Elena",middleName:null,surname:"Buruiana",fullName:"Felicia Elena Buruiana",slug:"felicia-elena-buruiana",email:"f.buruiana@nhs.net",position:null,institution:null},{id:"325746",title:"Dr.",name:"Lamiese",middleName:null,surname:"Ismail",fullName:"Lamiese Ismail",slug:"lamiese-ismail",email:"lamiese.ismail@ouh.nhs.uk",position:null,institution:{name:"Oxford University Hospitals NHS Trust",institutionURL:null,country:{name:"United Kingdom"}}},{id:"325747",title:"Dr.",name:"Hooman",middleName:null,surname:"Soleymani Majd",fullName:"Hooman Soleymani Majd",slug:"hooman-soleymani-majd",email:"hooman.soleymani@ouh.nhs.uk",position:null,institution:{name:"Oxford University Hospitals NHS Trust",institutionURL:null,country:{name:"United Kingdom"}}},{id:"353890",title:"Dr.",name:"Federico",middleName:null,surname:"Ferrari",fullName:"Federico Ferrari",slug:"federico-ferrari",email:"f.ferrari.obgyn@gmail.com",position:null,institution:{name:"Oxford University Hospitals NHS Trust",institutionURL:null,country:{name:"United Kingdom"}}}]}},chapter:{id:"78061",slug:"the-role-of-ultra-radical-surgery-in-the-management-of-advanced-ovarian-cancer-state-of-the-art",signatures:"Felicia Elena Buruiana, Lamiese Ismail, Federico Ferrari and Hooman Soleymani Majd",dateSubmitted:"March 15th 2021",dateReviewed:"April 8th 2021",datePrePublished:"August 12th 2021",datePublished:"October 6th 2021",book:{id:"10342",title:"Ovarian Cancer",subtitle:"Updates in Tumour Biology and Therapeutics",fullTitle:"Ovarian Cancer - Updates in Tumour Biology and Therapeutics",slug:"ovarian-cancer-updates-in-tumour-biology-and-therapeutics",publishedDate:"October 6th 2021",bookSignature:"Gwo-Yaw Ho and Kate Webber",coverURL:"https://cdn.intechopen.com/books/images_new/10342.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"297757",title:null,name:"Gwo-Yaw",middleName:null,surname:"Ho",slug:"gwo-yaw-ho",fullName:"Gwo-Yaw Ho"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:[{id:"325727",title:"Dr.",name:"Felicia Elena",middleName:null,surname:"Buruiana",fullName:"Felicia Elena Buruiana",slug:"felicia-elena-buruiana",email:"f.buruiana@nhs.net",position:null,institution:null},{id:"325746",title:"Dr.",name:"Lamiese",middleName:null,surname:"Ismail",fullName:"Lamiese Ismail",slug:"lamiese-ismail",email:"lamiese.ismail@ouh.nhs.uk",position:null,institution:{name:"Oxford University Hospitals NHS Trust",institutionURL:null,country:{name:"United Kingdom"}}},{id:"325747",title:"Dr.",name:"Hooman",middleName:null,surname:"Soleymani Majd",fullName:"Hooman Soleymani Majd",slug:"hooman-soleymani-majd",email:"hooman.soleymani@ouh.nhs.uk",position:null,institution:{name:"Oxford University Hospitals NHS Trust",institutionURL:null,country:{name:"United Kingdom"}}},{id:"353890",title:"Dr.",name:"Federico",middleName:null,surname:"Ferrari",fullName:"Federico Ferrari",slug:"federico-ferrari",email:"f.ferrari.obgyn@gmail.com",position:null,institution:{name:"Oxford University Hospitals NHS Trust",institutionURL:null,country:{name:"United Kingdom"}}}]},book:{id:"10342",title:"Ovarian Cancer",subtitle:"Updates in Tumour Biology and Therapeutics",fullTitle:"Ovarian Cancer - Updates in Tumour Biology and Therapeutics",slug:"ovarian-cancer-updates-in-tumour-biology-and-therapeutics",publishedDate:"October 6th 2021",bookSignature:"Gwo-Yaw Ho and Kate Webber",coverURL:"https://cdn.intechopen.com/books/images_new/10342.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"297757",title:null,name:"Gwo-Yaw",middleName:null,surname:"Ho",slug:"gwo-yaw-ho",fullName:"Gwo-Yaw Ho"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}}},ofsBook:{item:{type:"book",id:"7972",leadTitle:null,title:"Bilirubin",subtitle:null,reviewType:"peer-reviewed",abstract:"This book will be a self-contained collection of scholarly papers targeting an audience of practicing researchers, academics, PhD students and other scientists. The contents of the book will be written by multiple authors and edited by experts in the field.",isbn:null,printIsbn:null,pdfIsbn:null,doi:null,price:0,priceEur:0,priceUsd:0,slug:null,numberOfPages:0,isOpenForSubmission:!1,isSalesforceBook:!1,hash:"ff758a04d66cc8a5ed13a1011517a50f",bookSignature:"",publishedDate:null,coverURL:"https://cdn.intechopen.com/books/images_new/7972.jpg",keywords:null,numberOfDownloads:null,numberOfWosCitations:0,numberOfCrossrefCitations:0,numberOfDimensionsCitations:0,numberOfTotalCitations:0,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"August 8th 2018",dateEndSecondStepPublish:"August 29th 2018",dateEndThirdStepPublish:"October 28th 2018",dateEndFourthStepPublish:"January 16th 2019",dateEndFifthStepPublish:"March 17th 2019",remainingDaysToSecondStep:"4 years",secondStepPassed:!0,currentStepOfPublishingProcess:1,editedByType:null,kuFlag:!1,biosketch:null,coeditorOneBiosketch:null,coeditorTwoBiosketch:null,coeditorThreeBiosketch:null,coeditorFourBiosketch:null,coeditorFiveBiosketch:null,editors:null,coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"16",title:"Medicine",slug:"medicine"}],chapters:null,productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},personalPublishingAssistant:null},relatedBooks:[{type:"book",id:"6550",title:"Cohort Studies in Health Sciences",subtitle:null,isOpenForSubmission:!1,hash:"01df5aba4fff1a84b37a2fdafa809660",slug:"cohort-studies-in-health-sciences",bookSignature:"R. Mauricio Barría",coverURL:"https://cdn.intechopen.com/books/images_new/6550.jpg",editedByType:"Edited by",editors:[{id:"88861",title:"Dr.",name:"R. Mauricio",surname:"Barría",slug:"r.-mauricio-barria",fullName:"R. Mauricio Barría"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9500",title:"Recent Advances in Bone Tumours and Osteoarthritis",subtitle:null,isOpenForSubmission:!1,hash:"ea4ec0d6ee01b88e264178886e3210ed",slug:"recent-advances-in-bone-tumours-and-osteoarthritis",bookSignature:"Hiran Amarasekera",coverURL:"https://cdn.intechopen.com/books/images_new/9500.jpg",editedByType:"Edited by",editors:[{id:"67634",title:"Dr.",name:"Hiran",surname:"Amarasekera",slug:"hiran-amarasekera",fullName:"Hiran Amarasekera"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophile",surname:"Theophanides",slug:"theophile-theophanides",fullName:"Theophile Theophanides"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3161",title:"Frontiers in Guided Wave Optics and Optoelectronics",subtitle:null,isOpenForSubmission:!1,hash:"deb44e9c99f82bbce1083abea743146c",slug:"frontiers-in-guided-wave-optics-and-optoelectronics",bookSignature:"Bishnu Pal",coverURL:"https://cdn.intechopen.com/books/images_new/3161.jpg",editedByType:"Edited by",editors:[{id:"4782",title:"Prof.",name:"Bishnu",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"371",title:"Abiotic Stress in Plants",subtitle:"Mechanisms and Adaptations",isOpenForSubmission:!1,hash:"588466f487e307619849d72389178a74",slug:"abiotic-stress-in-plants-mechanisms-and-adaptations",bookSignature:"Arun Shanker and B. Venkateswarlu",coverURL:"https://cdn.intechopen.com/books/images_new/371.jpg",editedByType:"Edited by",editors:[{id:"58592",title:"Dr.",name:"Arun",surname:"Shanker",slug:"arun-shanker",fullName:"Arun Shanker"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"72",title:"Ionic Liquids",subtitle:"Theory, Properties, New Approaches",isOpenForSubmission:!1,hash:"d94ffa3cfa10505e3b1d676d46fcd3f5",slug:"ionic-liquids-theory-properties-new-approaches",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/72.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2270",title:"Fourier Transform",subtitle:"Materials Analysis",isOpenForSubmission:!1,hash:"5e094b066da527193e878e160b4772af",slug:"fourier-transform-materials-analysis",bookSignature:"Salih Mohammed Salih",coverURL:"https://cdn.intechopen.com/books/images_new/2270.jpg",editedByType:"Edited by",editors:[{id:"111691",title:"Dr.Ing.",name:"Salih",surname:"Salih",slug:"salih-salih",fullName:"Salih Salih"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"117",title:"Artificial Neural Networks",subtitle:"Methodological Advances and Biomedical Applications",isOpenForSubmission:!1,hash:null,slug:"artificial-neural-networks-methodological-advances-and-biomedical-applications",bookSignature:"Kenji Suzuki",coverURL:"https://cdn.intechopen.com/books/images_new/117.jpg",editedByType:"Edited by",editors:[{id:"3095",title:"Prof.",name:"Kenji",surname:"Suzuki",slug:"kenji-suzuki",fullName:"Kenji Suzuki"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3828",title:"Application of Nanotechnology in Drug Delivery",subtitle:null,isOpenForSubmission:!1,hash:"51a27e7adbfafcfedb6e9683f209cba4",slug:"application-of-nanotechnology-in-drug-delivery",bookSignature:"Ali Demir Sezer",coverURL:"https://cdn.intechopen.com/books/images_new/3828.jpg",editedByType:"Edited by",editors:[{id:"62389",title:"PhD.",name:"Ali Demir",surname:"Sezer",slug:"ali-demir-sezer",fullName:"Ali Demir Sezer"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},chapter:{item:{type:"chapter",id:"74032",title:"Wavelets for EEG Analysis",doi:"10.5772/intechopen.94398",slug:"wavelets-for-eeg-analysis",body:'
1. Introduction
Biomedical signals are electrical activities recorded by sensors from a part of the body, such as the brain, heart, muscles, etc. They can be recorded as images e.g. functional Magnetic resonance Image (fMRI) from brain or a temporal signal e.g. Electrocardiogram (ECG), Electroencephalogram (EEG), Electromyogram (EMG), Galvanic Skin Response (GSR), etc. These signals contain useful information to analyse and understand the underlying physiological response of the body, thus they are also referred to as physiological signals. Biomedical signals are extensively used in healthcare to diagnose deceases and monitor health. With recent advancements and ease of using the devices to record the biomedical signals have open a window to use it to analyse and understand the day-to-day activities, emotions, and, experiences [1, 2, 3]. While recording the physiological activities through sensors, the signals are usually contaminated by noise and various artefacts [4]. Corrupted signals mislead the analysis and understanding of the underlying physiology [5]. The characteristics of wavelet to identify the time-localised events makes it suitable for the biomedical signals to clean, process, feature extraction, and analyse for various applications. Recent studies have shown the promising results of using wavelet in biomedical signals [6].
In this chapter, first, we introduce one kind of biomedical signal - EEG. We will explain the conventional features used in EEG studies. We will introduce the artefacts that commonly contaminate EEG signals, which makes it harder to use. The chapter then will move towards a short description of Wavelet analysis techniques, namely Continues Wavelet Transform (CWT), Discrete Wavelet Transform (DWT), and Wavelet Packet Decomposition (WPD). We would, then, compare CWT and STFT for EEG signal. Then, we will discuss artefact removal algorithms, with more details on Wavelet-based algorithms. The chapter will show the comparative analysis of artefact removal algorithm. The approach and analysis shown in this chapter for EEG signals can easily be applied to other biological signals.
2. Electroencephogram - EEG
The brain processes any information by means of neurons that use electrical and chemical signals to communicate by releasing and receiving neurotransmitters. The neural activity in the human brain is an electrical change. The brain generates electrical signals throughout the day for various activities. Studying these electrical signals is vital to understanding the neurophysiological behaviour of the brain [4]. A number of techniques are used to study brain activities. Functional magnetic resonance imaging (fMRI), Functional Near-Infrared Spectroscopy (firs), and Electroencephalography (EEG) recordings widely used techniques. The fMRI measures brain activity by scanning the blood flow. The fNIRS measures brain activity by measuring hemodynamic response in the brain through detecting the temporal changes in infrared light source. The EEG measures the electrical activity of the brain by electrodes placed on the scalp. Comparing to the other two, EEG measures brain activity directly, with high temporal resolution and most accessible and portable for the research. The fMRI has a high spatial resolution but very expensive, therefore it is mostly limited to medical diagnosis and treatments.
2.1 The EEG measure
The EEG signal is measured by placing multiple electrodes on the scalp that measure the current flow from neurons. A setup for EEG recording is shown in Figure 1. Each neuron (brain cell), when activated, it produced an electrical and magnetic field around the scalp. Since there are 100 billion neurons in the brain, when an electrode is placed on the scalp, it measures the accumulative activity of many neurons together. The complex structure of the brain attenuates the electrical signals, therefore an electrode can record the brain activity, only when a large number of neurons generate enough potential. The EEG devices amplify the recorded signal to store and process it [4].
Figure 1.
EEG recording setup: (a) a wireless device Emotiv Epoch mounted on a subject, transmitting EEG signal to a computer. (b) Electrode positions as 10–20 system, source: https://www.emotiv.com/.
The placement of electrodes has been standardised with the specific anatomical landmarks with a distance between electrodes as 10% or 20% of total length. This placement is called the 10–20 system, as shown in Figure 1b. The number of electrodes used for EEG recording varies, depending on the device. One of the low spatial resolutions can be of a 14-channel EEG device and high spatial resolution with 128 or 256 channels. The name of the electrode position is labelled as character followed by a number to identify the part of the brain. The characters are Fop for pre-frontal, F for frontal, P for parietal, T for temporal, O for occipital, and C for central lobe of the brain. A few in between two landmarks are named with two characters, such as AF, between Fp and F and FC, between F and C [4]. An example of 14-channel is shown in Figure 1b.
The raw recording of EEG signal in the time-domain is complex to interpret. Similar to many other signals, frequency domain analysis has been widely used. The decades of work on EEG studies have identified five major frequency bands for EEG signals and established the correlation between behaviour and neural activity of a certain part of the brain. The frequency bands widely used are; Delta (0.1−4 Hz or 0.5−4 Hz), Theta (4−8 Hz), Alpha (8−14 Hz), Beta (14−30 Hz), Gamma (30−63 Hz). A raw EEG signal from a channel and corresponding signal in different bands are shown in Figure 2. It can be observed that low frequency, Delta activity, is the dominating wave in raw EEG and high-frequency Gamma is almost noise like with a little amplitude [4].
Figure 2.
The signal channel raw EEG signal and corresponding frequency bands: Delta (0.1−4 Hz), theta (4−8 Hz), alpha (8−14 Hz), Beta (14−30 Hz), gamma (30−63 Hz).
Due to multichannel signals, it is usually viewed as topographical brain activity (heatmap over an image of head) under different frequency bands. An example of 5 seconds EEG recording with a 14-channel device is shown in Figure 3. The first second of all the channels are used to compute the energy distribution over brain regions. In Figure 3, the top left shows the raw EEG signal and corresponding brain activity, which shows a high activity in the frontal lobe of the brain. However, under different frequency bands, the different part of the brain shows higher activity.
Figure 3.
Topographical view of brain activity: Energy distribution of EEG recording over different brain regions under five frequency bands and raw signal.
The frequency bands; Delta, Theta, Alpha, Beta, and Gamma, are also called brain rhythms. Brain rhythms have been investigated over decades and a few characteristic behaviour of these brain rhythms have been established [4].
Delta: Delta waves were first introduced by Walter in 1936, it ranges from 0.1 (or 0.5) to 4 Hz in frequency. Delta waves are usually observed in deep sleep. Since delta wave is the low-frequency wave, it is easily confused by the movement artefact, due to similar nature. Delta waves have also been linked to continuous attention tasks.
Theta: Theta waves were introduced by Dovey and Wolter, ranges from 4 to 8 Hz in frequency. Theta waves are linked to drowsiness and deep meditation state.
Alpha: Alpha waves, perhaps are the most widely investigated waves in EEG studies. Alpha waves were introduced by Berger in 1929. They lie in a range from 8 to 14 Hz. Alpha waves usually appear on the occipital lobe of the brain. Alpha waves are the most common indication of a relaxing state of mind and are also linked to closing eyes. Any sign of anxiety or attention reduces the alpha waves.
Beta: Beta waves lie in the range of 14–30 Hz of frequency. Beta waves have been associated with active thinking, anxious, high alert, and focus of the brain.
Gamma: Gamma waves are the higher frequency waves, ranges from 30 to onwards. Gamma wave is considered to play a complex role in brain functionality, such as combining information from two different sensory inputs. It is also used to confirm certain brain diseases.
2.2 Artefacts in EEG
While recording, EEG signals are frequently contaminated with various artefacts. The most common types of artefacts are motion, muscular, ocular, and cardiac artefacts [4], which are shown in Figure 4. The motion artefacts are caused by the physical movement of the person’s body. As shown in Figure 4a, motion artefacts produce a sudden high valued spike in all the channels of EEG recording. The muscular artefacts, shown in Figure 4b are caused by any muscular contraction such as grinding the teeth. It produces high-frequency bursts in EEG recording as circled in the Figure 4b. The cardiac artefacts, shown in Figure 4c, are caused by the electrical activities of the heart. They appear as a weak form of QRS wave of heart and most likely to be appeared in the channels near to ears (temporal lobe), though it can be sometimes present in channels from the frontal lobe [7]. The ocular artefacts are slow oscillating waves appear on the frontal lobe, caused by the eye movements or closed eyes, as circled in the Figure 4d. The higher magnitude of the artefacts corrupts the EEG recording and leads to misinterpretations of the results and analysis [5]. Even though there are many algorithms to remove the artefacts, but there is always a possibility of losing the cerebral information while removing the artefacts.
Figure 4.
Common type of artefacts in EEG. Corresponding artefacts are circled in the figure.
3. Wavelet analysis
Most of the real-life signals are non-stationary in behaviour, which means their properties change over time. To localise the events of interest, time-frequency analysis is widely used. The conventional way of time-frequency analysis is the Short-Time Fourier Transform (STFT), where Fourier transform of the signal is taken over short-windows, resulting spectrogram plot. STFT has limitations on resolutions, due to Heisenberg’s uncertainty principle, e.g. improvement in time resolution results in poorer frequency resolution and vice-versa. The alternative to STFT is wavelet transform, which exploits the property of low-frequency signals being widespread over time and high-frequency bursts occurring on short intervals. Wavelet transform uses the variable size of windows with a wavelet function.
Wavelet analysis is usually applied in two ways, Continuous Wavelet Transform (CWT) and Discrete Wavelet Transform (DWT). CWT uses a wavelet function ψt and produces a scalogram, similar to a spectrogram for time-frequency analysis. However, DWT decomposes a signal into two (1) average or lowpass signal, using scaling function and (2) difference or highpass signal using wavelet function. The conventional DWT recursively decomposes lowpass signal with the same scaling and wavelet functions to the desired level of decomposition. A decomposition tree for DWT is shown in Figure 5a. For some applications, it is useful to decompose highpass signal at each level too, this is called Wavelet Packet Decomposition (WPD). A tree for WPD is shown in Figure 5b.
Figure 5.
4-level decomposition tree for (a) discrete wavelet transform (DWT), (b) wavelet packet decomposition (WPD).
As shown in Figure 5, block LP is a lowpass filter hn and block HP is a highpass filter gn, both followed by downsampler (↓2). The coefficients of lowpass filter are corresponds to scalling function ϕn and coefficients of highpass filter are corresponds to wavelet funciton ψn. A N-level DWT decomposes a signal xn into set of signals: [XLN,XHN,XHN−1,…,XH1], each with different dimensions. However, a N-level WPD decomposes a signal xn into set of packets: [XN1,XN2,…,XN2N], each with same dimensions.
4. Time-frequency analysis of EEG using CWT
As discussed, a conventional way to time-frequency analysis is STFT, however, using CWT with different wavelet functions can enrich the analysis with more details. In this section, we will show, how a continuous wavelet function (ψt), can be applied to a discrete EEG signal xn, and compare the spectrogram with scalogram of different wavelet functions.
A spectrogram is obtained using STFT, which is Fourier Transform computed for a short windows. STFT Xstftτω of signal xt as given as Eq. (1), where wt is a window function. On the other hand, CWT Xcwtab of a signal xt is given by Eq. (2), where ψa,b∗t is a complex conjugate of scaled and shifted version of mother wavelet ψt, a is scaling parameter and b is shifting parameter.
Xstftτω=∫−∞∞xtwτ−te−jωtdtE1
Xcwtab=∫−∞∞xtψa,b∗tdt.E2
CWT operation from Eq. (2) can be seen as convolution of input signal xt with scaled version of wavelet function ψt.
Xcwta=xt⊛ψa∗tE3
Xcwtf=Xfψa∗fE4
where Xf is Fourier transform of xt, and the same for others. For computations with discrete signal xn, both equations; 3 and 4 can be used with discrete operations, e.g. convolution and multiplication and discrete wavelet function ψn, while for Fourier Transform, Fast Fourier Transform (FFT) is used. For computational efficiency, however, Eq. (4) is widely used, by multiplying FFT of xn and FFT of scaled and discrete version ψn. Even though, for discrete signal xn, discrete wavelet function ψn is used, however, the conventional definitions of wavelet functions for CWT are defined in continues time-domain. A set time-domain and frequency-domain equations for six complex wavelet functions are defined below. Figure 6 shows all the six wavelet functions, with their real and imaginary part. All six functions are similar, in terms of smoothness and being derived from exponential and sinusoidal functions, however, they have different parameters to control the oscillation and frequency band to be captured.
Figure 6.
Continues wavelet functions.
Gaussian Wavelet: A time-domain wavelet it derived from a Gaussian function centered at t0 and modulated by a complex exponential function with frequency f0 [8].
ψt=e−at−t02⋅e−2πjf0t−t0E5
ψf=π/ae−2πjft0⋅e−π2f−f02/aE6
where a=f0Q2.
Gabor Wavelet: Gabor wavelet is perhaps the most widely used function for various applications. It is essentially the same as Gaussian wavelet function, with simplified equations, as follow [8, 9];
ψt=e−t−t02/a2e−jf0t−t0E7
ψf=e−f−f0a2e−jt0f−f0E8
where a is oscillation rate and f0 is center frequency, t0 is centred time.
Morlet Wavelet: Morlet is considered very similar to Gabor wavelet and Gabor filters. The oscillation of Morlet wavelet is controlled by σ. A higher value of σ results in higher oscillation [10].
ψt=Cσπ−0.25e−0.5t2ejσt−KσE9
ψw=Cσπ−0.25e−0.5σ−w2−Kσe−0.5w2E10
where Cσ=1+e−σ2−2e−34σ2−0.5, Kσ=e−0.5σ2, and w=2πf.
Poisson Wavelet: Poisson wavelet is defined by positive integers (n), unlike other, and associated with Poisson probability distribution [11, 12].
ψt=12π1−jt−n+1E11
ψw=1Γn+1wne−wuwE12
where w=2πf and uw is a unit step function, e.g. uw=1 if w>=0, 0 else.
Complex Mexican hat wavelet: Complex Mexican hat wavelet is derived from the conventional Mexican hat wavelet. It is a low-oscillation wavelet which is modulated by a complex exponential function with frequency f0 [13].
Complex Shannon wavelet: Complex Shannon wavelet is the most simplified wavelet function, exploiting Sinc function by modulating with sinusoidal, which results in an ideal bandpass filter. Real Shannon wavelet is modulated by only a cos function [14].
ψt=Sinct/2⋅e−2jπf0tE15
ψw=∏w−w0πE16
where ∏x=1 if x≤0.5, 0 else and w=2πf and w0=2πf0.
An example of using the above six wavelet functions for a small single-channel EEG segment is shown in Figure 7, along with spectrogram. It can be observed, spectrogram highlights a few events in signal (sharp peaks and lowpass wave), however, using CWT with different Wavelet functions, much richer information can be observed. Since, we observed that in the formulation of wavelet functions that they are similar to the underlying principle, we could also observe the similarities across different scalograms. Specifically, spectrogram using Complex Shannon and Complex Mexican hat wavelet are much similar. Interestingly, Morlate and Poisson wavelet functions are able to produce a better resolution towards lower frequencies.
Figure 7.
Scalogram and spectrogram of a segment of signal channel EEG signal with six wavelet functions and STFT. Figure obtained using spkit python library - https://spkit.github.iohttps://spkit.github.io
5. Artefact removal algorithms using DWT and WPD
Artefacts in EEG recording is a primary obstacle that all researchers have to deal with. There are decades of research work in literature to remove these artefacts [15, 16]. A range of methods have been proposed to remove the artefacts, starts with a statistical with interpolation method [17] and regression method [18]. The most commonly used approaches are based on Blind Source Separation (BSS) using Independent Component Analysis (ICA) [19, 20]. ICA based approach have been widely explored with statistical measures [21, 22, 23, 24], and variant of ICA as FastICA, InfoMax, and Extended InfoMax [25, 26, 27]. Wavelet-based approaches are well suited for time-localised short events, as opposed to ICA. This property has been exploited to remove artefacts from single-channel EEG. In contrast to a single channel, wavelet has also been used for multi-channel EEG [28] and in combination with ICA [29, 30, 31, 32, 33, 34], in which identified artifactual component is cleaned with wavelet rather than removed. The ICA-based approaches can only be applied to multi-channel EEG and need an expert to select artifactual component, which has been automated with heuristics [21, 35, 36]. In contrast, most wavelet-based algorithms remove artefacts from each channel individually.
The key idea of wavelet-based artefact removal algorithms is to apply DWT on single-channel EEG signal xn and remove (set to zero) wavelet coefficients that fall above some statistical threshold and reconstruct signal back using inverse-DWT (IDWT) x̂n [37, 38, 39]. With linear property of electrical activities, recorded EEG signal is considered as xn=sn+vn, where sn is source signal of brain activity and vn is artifactual components. The two most widely used threshold formulations are used with wavelet.
Global Threshold: Also known as the optimal threshold for removing white-gaussian noise from any signal [40] using DWT. Global Threshold (TG) is defined as;
TG=σ̂2logNforσ̂=medianw0.6745E17
where N is the length of signal and for wavelet coefficients w, σ̂ is the estimate of noise variance. To denoise a signal, wavelet coefficients with magnitude below the threshold TG are set to zero and reconstruct the signal back. However, for recorded EEG signal xn, source signal sn is considered to be zero mean and normally distributed, i.g. sn∼N0σ [4]. For which any wavelet coefficients with a magnitude above the threshold TG is considered to be artifactual and removed (set to zero).
Standard Deviation (STD) Threshold: As name suggests, STD threshold is based on Standard Deviation (STD) of wavelet coefficients [39].
TSTD=1.5×STDwE18
ATAR algorithm: A recent study has shown that approaches based on above thresholds are very aggressive, since, statistically, a few wavelet coefficients of any signal will always fall above these thresholds [14]. In contrast, an Automatic and Tunable Artefact Removal (ATAR) Algorithm based on WPD was proposed [41], which provides three different wavelet filtering modes and a tunable parameter. As shown a block diagram of ATAR algorithm in Figure 8, a single channel EEG signal xn is first split into smaller windows xwn, apply L-level WPD to get wavelet coefficients w=XLk=WPDxwn, then wavelet coefficients are filtered using wavelet filtering ŵ=λw to reconstruct signal x̂n from corrected windows x̂wn. The three filtering modes in ATAR algorithm are namely; Elimination λe⋅, Linear attenuation λa⋅, and soft thresholding λs⋅, which are defined below;
where w is a wavelet coefficient, sgn⋅ is the signum function, and θα>θγ. A default setting for θγ and θβ is; θγ=0.8θα and θβ=2θα. The characteristics of wavelet filtering mode are shown in Figure 9. From Figure 9, it can be seen that Elimination mode of filtering is the same as conventional filtering, however, Linear attenuation and soft-thresholding modes do not remove the wavelet coefficient, rather suppress them softly. Another distinction ATAR algorithm has over others is the threshold selection. The threshold θα is computed from Interquartile Range (IQR) of wavelet coefficients using Eq. (22), which is robust against outliers, as oppose to STD.
Figure 9.
Wavelet filtering modes for ATAR algorithm. For θα=200,θγ=0.8θα=160,θβ=2θα=400 [41].
θα=fβriffβr≥k1k1elsewherefβr=k2exp−β100k2r2E22
where r is Interquartile Range (IQR) of coefficients i.e. r=IQRw and k1 and k2 are lower and upper bounds on filtering.
Figure 10 shows a visual comparative analysis of wavelet-based approaches (i.e. Global threshold, STD threshold, and ATAR algorithm) and ICA based approaches (FastICA, InfoMax, and Extended-InfoMax) to remove the artefacts. It is visually apparent that wavelet-based approaches are better than ICA-based approaches. Among wavelet-based approaches, using ATAR gives much control over Global and STD based threshold selection. Other quantitative analyses of the above-mentioned approaches are discussed in the article [41], which also demonstrate the effect of tuning parameter and filtering modes on different predictive tasks of EEG signal. The formulation of relationship, algorithmic implementation details, and comparative results are given in article [41].
Figure 10.
Comparison of artefact removal approaches from [41].
6. Conclusions
This chapter presents the overview of Wavelet for EEG analysis. The first chapter introduces EEG signal, commonly used features for predictive analysis, and artefacts that often contaminate EEG signal. Then chapter discusses the Wavelet analysis approaches, namely CWT, DWT, and WPD. The richness of CWT over STFT for time-frequency analysis using various wavelet functions is demonstrated. Finally, the artefact removal algorithms based on wavelet and ICA are discussed. The comparative analysis present in the chapter shows that the wavelet-based approach outperforms ICA based approach. Specifically, a recent algorithm (ATAR) allows controlling the removal or suppression of assumed artifactual components in the signal, which can be tuned to improve the performance of any predictive tasks. The techniques presented in this chapter show how wavelet can be used for EEG studies to extract rich information and removing the artefacts. The comparative analysis shows wavelet based approaches are well suited for EEG signal processing. Further, similar approaches can be used with other biomedical signals such as electrocardiogram (ECG or EKG), Electromyography (EMG) etc.
\n',keywords:"EEG, artefacts, wavelet analysis, CWT, DWT, WPD, artefact removal algorithms, time-frequency analysis",chapterPDFUrl:"https://cdn.intechopen.com/pdfs/74032.pdf",chapterXML:"https://mts.intechopen.com/source/xml/74032.xml",downloadPdfUrl:"/chapter/pdf-download/74032",previewPdfUrl:"/chapter/pdf-preview/74032",totalDownloads:1151,totalViews:0,totalCrossrefCites:2,totalDimensionsCites:2,totalAltmetricsMentions:0,impactScore:1,impactScorePercentile:69,impactScoreQuartile:3,hasAltmetrics:0,dateSubmitted:"July 5th 2020",dateReviewed:"October 8th 2020",datePrePublished:"November 12th 2020",datePublished:"February 24th 2021",dateFinished:"November 12th 2020",readingETA:"0",abstract:"This chapter introduces the applications of wavelet for Electroencephalogram (EEG) signal analysis. First, the overview of EEG signal is discussed to the recording of raw EEG and widely used frequency bands in EEG studies. The chapter then progresses to discuss the common artefacts that contaminate EEG signal while recording. With a short overview of wavelet analysis techniques, namely; Continues Wavelet Transform (CWT), Discrete Wavelet Transform (DWT), and Wavelet Packet Decomposition (WPD), the chapter demonstrates the richness of CWT over conventional time-frequency analysis technique e.g. Short-Time Fourier Transform. Lastly, artefact removal algorithms based on Independent Component Analysis (ICA) and wavelet are discussed and a comparative analysis is demonstrated. The techniques covered in this chapter show that wavelet analysis is well-suited for EEG signals for describing time-localised event. Due to similar nature, wavelet analysis is also suitable for other biomedical signals such as Electrocardiogram and Electromyogram.",reviewType:"peer-reviewed",bibtexUrl:"/chapter/bibtex/74032",risUrl:"/chapter/ris/74032",book:{id:"10065",slug:"wavelet-theory"},signatures:"Nikesh Bajaj",authors:[{id:"326400",title:"Dr.",name:"Nikesh",middleName:null,surname:"Bajaj",fullName:"Nikesh Bajaj",slug:"nikesh-bajaj",email:"n.bajaj@qmul.ac.uk",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",institution:{name:"University of East London",institutionURL:null,country:{name:"United Kingdom"}}}],sections:[{id:"sec_1",title:"1. Introduction",level:"1"},{id:"sec_2",title:"2. Electroencephogram - EEG",level:"1"},{id:"sec_2_2",title:"2.1 The EEG measure",level:"2"},{id:"sec_3_2",title:"2.2 Artefacts in EEG",level:"2"},{id:"sec_5",title:"3. Wavelet analysis",level:"1"},{id:"sec_6",title:"4. Time-frequency analysis of EEG using CWT",level:"1"},{id:"sec_7",title:"5. Artefact removal algorithms using DWT and WPD",level:"1"},{id:"sec_8",title:"6. Conclusions",level:"1"}],chapterReferences:[{id:"B1",body:'D. Petit, J.-F. Gagnon, M. L. Fantini, L. Ferini-Strambi, J. Montplaisir, Sleep and quantitative eeg in neurodegenerative disorders, Journal of psychosomatic research 56 (2004) 487–496'},{id:"B2",body:'M. L. Perlis, M. T. Smith, P. J. Andrews, H. Orff, D. E. Giles, Beta/gamma eeg activity in patients with primary and secondary insomnia and good sleeper controls, Sleep 24 (2001) 110–117.'},{id:"B3",body:'A. R. Clarke, R. J. Barry, R. McCarthy, M. Selikowitz, Eeg analysis in attention-deficit/hyperactivity disorder: a comparative study of two subtypes, Psychiatry research 81 (1998) 19–29.'},{id:"B4",body:'S. Sanei, J. A. Chambers, EEG signal processing, John Wiley & Sons, 2013.'},{id:"B5",body:'D. Hagemann, E. Naumann, The effects of ocular artifacts on (lateralized) broadband power in the eeg, Clinical Neurophysiology 112 (2001) 215–231.'},{id:"B6",body:'H. Olkkonen, Discrete Wavelet Transforms: Biomedical Applications, BoD–Books on Demand, 2011.'},{id:"B7",body:'G. Dirlich, T. Dietl, L. Vogl, F. Strian, Topography and morphology of heart action-related eeg potentials, Electroencephalography and Clinical Neurophysiology/Evoked Potentials Section 108 (1998) 299–305.'},{id:"B8",body:'T. S. Lee, Image representation using 2d gabor wavelets, IEEE Transactions on pattern analysis and machine intelligence 18 (1996) 959–971.'},{id:"B9",body:'Gabor wavelet, https://en.wikipedia.org/wiki/Gabor wavelet, 2020.'},{id:"B10",body:'Morlate wavelet, https://en.wikipedia.org/wiki/Morlet wavelet, 2020.'},{id:"B11",body:'K. A. Kosanovich, A. R. Moser, M. J. Piovoso, A new family of wavelets: the poisson wavelet transform, Computers & chemical engineering 21 (1997) 601–620.'},{id:"B12",body:'Poisson wavelet, https://en.wikipedia.org/wiki/Poisson wavelet, 2020.'},{id:"B13",body:'Complex mexican hat wavelet, https://en.wikipedia.org/wiki/Complex Mexican hat wavelet, 2020.'},{id:"B14",body:'Shannon wavelet, https://en.wikipedia.org/wiki/Shannon wavelet, 2020.'},{id:"B15",body:'J. A. Urigüen, B. Garcia-Zapirain, EEG artifact removal—state-of-the-art and guidelines, Journal of neural engineering 12 (2015) 031001.'},{id:"B16",body:'M. Fatourechi, A. Bashashati, R. K. Ward, G. E. Birch, Emg and eog artifacts in brain computer interface systems: A survey, Clinical neurophysiology 118 (2007) 480–494.'},{id:"B17",body:'M. Junghöfer, T. Elbert, D. M. Tucker, B. Rockstroh, Statistical control of artifacts in dense array EEG/MEG studies, Psychophysiology 37 (2000) 523–532.'},{id:"B18",body:'J. Woestenburg, M. Verbaten, J. Slangen, The removal of the eye-movement artifact from the eeg by regression analysis in the frequency domain, Biological psychology 16 (1983) 127–147.'},{id:"B19",body:'T.-P. Jung, S. Makeig, C. Humphries, T.-W. Lee, M. J. Mckeown, V. Iragui, T. J. Sejnowski, Removing electroencephalographic artifacts by blind source separation, Psychophysiology 37 (2000) 163–178.'},{id:"B20",body:'L. Shoker, S. Sanei, W. Wang, J. A. Chambers, Removal of eye blinking artifact from the electro-encephalogram, incorporating a new constrained blind source separation algorithm, Medical and Biological Engineering and Computing 43 (2005) 290–295.'},{id:"B21",body:'H. Nolan, R. Whelan, R. Reilly, FASTER: fully automated statistical thresholding for EEG artifact rejection, Journal of neuroscience methods 192 (2010) 152–162.'},{id:"B22",body:'R. R. Vázquez, H. Velez-Perez, R. Ranta, V. L. Dorr, D. Maquin, L. Maillard, Blind source separation, wavelet denoising and discriminant analysis for eeg artefacts and noise cancelling, Biomedical Signal Processing and Control 7 (2012) 389–400.'},{id:"B23",body:'A. Mognon, J. Jovicich, L. Bruzzone, M. Buiatti, Adjust: An automatic eeg artifact detector based on the joint use of spatial and temporal features, Psychophysiology 48 (2011) 229–240.'},{id:"B24",body:'A. Belouchrani, K. Abed-Meraim, J.-F. Cardoso, E. Moulines, A blind source separation technique using second-order statistics, IEEE Transactions on signal processing 45 (1997) 434–444.'},{id:"B25",body:'D. Langlois, S. Chartier, D. Gosselin, An introduction to independent component analysis: Infomax and fastica algorithms, Tutorials in Quantitative Methods for Psychology 6 (2010) 31–38.'},{id:"B26",body:'A. J. Bell, T. J. Sejnowski, An information-maximization approach to blind separation and blind deconvolution, Neural computation 7 (1995) 1129–1159.'},{id:"B27",body:'T.-W. Lee, M. Girolami, T. J. Sejnowski, Independent component analysis using an extended infomax algorithm for mixed subgaussian and supergaussian sources, Neural computation 11 (1999) 417–441.'},{id:"B28",body:'G. Inuso, F. La Foresta, N. Mammone, F. C. Morabito, Brain activity investigation by eeg processing: wavelet analysis, kurtosis and renyi’s entropy for artifact detection, in: 2007 International Conference on Information Acquisition, IEEE, pp. 195–200.'},{id:"B29",body:'N. P. Castellanos, V. A. Makarov, Recovering eeg brain signals: artifact suppression with wavelet enhanced independent component analysis, Journal of neuroscience methods 158 (2006) 300–312.'},{id:"B30",body:'M. T. Akhtar, W. Mitsuhashi, C. J. James, Employing spatially constrained ica and wavelet denoising, for automatic removal of artifacts from multichannel eeg data, Signal Processing 92 (2012) 401–416.'},{id:"B31",body:'H. Ghandeharion, A. Erfanian, A fully automatic ocular artifact suppression from eeg data using higher order statistics: Improved performance by wavelet analysis, Medical engineering & physics 32 (2010) 720–729.'},{id:"B32",body:'N. K. Al-Qazzaz, S. H. B. M. Ali, S. A. Ahmad, M. S. Islam, J. Escudero, Discrimination of stroke-related mild cognitive impairment and vascular dementia using eeg signal analysis, Medical & biological engineering & computing 56 (2018) 137–157.'},{id:"B33",body:'R. Mahajan, B. I. Morshed, Unsupervised eye blink artifact denoising of eeg data with modified multiscale sample entropy, kurtosis, and wavelet-ica, IEEE journal of Biomedical and Health Informatics 19 (2014) 158–165.'},{id:"B34",body:'N. Al-Qazzaz, S. Hamid Bin Mohd Ali, S. Ahmad, M. Islam, J. Escudero, Automatic artifact removal in eeg of normal and demented individuals using ica–wt during working memory tasks, Sensors 17 (2017) 1326.'},{id:"B35",body:'W. Kong, Z. Zhou, S. Hu, J. Zhang, F. Babiloni, G. Dai, Automatic and direct identification of blink components from scalp eeg, Sensors 13 (2013) 10783–10801.'},{id:"B36",body:'R. N. Vigário, Extraction of ocular artefacts from EEG using independent component analysis, Electroencephalography and clinical neurophysiology 103 (1997) 395–404.'},{id:"B37",body:'S. V. Ramanan, N. Kalpakam, J. Sahambi, A novel wavelet based technique for detection and de-noising of ocular artifact in normal and epileptic electroencephalogram (2004).'},{id:"B38",body:'V. Krishnaveni, S. Jayaraman, S. Aravind, V. Hariharasudhan, K. Ramadoss, Automatic identification and removal of ocular artifacts from eeg using wavelet transform, Measurement science review 6 (2006) 45–57.'},{id:"B39",body:'P. S. Kumar, R. Arumuganathan, K. Sivakumar, C. Vimal, Removal of ocular artifacts in the eeg through wavelet transform without using an eog reference channel, Int. J. Open Problems Compt. Math 1 (2008) 188–200.'},{id:"B40",body:'D. L. Donoho, J. M. Johnstone, Ideal spatial adaptation by wavelet shrinkage, biometrika 81 (1994) 425–455.'},{id:"B41",body:'N. Bajaj, J. R. Carrión, F. Bellotti, R. Berta, A. De Gloria, Automatic and tunable algorithm for eeg artifact removal using wavelet decomposition with applications in predictive modeling during auditory tasks, Biomedical Signal Processing and Control 55 (2020) 101624.'}],footnotes:[],contributors:[{corresp:"yes",contributorFullName:"Nikesh Bajaj",address:"n.bajaj@uel.ac.uk;, n.bajaj@qmul.ac.uk",affiliation:'
University of East London, United Kingdom
Queen Mary University of London, United Kingdom
'}],corrections:null},book:{id:"10065",type:"book",title:"Wavelet Theory",subtitle:null,fullTitle:"Wavelet Theory",slug:"wavelet-theory",publishedDate:"February 24th 2021",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",isbn:"978-1-83881-948-4",printIsbn:"978-1-83881-947-7",pdfIsbn:"978-1-83881-955-2",reviewType:"peer-reviewed",numberOfWosCitations:2,isAvailableForWebshopOrdering:!0,editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"974"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"74096",type:"chapter",title:"Time Frequency Analysis of Wavelet and Fourier Transform",slug:"time-frequency-analysis-of-wavelet-and-fourier-transform",totalDownloads:1158,totalCrossrefCites:6,signatures:"Karlton Wirsing",reviewType:"peer-reviewed",authors:[{id:"325178",title:"Dr.",name:"Karlton",middleName:null,surname:"Wirsing",fullName:"Karlton Wirsing",slug:"karlton-wirsing"}]},{id:"74371",type:"chapter",title:"Wavelet Theory: Applications of the Wavelet",slug:"wavelet-theory-applications-of-the-wavelet",totalDownloads:405,totalCrossrefCites:1,signatures:"Mohammed S. Mechee, Zahir M. Hussain and Zahrah Ismael Salman",reviewType:"peer-reviewed",authors:[{id:"323755",title:"Prof.",name:"Mohammed S Mechee",middleName:null,surname:"Mechee",fullName:"Mohammed S Mechee Mechee",slug:"mohammed-s-mechee-mechee"},{id:"324142",title:"Prof.",name:"Zahir",middleName:null,surname:"Hussain",fullName:"Zahir Hussain",slug:"zahir-hussain"},{id:"346621",title:"Dr.",name:"Zahrah Ismael",middleName:null,surname:"Salman",fullName:"Zahrah Ismael Salman",slug:"zahrah-ismael-salman"}]},{id:"74766",type:"chapter",title:"Wavelet Theory and Application in Communication and Signal Processing",slug:"wavelet-theory-and-application-in-communication-and-signal-processing",totalDownloads:647,totalCrossrefCites:1,signatures:"Nizar Al Bassam, Vidhyalavanya Ramachandran and Sumesh Eratt Parameswaran",reviewType:"peer-reviewed",authors:[{id:"209205",title:"Dr.",name:"Nizar",middleName:null,surname:"Albassam",fullName:"Nizar Albassam",slug:"nizar-albassam"},{id:"329233",title:"Dr.",name:"Sumesh",middleName:null,surname:"EP",fullName:"Sumesh EP",slug:"sumesh-ep"},{id:"335241",title:"Dr.",name:"Dr. Vidhya Lavanya",middleName:null,surname:"Ramachandran",fullName:"Dr. Vidhya Lavanya Ramachandran",slug:"dr.-vidhya-lavanya-ramachandran"}]},{id:"74374",type:"chapter",title:"Wavelet Based Multicarrier Modulation (MCM) Systems: PAPR Analysis",slug:"wavelet-based-multicarrier-modulation-mcm-systems-papr-analysis",totalDownloads:342,totalCrossrefCites:1,signatures:"Jamaluddin Zakaria and Mohd Fadzli Mohd Salleh",reviewType:"peer-reviewed",authors:[{id:"325304",title:"Associate Prof.",name:"Mohd Fadzli",middleName:null,surname:"Mohd Salleh",fullName:"Mohd Fadzli Mohd Salleh",slug:"mohd-fadzli-mohd-salleh"},{id:"325310",title:"Dr.",name:"Jamaluddin",middleName:null,surname:"Zakaria",fullName:"Jamaluddin Zakaria",slug:"jamaluddin-zakaria"}]},{id:"74032",type:"chapter",title:"Wavelets for EEG Analysis",slug:"wavelets-for-eeg-analysis",totalDownloads:1151,totalCrossrefCites:2,signatures:"Nikesh Bajaj",reviewType:"peer-reviewed",authors:[{id:"326400",title:"Dr.",name:"Nikesh",middleName:null,surname:"Bajaj",fullName:"Nikesh Bajaj",slug:"nikesh-bajaj"}]},{id:"74490",type:"chapter",title:"Ultra-High Performance and Low-Cost Architecture of Discrete Wavelet Transforms",slug:"ultra-high-performance-and-low-cost-architecture-of-discrete-wavelet-transforms",totalDownloads:421,totalCrossrefCites:0,signatures:"Mouhamad Chehaitly, Mohamed Tabaa, Fabrice Monteiro, Safa Saadaoui and Abbas Dandache",reviewType:"peer-reviewed",authors:[{id:"323340",title:"Dr.",name:"Mohamed",middleName:null,surname:"Tabaa",fullName:"Mohamed Tabaa",slug:"mohamed-tabaa"},{id:"323344",title:"Dr.",name:"Safa",middleName:null,surname:"Saadaoui",fullName:"Safa Saadaoui",slug:"safa-saadaoui"},{id:"323345",title:"Dr.",name:"Mouhamad",middleName:null,surname:"Chehaitly",fullName:"Mouhamad Chehaitly",slug:"mouhamad-chehaitly"},{id:"344628",title:"Dr.",name:"Fabrice",middleName:null,surname:"Monteiro",fullName:"Fabrice Monteiro",slug:"fabrice-monteiro"},{id:"344629",title:"Dr.",name:"Abbas",middleName:null,surname:"Dandache",fullName:"Abbas Dandache",slug:"abbas-dandache"}]},{id:"74031",type:"chapter",title:"Fault Detection, Diagnosis, and Isolation Strategy in Li-Ion Battery Management Systems of HEVs Using 1-D Wavelet Signal Analysis",slug:"fault-detection-diagnosis-and-isolation-strategy-in-li-ion-battery-management-systems-of-hevs-using-",totalDownloads:440,totalCrossrefCites:0,signatures:"Nicolae Tudoroiu, Mohammed Zaheeruddin, Roxana-Elena Tudoroiu and Sorin Mihai Radu",reviewType:"peer-reviewed",authors:[{id:"239295",title:"Dr.Ing.",name:"Nicolae",middleName:null,surname:"Tudoroiu",fullName:"Nicolae Tudoroiu",slug:"nicolae-tudoroiu"},{id:"239611",title:"Dr.",name:"Sorin-Mihai",middleName:null,surname:"Radu",fullName:"Sorin-Mihai Radu",slug:"sorin-mihai-radu"},{id:"243050",title:"Dr.",name:"Mohamed",middleName:null,surname:"Zaheeruddin",fullName:"Mohamed Zaheeruddin",slug:"mohamed-zaheeruddin"},{id:"326060",title:"Dr.",name:"Roxana-Elena",middleName:null,surname:"Tudoroiu",fullName:"Roxana-Elena Tudoroiu",slug:"roxana-elena-tudoroiu"}]},{id:"73918",type:"chapter",title:"Industrial IoT Using Wavelet Transform",slug:"industrial-iot-using-wavelet-transform",totalDownloads:328,totalCrossrefCites:0,signatures:"Mohamed Tabaa, Safa Saadaoui, Mouhamad Chehaitly, Aamre Khalil, Fabrice Monteiro and Abbas Dandache",reviewType:"peer-reviewed",authors:[{id:"323340",title:"Dr.",name:"Mohamed",middleName:null,surname:"Tabaa",fullName:"Mohamed Tabaa",slug:"mohamed-tabaa"},{id:"323344",title:"Dr.",name:"Safa",middleName:null,surname:"Saadaoui",fullName:"Safa Saadaoui",slug:"safa-saadaoui"},{id:"323345",title:"Dr.",name:"Mouhamad",middleName:null,surname:"Chehaitly",fullName:"Mouhamad Chehaitly",slug:"mouhamad-chehaitly"},{id:"323346",title:"Dr.",name:"Aamre",middleName:null,surname:"Khalil",fullName:"Aamre Khalil",slug:"aamre-khalil"},{id:"323347",title:"Prof.",name:"Fabrice",middleName:null,surname:"Monteiro",fullName:"Fabrice Monteiro",slug:"fabrice-monteiro"},{id:"323348",title:"Prof.",name:"Abbas",middleName:null,surname:"Dandache",fullName:"Abbas Dandache",slug:"abbas-dandache"}]},{id:"74597",type:"chapter",title:"Wavelet Transform for Signal Processing in Internet-of-Things (IoT)",slug:"wavelet-transform-for-signal-processing-in-internet-of-things-iot-",totalDownloads:348,totalCrossrefCites:1,signatures:"Indrakshi Dey and Shama Siddiqui",reviewType:"peer-reviewed",authors:[{id:"321151",title:"Dr.",name:"Indrakshi",middleName:null,surname:"Dey",fullName:"Indrakshi Dey",slug:"indrakshi-dey"}]},{id:"74434",type:"chapter",title:"The Discrete Quincunx Wavelet Packet Transform",slug:"the-discrete-quincunx-wavelet-packet-transform",totalDownloads:448,totalCrossrefCites:0,signatures:"Abdesselam Bassou",reviewType:"peer-reviewed",authors:[{id:"325295",title:"Prof.",name:"Abdesselam",middleName:null,surname:"Bassou",fullName:"Abdesselam Bassou",slug:"abdesselam-bassou"}]},{id:"74347",type:"chapter",title:"Uncertainty and the Oracle of Market Returns: Evidence from Wavelet Coherence Analysis",slug:"uncertainty-and-the-oracle-of-market-returns-evidence-from-wavelet-coherence-analysis",totalDownloads:332,totalCrossrefCites:0,signatures:"Joan Nix and Bruce D. McNevin",reviewType:"peer-reviewed",authors:[{id:"225668",title:"Ph.D.",name:"Joan",middleName:null,surname:"Nix",fullName:"Joan Nix",slug:"joan-nix"},{id:"323479",title:"Dr.",name:"Bruce",middleName:null,surname:"McNevin",fullName:"Bruce McNevin",slug:"bruce-mcnevin"}]},{id:"75021",type:"chapter",title:"Case Study: Coefficient Training in Paley-Wiener Space, FFT, and Wavelet Theory",slug:"case-study-coefficient-training-in-paley-wiener-space-fft-and-wavelet-theory",totalDownloads:334,totalCrossrefCites:0,signatures:"Kayupe Kikodio Patrick",reviewType:"peer-reviewed",authors:[{id:"325290",title:"Dr.",name:"Kayupe Kikodio",middleName:null,surname:"Patrick",fullName:"Kayupe Kikodio Patrick",slug:"kayupe-kikodio-patrick"}]},{id:"74258",type:"chapter",title:"Wavelet Filter Banks Using Allpass Filters",slug:"wavelet-filter-banks-using-allpass-filters",totalDownloads:336,totalCrossrefCites:0,signatures:"Xi Zhang",reviewType:"peer-reviewed",authors:[{id:"323093",title:"Prof.",name:"Xi",middleName:null,surname:"Zhang",fullName:"Xi Zhang",slug:"xi-zhang"}]},{id:"73875",type:"chapter",title:"A Wavelet Threshold Function for Treatment of Partial Discharge Measurements",slug:"a-wavelet-threshold-function-for-treatment-of-partial-discharge-measurements",totalDownloads:373,totalCrossrefCites:0,signatures:"Caio F.F.C. Cunha, Mariane R. Petraglia, André T. Carvalho and Antonio C.S. Lima",reviewType:"peer-reviewed",authors:[{id:"1553",title:"Prof.",name:"Mariane",middleName:null,surname:"Petraglia",fullName:"Mariane Petraglia",slug:"mariane-petraglia"},{id:"272211",title:"Dr.",name:"Caio Fleming",middleName:"Ferreira De Carvalho",surname:"Cunha",fullName:"Caio Fleming Cunha",slug:"caio-fleming-cunha"},{id:"324697",title:"Dr.",name:"André",middleName:null,surname:"Carvalho",fullName:"André Carvalho",slug:"andre-carvalho"},{id:"324699",title:"Prof.",name:"Antonio Carlos",middleName:"Siqueira",surname:"S. Lima",fullName:"Antonio Carlos S. Lima",slug:"antonio-carlos-s.-lima"}]},{id:"73428",type:"chapter",title:"Use of Daubechies Wavelets in the Representation of Analytical Functions",slug:"use-of-daubechies-wavelets-in-the-representation-of-analytical-functions",totalDownloads:378,totalCrossrefCites:0,signatures:"Paulo César Linhares da Silva",reviewType:"peer-reviewed",authors:[{id:"329037",title:"Prof.",name:"Paulo",middleName:null,surname:"Silva",fullName:"Paulo Silva",slug:"paulo-silva"}]},{id:"74037",type:"chapter",title:"Higher Order Haar Wavelet Method for Solving Differential Equations",slug:"higher-order-haar-wavelet-method-for-solving-differential-equations",totalDownloads:408,totalCrossrefCites:0,signatures:"Jüri Majak, Mart Ratas, Kristo Karjust and Boris Shvartsman",reviewType:"peer-reviewed",authors:[{id:"323886",title:"Prof.",name:"Jüri",middleName:null,surname:"Majak",fullName:"Jüri Majak",slug:"juri-majak"},{id:"329594",title:"Mr.",name:"Mart",middleName:null,surname:"Ratas",fullName:"Mart Ratas",slug:"mart-ratas"},{id:"329595",title:"Prof.",name:"Kristo",middleName:null,surname:"Karjust",fullName:"Kristo Karjust",slug:"kristo-karjust"},{id:"329596",title:"Prof.",name:"Boris",middleName:null,surname:"Shvartsman",fullName:"Boris Shvartsman",slug:"boris-shvartsman"}]},{id:"74536",type:"chapter",title:"COVID-19 Outbreak and Co-Movement of Global Markets: Insight from Dynamic Wavelet Correlation Analysis",slug:"covid-19-outbreak-and-co-movement-of-global-markets-insight-from-dynamic-wavelet-correlation-analysi",totalDownloads:391,totalCrossrefCites:1,signatures:"Maurice Omane-Adjepong, Imhotep Paul Alagidede and John Bosco Dramani",reviewType:"peer-reviewed",authors:[{id:"324897",title:"Ph.D. Student",name:"Maurice",middleName:null,surname:"Omane-Adjepong",fullName:"Maurice Omane-Adjepong",slug:"maurice-omane-adjepong"},{id:"327959",title:"Prof.",name:"Imhotep",middleName:null,surname:"Paul Alagidede",fullName:"Imhotep Paul Alagidede",slug:"imhotep-paul-alagidede"},{id:"335781",title:"Dr.",name:"John",middleName:null,surname:"Dramani Bosco",fullName:"John Dramani Bosco",slug:"john-dramani-bosco"}]}]},relatedBooks:[{type:"book",id:"8383",title:"Multiplexing",subtitle:null,isOpenForSubmission:!1,hash:"57b7f473289c825517f17b8e18d893fc",slug:"multiplexing",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/8383.jpg",editedByType:"Edited by",editors:[{id:"109280",title:"Dr.",name:"Somayeh",surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"67242",title:"Introductory Chapter: Multiplexing History - How It Applies to Current Technologies",slug:"introductory-chapter-multiplexing-history-how-it-applies-to-current-technologies",signatures:"Somayeh Mohammady and Pooria Varahram",authors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",fullName:"Somayeh Mohammady",slug:"somayeh-mohammady"}]},{id:"67713",title:"Multiplexing",slug:"multiplexing",signatures:"Vijayakumar Nandalal and M.S. Sumalatha",authors:[{id:"285973",title:"Dr.",name:"Nandalal",middleName:null,surname:"Vijayakumar",fullName:"Nandalal Vijayakumar",slug:"nandalal-vijayakumar"},{id:"297986",title:"Mrs.",name:"Sumalatha",middleName:null,surname:"M S",fullName:"Sumalatha M S",slug:"sumalatha-m-s"}]},{id:"66562",title:"Overview of Multiplexing Techniques in Wireless Networks",slug:"overview-of-multiplexing-techniques-in-wireless-networks",signatures:"Pedram Kheirkhah Sangdeh and Huacheng Zeng",authors:[{id:"286202",title:"Dr.",name:"Huacheng",middleName:null,surname:"Zeng",fullName:"Huacheng Zeng",slug:"huacheng-zeng"},{id:"286204",title:"Mr.",name:"Pedram",middleName:null,surname:"Kheirkhah Sangdeh",fullName:"Pedram Kheirkhah Sangdeh",slug:"pedram-kheirkhah-sangdeh"}]},{id:"66803",title:"Coherent Receiver for Turbo Coded Single-User Massive MIMO-OFDM with Retransmissions",slug:"coherent-receiver-for-turbo-coded-single-user-massive-mimo-ofdm-with-retransmissions",signatures:"K. Vasudevan, Shivani Singh and A. Phani Kumar Reddy",authors:[{id:"284388",title:"Prof.",name:"Kasturi",middleName:null,surname:"Vasudevan",fullName:"Kasturi Vasudevan",slug:"kasturi-vasudevan"},{id:"284392",title:"Ms.",name:"Shivani",middleName:null,surname:"Singh",fullName:"Shivani Singh",slug:"shivani-singh"},{id:"284393",title:"Mr.",name:"A. Phani Kumar",middleName:null,surname:"Reddy",fullName:"A. Phani Kumar Reddy",slug:"a.-phani-kumar-reddy"}]},{id:"66776",title:"Direct Sequence-Optical Code-Division Multiple Access (DS-OCDMA): Receiver Structures for Performance Improvement",slug:"direct-sequence-optical-code-division-multiple-access-ds-ocdma-receiver-structures-for-performance-i",signatures:"Younes Zouine and Zhour Madini",authors:[{id:"289842",title:"Prof.",name:"Younes",middleName:null,surname:"Zouine",fullName:"Younes Zouine",slug:"younes-zouine"},{id:"289844",title:"Prof.",name:"Zhour",middleName:null,surname:"Madini",fullName:"Zhour Madini",slug:"zhour-madini"}]},{id:"68586",title:"Optically Multiplexed Systems: Wavelength Division Multiplexing",slug:"optically-multiplexed-systems-wavelength-division-multiplexing",signatures:"Meena Dasan, Fredy Francis, Kundil T. Sarath, Elambilayi Dipin and Talabattula Srinivas",authors:[{id:"292618",title:"Dr.",name:"Meena",middleName:null,surname:"Dasan",fullName:"Meena Dasan",slug:"meena-dasan"},{id:"292620",title:"Mr.",name:"Fredy",middleName:null,surname:"Francis",fullName:"Fredy Francis",slug:"fredy-francis"},{id:"292622",title:"Mr.",name:"Sarath",middleName:null,surname:"K T",fullName:"Sarath K T",slug:"sarath-k-t"},{id:"292623",title:"Mr.",name:"Dipin",middleName:null,surname:"E",fullName:"Dipin E",slug:"dipin-e"},{id:"292624",title:"Dr.",name:"Srinivas",middleName:null,surname:"T",fullName:"Srinivas T",slug:"srinivas-t"}]}]}],publishedBooks:[{type:"book",id:"5411",title:"Fourier Transforms",subtitle:"High-tech Application and Current Trends",isOpenForSubmission:!1,hash:"5c45d1a91daef66093a42a82448a70f0",slug:"fourier-transforms-high-tech-application-and-current-trends",bookSignature:"Goran S. Nikolic, Milorad D. Cakic and Dragan J. Cvetkovic",coverURL:"https://cdn.intechopen.com/books/images_new/5411.jpg",editedByType:"Edited by",editors:[{id:"23261",title:"Prof.",name:"Goran",surname:"Nikolic",slug:"goran-nikolic",fullName:"Goran Nikolic"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editedByType:"Edited by",editors:[{id:"109280",title:"Dr.",name:"Somayeh",surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6444",title:"New Insights into Bayesian Inference",subtitle:null,isOpenForSubmission:!1,hash:"8a6c48ec7bdf923a126816fdbbb24274",slug:"new-insights-into-bayesian-inference",bookSignature:"Mohammad Saber Fallah Nezhad",coverURL:"https://cdn.intechopen.com/books/images_new/6444.jpg",editedByType:"Edited by",editors:[{id:"150393",title:"Dr.",name:"Mohammad Saber Fallah",surname:"Nezhad",slug:"mohammad-saber-fallah-nezhad",fullName:"Mohammad Saber Fallah Nezhad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7653",title:"Wavelet Transform and Complexity",subtitle:null,isOpenForSubmission:!1,hash:"74bd7559ad44e50940d35974905e98ee",slug:"wavelet-transform-and-complexity",bookSignature:"Dumitru Baleanu",coverURL:"https://cdn.intechopen.com/books/images_new/7653.jpg",editedByType:"Edited by",editors:[{id:"105623",title:"Dr.",name:"Dumitru",surname:"Baleanu",slug:"dumitru-baleanu",fullName:"Dumitru Baleanu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8181",title:"Applied Mathematics",subtitle:null,isOpenForSubmission:!1,hash:"85b873324d4e1af230fea39738ba9be5",slug:"applied-mathematics",bookSignature:"Bruno Carpentieri",coverURL:"https://cdn.intechopen.com/books/images_new/8181.jpg",editedByType:"Edited by",editors:[{id:"92921",title:"Dr.",name:"Bruno",surname:"Carpentieri",slug:"bruno-carpentieri",fullName:"Bruno Carpentieri"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],publishedBooksByAuthor:[{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editedByType:"Edited by",editors:[{id:"109280",title:"Dr.",name:"Somayeh",surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},onlineFirst:{chapter:{type:"chapter",id:"64592",title:"Biological Therapies that Target Inflammatory Cytokines to Treat Uveitis",doi:"10.5772/intechopen.82252",slug:"biological-therapies-that-target-inflammatory-cytokines-to-treat-uveitis",body:'
1. Introduction
Uveitis is the third leading cause of blindness in western countries and fourth worldwide [1, 2]. The ocular inflammation associated with uveitis can occur in every tissue within the eye so is frequently described according to the anatomical location of the inflammation [3, 4]. Anterior uveitis includes inflammation of the iris, ciliary body, and anterior chamber. Intermediate uveitis involves the vitreous and pars plana, while posterior uveitis describes inflammation of the retina and choroid [5, 6]. Sometimes, both anterior or intermediate and posterior uveitides can occur, which is referred to as panuveitis [5, 6]. Uveitis can be due to infectious or noninfectious causes; the latter is thought to be immune mediated and is commonly referred to as autoimmune uveitis (AU) [7, 8]. Both infectious and noninfectious uveitides lead to damaging inflammation, and undertreatment leads to destruction of ocular tissue which can result in vision loss [9, 10]. So, the goal of treatment is to suppress the ocular inflammation to preserve vision [7]. Generally, uveitis of infectious origin is treated with systemic and/or local antibiotics, antivirals, or antifungals, and inflammation usually resolves once the pathogen is eliminated [7]. Because noninfectious uveitis is immune-mediated, suppression of the immune system is necessary [7, 11].
The current treatment paradigm for noninfectious uveitis is to treat with medications that suppress the immune system to drive the inflammatory response into remission [2, 7]. Corticosteroids can be given locally and/or systemically to rapidly suppress inflammation, but they are not a long-term treatment option due to their side effects [7, 12, 13, 14]. When the steroids are discontinued, there is a risk of recurrent disease [15]. Localized slow-releasing steroid implants have been developed and have shown some efficacy, but these can result in cataract and glaucoma [14, 16]. As such, immunomodulating or immunosuppressants are used concomitantly to supplement or taper off the steroids in severe or chronic cases [7]. These immunosuppressive therapies, also called “steroid-sparing drugs,” include nonsteroidal anti-inflammatory drugs (NSAIDs); antimetabolites such as methotrexate, azathioprine, and mycophenolate; T-cell inhibitors such as tacrolimus; and cyclosporine and mTOR inhibitors such as rapamycin and derivatives of rapamycin [2, 7]. Also, DNA alkylating agents such as chlorambucil and cyclophosphamide can also be utilized. The steroid-sparing drugs have significantly improved the outcome of uveitis and provide additional more targeted treatment options [17]. However, as with steroids, these drugs may produce significant side effects, including an increased susceptibility to infection, and many still fail to provide lasting remission [2, 18]. It is conceivable that a targeted therapy that only suppresses one or two inflammatory pathways may offer a more favorable side effect profile than standard steroid-sparing agents [2]. Biologics are a relatively new class of medications that specifically target specific molecules involved in inflammation. The major hurdles to implement biological therapies include a large financial burden and questions about long-term efficacy. Therefore, in this report we discuss the outcomes of treating uveitis with biologics with a specific focus on inhibition of TNF-α, IL-1β, IL-6, and IL-17 inflammatory cytokines.
1.1 Biologics in uveitis
Progress in the field of ocular immunology has provided a basic understanding of the inflammatory mechanisms that contribute to the pathogenesis of noninfectious uveitis. This allows for a better understanding of the mechanism of action of many medications. Many of the current immunosuppressive therapies suppress inflammation via broad mechanisms of action. For example, mycophenolate inhibits expansion and survival of lymphocytes by limiting the transport of purines into the cell, thus preventing proliferation of T cells and B cells which are dependent on extracellular purines [19]. The disadvantage of this strategy is that differentiation of regulatory T cells (Tregs), a subset of T cells, that have been demonstrated to suppress autoimmune disease would also be inhibited [20, 21]. Rapamycin inhibition of mTOR is effective in suppressing rapidly dividing cells such as leukocytes, but the mTOR pathway is utilized by many cells in the body, so mTOR inhibitors are associated with a wide array of side effects [22]. Therefore, the effective treatment of autoimmune uveitis with a minimal side effect is dependent on the development of much more targeted treatments.
A better understanding of autoimmune diseases and specifically of ocular immunology now provides the possibility of specifically targeting important inflammatory pathways rather than broadly suppressing the immune response [14]. One such method to target specific inflammatory cytokines or receptors is with the use of biologics [2, 14, 23]. The biological agents, also called “biological response modifiers” or “biologics,” are a broad group of molecules that have been utilized to interfere and alter inflammation during immune-mediated processes [2]. These agents include recombinant cytokines, monoclonal antibodies that target cell surface proteins and receptors, specific antagonists of cytokines, and soluble receptors [14, 24]. These drugs function by specifically suppressing a single pathway through targeting of an effector molecule [14, 23]. As such, biological agents are being used as a treatment for refractory uveitis [25, 26]. Unfortunately, biologics are not always an option because of extremely high costs that limit approval for off-label use by insurance. The justification to insurance can be even more challenging because of the limited number of published reports documenting the effectiveness of biologics. As such, it is necessary to demonstrate that current biologics are effective in providing sustained remission. Therefore, the purpose of this review is to provide a summary of the literature of the outcomes and effectiveness of biologics that target the key inflammatory mediators especially TNF-α, IL-1β, IL-6, and IL-17. In addition, in order to provide a better understanding of the immunological function of these biologics, we will also provide a limited discussion of the immunological pathways that are targeted by TNF-α, IL-1β, IL-6, and IL-17.
1.2 Basic immunology of uveitis
Immune-mediated or autoimmune uveitis is a group of heterogeneous diseases that can be restricted to the eye, as in pars planitis or birdshot chorioretinopathy. The vast majority of uveitis patients experience localized inflammation. However, ocular inflammation can also be associated with systemic disease, such as in lupus, ankylosing spondylitis, and multiple sclerosis [27]. There are still many unknown aspects of the pathogenesis of autoimmune uveitis, but results from human and animal research supported potential mechanisms. One theory is the molecular mimicry model, in which the manifestation of autoimmune uveitis is thought to result from clearance of a pathogen with an antigen with a similar structure to a self-antigen in the eye [28, 29, 30]. However, the initiating antigens have not been isolated nor is it likely to be identified due to antigenic shift that occurs with chronic tissue inflammation [31]. In some cases, there is a genetic component, as evidenced with gene associations mapping to the HLA locus, such as HLA-B27, HLA-A29, and HLA-B51 [32, 33, 34]. HLA-B27 is associated with anterior uveitis, reactive/rheumatoid arthritis, and ankylosing spondylitis. HLA-A29 is associated with birdshot chorioretinopathy, and HLA-B51 is associated with Behcet’s disease [35, 36, 37]. Because there is not 100% penetrance with these HLA alleles, there is likely also an environmental trigger that is required as well. This demonstrates the heterogeneity associated with autoimmune uveitis and illustrates why a single therapy may not be effective for all uveitis patients. Thus, additional research is necessary to further our understanding of this disease.
Innate and adaptive immune cells are intricately connected during a normal immune response and aberrant responses as in autoimmune uveitis [30, 38]. The trigger of immune activation during uveitis is not well understood, but it is speculated that both environmental and genetic predispositions can initiate an inflammatory response that would eventually cause damage to the eye during uveitis [39, 40]. Innate immune cells such as monocytes, macrophages, and dendritic cells generally respond first to these inflammatory cues [41, 42]. These activated innate immune cells secrete proinflammatory cytokines such as TNF-α, IL-6, and IL-1β which serve as mediators of inflammation [34, 38, 43]. The role of innate immunity in the pathogenesis of uveitis is evident in both human and animal studies, where markers of inflammatory monocytes are more abundant in uveitis patients than their healthy controls [44]. Likewise, high levels of these inflammatory cytokines have been shown to be elevated in the ocular fluids of uveitis patients [45]. Also, animal models of uveitis which recapitulate the pathologies seen in human uveitis require adjuvants in the induction of the T-cell-mediated uveitis [46]. These required adjuvants activate the pattern recognition receptors (PRR) on innate immune cells that result in the production of these TNF-α, IL-1β, and IL-6 [34, 38]. As such, inhibition of TNF-α, IL-1β, and IL-6 is effective in reducing the ocular inflammation observed in numerous mouse models of uveitis [47, 48, 49]. Activated innate immune cells can act as antigen-presenting cells (APCs) and/or cytokine-secreting cells to provide signals that activate B and T cells [50]. In response to this activation, T cells differentiate into effector cells and largely produce inflammatory mediators such as cytokines that activate and recruit other immune cells that enhance ocular damage [34].
Several studies have highlighted the involvement of mediators and cellular responses that integrate both innate and adaptive immunities in the pathogenesis of uveitis [30, 41]. In this review, TNF-α, IL-17, IL-6, and IL-1β are the mediators of interest. While TNF-α, IL-6, and IL-1β are central mediators of inflammation that lead to activation of both innate and adaptive immunities, IL-17 is produced by a specific effector T cells (Th17 cells) that has a strong association with autoimmunity [51, 52]. Elevated levels of these cytokines are seen in the ocular fluids and plasma of uveitis patients [53, 54, 55].
Biological agents that specifically target these immune mediators or T-cell-activating molecules have gained wide recognition as effective therapy for immune-mediated diseases such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriasis, sarcoidosis, and organ rejection and are therefore being used for the treatment of uveitis [56]. Results from treatment of animal models and biological samples of uveitis patients with antagonists of the inflammatory mediators have demonstrated the involvement of these mediators with autoimmune uveitis [57, 58]. Currently, there are numerous clinical trials that are testing the efficacies of biological agents for the treatment of autoimmune uveitis.
2. TNF-α inhibitors
TNF-α inhibitors are biological agents that target tumor necrosis factor alpha (TNF-α) and its receptors. TNF-α was initially studied for its ability to stimulate necrosis of malignant tumors [59, 60]. An immunological role was later discovered as it is also an important inflammatory mediator [59, 60]. TNF-α is a proinflammatory cytokine that is secreted by many immune cells of the innate and adaptive arm of the immune response, including T cells, and macrophages, and nonimmune cells such as keratinocytes [60]. TNF-α binding to one of the two isoforms of its transmembrane receptor (TNFr1 and TNFr2) is the first step in triggering a response [59]. Binding of TNF ligand to its receptor activates downstream signals that lead to a cascade of cellular events that include cellular proliferation, differentiation, apoptosis, survival, and regulation of inflammatory cytokine production [60]. Because these events lead to activation of inflammatory cells, TNF-α is considered a master regulator of inflammation [60, 61]. TNF-α has been implicated in the pathogenesis of autoimmune uveitis and other immune-mediated diseases especially organ-specific diseases [62, 63, 64]. High levels of TNF-α have been reported in the aqueous humor and sera of uveitis patients compared to their healthy controls [65]. Also, elevated levels of this cytokine are observed in the animal models of autoimmune uveitis, and inhibition of TNF-α activity results in disease remission in these animal models [47, 66]. Involvement of TNF-α in many autoimmune diseases has made it a therapeutic target [60]. Currently, there are numerous biologics that target TNF-α activity; these include infliximab, etanercept, adalimumab, golimumab, and certolizumab [67]. Biologics that target TNF-α and its interaction with its receptors were developed and approved for the treatment of autoimmune diseases such as RA, psoriasis, sarcoidosis, inflammatory bowel disease, etc. [67]. The efficacy of TNF-α inhibitors in the treatment of these diseases has led to great interest in the use of these biological agents for the treatment of uveitis.
2.1 Etanercept
Etanercept is a recombinant fusion protein that contains the extracellular ligand-binding portion of the human TNF receptor (TNFr2) and the Fc portion of human IgG1 [68]. Because the structure of etanercept contains no membrane-bound portion, it is essentially a soluble TNF receptor that binds the free form of all TNF isoforms (TNF-α, TNF-β, and TNF-γ) [68]. Because the soluble form of TNF and membrane-bound TNF have opposing immunological effects, it is of note that etanercept does not bind to the membrane-bound form [69].
For two decades, etanercept has been used to treat rheumatic diseases, and it is FDA approved for the treatment of JIA, RA, ankylosing spondylitis (AS), psoriatic arthritis (PA), and plaque psoriasis (PP) [68, 70]. Effectiveness of etanercept in the treatment of these diseases led to interest in the use of this drug for uveitis. Etanercept has been reported to be a treatment for refractory uveitis in pediatric patients [71]. In the prospective study, beneficial effects of etanercept were observed in at least 63% of the patients after 3 months of treatment [71]. Another prospective study of the efficacy of etanercept in patients with JIA-associated uveitis showed 73% of the patients had an initial response after 3 months of treatment; however, only about half of the responders (39%) remained in remission after 1 year [72]. In addition, several prospective and retrospective studies of etanercept did not show treatment efficacy in uveitis associated with systemic diseases such as JIA [73], sarcoidosis [74], or chronic uveitis [75]. Some studies have shown an increased incidence of uveitis in patients treated with etanercept for ankylosing spondylitis [76, 77, 78]. In general, the efficacy of etanercept for uveitis is poor, and several studies have shown that other TNF inhibitors (adalimumab and infliximab) are more effective and preferred for the treatment of uveitis as discussed below [79, 80].
Administration and dosing: Enbrel (Immunex, Thousand Oaks, CA) is the brand name for etanercept, and it is typically administered subcutaneously at a dose of 50 mg every 1–2 weeks or 0.8 mg/kg weekly. It was first approved by the FDA in 1998 for the treatment of rheumatic diseases.
Adverse effects: Side effects of etanercept can include localized effects such as pain and swelling at the injection site [81]. There are reported cases of an increased risk of fungal infection and TB reactivation [78, 82]. Some reports have shown exacerbation of uveitis or development of uveitis concurrent with etanercept treatment [78, 82]. Other serious side effects include lupus-like disease due to autoantibodies generated against etanercept, exacerbation of the central and peripheral nervous system demyelinating disorders, hematologic, and cardiovascular side effects [81, 83, 84]. Please see full prescribing information for complete list.
Contraindications: Sepsis [85]. Tuberculosis reactivation or newly acquired tuberculosis has been reported to have an increased incidence in patients on TNF inhibitors [86, 87]; additional discussion is provided at the end of this section.
2.2 Adalimumab
Adalimumab was the first fully human IgG1 monoclonal antibody to be approved by the FDA. It was approved as an antibody against TNF-α following the development of infliximab and etanercept. Adalimumab inhibits TNF-α activity by directly binding TNF-α to prevent it from interacting with TNF receptors [88]. Adalimumab is FDA approved for the treatment of RA, inflammatory bowel disease, PA, JIA, and AS [89]. Several prospective and retrospective studies report the efficacy of adalimumab in the treatment of uveitis. In a prospective VISUAL I and VISUAL II study (2010 to 2015) of 217 and 226 adult patients with active and inactive uveitis, respectively, Sheppard et al. found significant improvement in clinical outcomes in patients treated with adalimumab compared to the placebo group [90]. Also, a prospective study from 2006 to 2011 showed that 17 out of 19 adult patients with refractory uveitis in Behcet’s disease achieved clinical improvement [91]. Similar results were observed in another prospective study with 72 adult patients conducted between 2006 and 2012 [92]. This study reported that adalimumab reduced the frequency of uveitis attacks in patients with AS by 72% [92]. Another prospective study with 31 refractory uveitis patients reported 68% of these patients showed resolution of ocular inflammation at 10 weeks of treatment and after 1 year 39% of these patients maintained remission [93]. Similarly, in a retrospective study, the efficacy and safety of adalimumab in Behcet’s disease-related uveitis were reported using records of 40 patients treated with adalimumab for up to 12 months [94]. The retrospective chart review showed remission was achieved in 95% of the patients [94]. The use of adalimumab in pediatric patients was reported in a prospective study with 18 young patients (2–19 years) with chronic anterior uveitis; 88% of the patients responded to the therapy [95]. Similar results were reported in another pediatric study including 90 children and adolescents; this study shows responsiveness to adalimumab and lower treatment failure compared to a placebo treatment [96].
In 2014, the executive committee of the American Uveitis Society recommended adalimumab as a first-line treatment for uveitis associated with Behcet’s disease when uncontrolled by standard immunomodulatory drugs [24]. Importantly, in 2016, adalimumab became the first and the only drug to be FDA approved for the treatment of intermediate, posterior, and panuveitis [97].
Administration and dosing: Adalimumab is sold under the brand name Humira (AbbVie Inc., North Chicago, IL), and Amjevita is a biosimilar (Amgen, Inc., Thousand Oaks, CA), but Amjevita is not available in the USA due to patent issues, and it is typically given subcutaneously every 1–2 weeks at a dose of 40–80 mg or 20 mg if the body weight is less than 30 kg.
Adverse effects: In some of the studies mentioned above, adalimumab treatment for uveitis was associated with some severe side effects. These serious side effects include sarcoidosis, anaphylaxis, optic neuritis, Guillain-Barre syndrome, multiple sclerosis, adenoma, and melanoma [83, 91, 98, 99, 100]. Please see full prescribing information for complete list.
Contraindications: None are listed with the FDA [101]. Tuberculosis reactivation or newly acquired tuberculosis has been reported to have an increased incidence in patients on TNF inhibitors [86, 87]; additional discussion is provided at the end of this section.
2.3 Infliximab
Infliximab is a chimeric IgG1 monoclonal antibody that contains the human constant region and murine variable regions, and it binds both membrane-bound and free TNF-α [102]. This drug was initially developed and approved by the FDA in 1998 for the treatment of inflammatory bowel disease; subsequently, this drug was approved for the treatment of RA and other rheumatoid diseases [103, 104]. Clinical trials to assess the efficacy of infliximab as a treatment for uveitis demonstrate that it is a potential treatment option. One prospective study reported a rapid response to infliximab in six adult patients that had uveitis associated with Behcet’s disease or sarcoidosis [105]. Similarly, in another prospective study, 9 out of 11 patients with refractory posterior uveitis showed improvement of disease following treatment with infliximab [106]. Efficacy of infliximab in pediatric patients with uveitis has been demonstrated in retrospective studies of JIA patients [107, 108]. All 17 patients in one study showed a rapid and well-tolerated response to infliximab [108]. Also, several studies have demonstrated the effectiveness of infliximab in localized uveitis as well as systemic autoimmune diseases associated with uveitis. One prospective study demonstrated effective suppression of uveitis in 18 out of 23 patients at 10 weeks of treatment initiation, and clinical success was achieved in all patients at week 50 [109].
Numerous clinical trials have compared the efficacy between adalimumab and infliximab in the treatment of noninfectious uveitis; most of these studies concluded that, overall, both anti-TNF-α agents showed equivalent efficacies. In one study, 160 patients with refractory uveitis were treated with either infliximab or adalimumab, 93% of the patients achieved remission after 12 months of treatment, and no significant difference in terms of occurrence of uveitis was seen between the two treatment groups [110]. Also, the expert panel from the American Uveitis Society recommends infliximab or adalimumab as the first-line treatment for uveitis in Behcet’s disease [24].
Administration and dosing: Infliximab is sold under the brand name Remicade (Janssen Biotech, Horsham, PA) and is typically given intravenously at a dose of 3–5 mg/kg at weeks 0, 2, 6, and subsequently every 8 weeks [24].
Adverse effects: The most notable side effect of infliximab in some patients was generation of autoantibody against the non-humanized component of the drug [111]. Other serious side effects include an increased risk of lymphoma, reactivation of TB, and an increased risk of fungal infections [82]. Infliximab may also contribute to the exacerbation of demyelinating diseases and is not preferred in patients with multiple sclerosis [112, 113]. Please see full prescribing information for complete list.
Contraindications: Heart failure has been reported with doses greater than 5 mg/kg. Severe hypersensitivity to Remicade or to inactive components of Remicade or to proteins of mouse origin has been reported [114]. Tuberculosis reactivation or newly acquired tuberculosis has been reported to have an increased incidence in patients on TNF inhibitors [86, 87]; additional discussion is provided at the end of this section.
2.4 Golimumab
Golimumab is a promising TNF-α inhibitor for the treatment of autoimmune uveitis. It is a fully humanized IgG1 monoclonal antibody that binds to both soluble and membrane-bound TNF-α. This antibody has greater TNF-α binding affinity than infliximab and adalimumab [115]. This drug was FDA approved for the treatment of ulcerative colitis, RA, PA, and AS in 2013 [116]. The success of other TNF-α inhibitors (adalimumab and infliximab) in the treatment of uveitis paved way for the use of golimumab in uveitis [117]. Retrospective and prospective studies of golimumab in uveitis showed promising results of its effectiveness in maintaining remission. Retrospective analysis of the efficacy of golimumab in patients with recurrent uveitis between 2013 and 2015 showed remission achieved in 12 eyes out of 15 after a median follow-up period of 11 months [118]. A prospective study of 15 patients with refractory uveitis related with spondyloarthritis demonstrated the effectiveness of golimumab in uveitis. The results from this study showed rapid improvement of intraocular inflammation in most of the patients with chronic or relapsing uveitis including patients that were refractory to other TNF-α inhibitors [119].
Administration and dosing: Golimumab is marketed under the brand name Simponi (Janssen Biotech, Horsham, PA) and is given subcutaneously at a dose of 50 mg once a month or 200 mg then 100 mg at week 2 and 100 mg every 4 weeks for UC. It can be given intravenously at a dose of 2 mg/kg at week 0 and 4 and then every 8 weeks.
Adverse effects: Golimumab as with other TNF-α inhibitors interferes with the inflammatory response, so the use of this drug is associated with side effects similar to those seen in other TNF-α, specifically increased risk of bacterial infections and reactivation of TB [120, 121, 122]. When golimumab is combined with antimetabolites such as azathioprine or 6-mercaptopurine, it can lead to an increased risk of malignancies [123]. Please see full prescribing information for complete list.
Contraindications: None are listed with the FDA [124]. Tuberculosis reactivation or newly acquired tuberculosis has been reported to have an increased incidence in patients on TNF inhibitors [86, 87]; additional discussion is provided at the end of this section.
2.5 Certolizumab
Certolizumab is a member of the TNF-α inhibitors that was developed and approved by the FDA for the treatment of Crohn’s disease and RA in 2008 and 2009, respectively [125]. Certolizumab pegol is a humanized antigen-binding fragment (Fab) of monoclonal antibody that targets TNF-α and lacks the Fc region. The Fab fragment is conjugated to polyethylene glycol to increase the half-life of certolizumab compared to other TNF inhibitors [2]. Interest in effectiveness of certolizumab in the treatment of uveitis occurred as an indirect consequence of treatment of systemic diseases associated with uveitis [126]. A retrospective study reported the effectiveness of certolizumab in uveitis, which highlighted the efficacy of certolizumab in five of seven patients with uveitis refractory to other anti-TNF-α agents [126]. Prospective studies are ongoing to test the efficacy of certolizumab in anterior uveitis (NCT03020992 clinicaltrials.gov).
Administration and dosing: Certolizumab is marketed under the trade name Cimzia (UCB, Brussels, Belgium). It is administered subcutaneously at a dose of 400 mg at weeks 0, 2, and 4 and then 200–400 mg every 4 weeks.
Adverse effects: Studies of the effectiveness of certolizumab in the treatment of autoimmune diseases including uveitis have recorded serious side effects that include new-onset uveitis [127, 128]. Others have observed worsening of arthritis symptoms following treatment with certolizumab. Other serious side effects include increase risk of infection, lupus-like syndrome, and cancer [129]. Please see full prescribing information for complete list.
Contraindications: Serious hypersensitivity reaction to certolizumab pegol or the inactive components has been reported [130]. Tuberculosis reactivation or newly acquired tuberculosis has been reported to have an increased incidence in patients on TNF inhibitors [86, 87]; additional discussion is provided at the end of this section.
TNF inhibitors suppress the signals that occur early in the inflammatory cascade and with the exception of etanercept have produced remarkable outcomes in uveitis. Currently, adalimumab and infliximab have been shown to be effective in the treatment of refractory uveitis especially in Behcet’s disease-related uveitis or JIA. However, only adalimumab is approved by the FDA for the treatment of uveitis. Because uveitis has occurred in patients being treated with etanercept for autoimmune disease, it is not recommended for the treatment of uveitis [127]. The reactivation of latent tuberculosis or newly acquired tuberculosis is not listed as a contraindication by the FDA, but there are multiple reports that the incidence of tuberculosis reactivation or newly acquired infection is greater in patients on TNF inhibitor therapy [86, 87]. As such, tuberculosis screening before initiation of TNF inhibitor therapy and routine screening for tuberculosis are highly recommended. Additional clinical outcome data from large population studies will be required to demonstrate the safety and efficacy of golimumab and certolizumab. The effectiveness and utilization of TNF-α inhibitors in the treatment of uveitis are limited by the huge cost of these drugs, limited outcome data on clinical use of TNF-α inhibitors in some disease-specific uveitis, and severe side effects in some cases.
3. IL-1 inhibitors
The biological agents classified as IL-1 inhibitors target and inhibit the proinflammatory cytokine, IL-1β, and its receptor, IL-1R. IL-1 is a strong proinflammatory cytokine that plays a role in both local and systemic immune responses and is also involved in tissue damage during chronic inflammation [131, 132]. IL-1 mediates its inflammatory response through IL-1α and IL-1β. The latter has been reported to be a critical mediator of autoimmunity when compared with IL-1α [133]. IL-1β is secreted by innate immune cells such as macrophages, neutrophils, dendritic cells, and vascular endothelial cells [55]. IL-1β signals through the IL-1 receptor (IL-1R) to produce its inflammatory effects such as differentiation and expansion of antigen-specific T cells, cell maturation, and induction of acute-phase reaction [134]. This cytokine signaling is known to play a role in autoimmune diseases as demonstrated clinically with significantly elevated levels of IL-1β in biological samples including tears of uveitis patients compared to healthy controls [135]. Also, high levels of this cytokine are implicated in some systemic autoimmune diseases including those associated with uveitis [131].
Studies have shown that loss of IL-1 signaling provides protection from uveitis in animal models of autoimmune uveitis [131]. Being a pleiotropic cytokine, IL-1 activity is tightly regulated by a naturally occurring antagonist of IL-1 receptor (IL-1RA) which specifically inhibits the activities of IL-1 cytokines through blockade of IL-1 receptor. Under physiologic conditions, balance exists between the specific receptor antagonist and IL-1. However, imbalance in the levels of IL-1 and/or IL-1 RA can increase the risk of developing immune-mediated diseases [136]. Also, exogenous administration of IL-1RA in animal models showed inhibition of IL-1 signaling events [136]. Biological agents such as recombinant IL-1R antagonist (anakinra) which mimics the activity of IL-RA have been developed and have shown great success in the reduction of autoimmune diseases [137, 138]. Other biological agents such as soluble decoy IL-1 receptor (rilonacept) and neutralizing monoclonal antibodies (canakinumab and gevokizumab) that have specific inhibition of IL-1 activity have also been utilized in the treatment of autoimmune diseases. Suppression of ocular inflammation may be achieved due to the efficacy of IL-1β inhibitors in the control of inflammation in systemic autoimmune diseases that are associated with uveitis. Additional discussion of these inhibitors is provided below.
3.1 Anakinra
Anakinra was first introduced in 1993 (Kineret, Amgen Inc., Thousand Oaks, California), and it is a recombinant non-glycosylated human IL-1RA. It was first approved for the treatment of RA and neonatal-onset multisystem inflammatory disease (NOMID) by the FDA in 2001 [139]. There is limited data on the use of anakinra in the treatment of uveitis; however, a few case studies have reported its effectiveness in uveitis. One study looked at its effect as a treatment for NOMID, which is associated with childhood uveitis; anakinra produced resolution of ocular symptoms in addition to the systemic disease improvement. In this case study, a 4-year-old with chronic infantile neurological cutaneous articular (CINCA) syndrome that is associated with uveitis, who had a poor response to TNF-α inhibitors, showed a significant sustained improvement with anakinra [140]. Another case series also demonstrated the effectiveness of anakinra in two patients with anterior uveitis due to exposure to etanercept or uveitis refractory to infliximab [141]. Also, a retrospective study of 19 patients with Behcet’s disease-related uveitis showed effective control of inflammation and improvement in ocular symptoms after 12 months of treatment with anakinra [142].
Administration and dosing: Anakinra is sold under the brand name Kineret (Swedish Orphan Biovitrum Stockholm, Sweden) and is given subcutaneously at a dose of 100 mg daily or up to 8 mg/kg a day.
Adverse effects: Anakinra is associated with side effect that ranges from a local reaction at the injection site to more severe side effects such as hepatitis, neutropenia, and increase risk of infection [143, 144, 145]. Another side effect that could occur is the generation of autoantibodies against anakinra [146]. Please see full prescribing information for complete list.
Contraindications: Serious hypersensitivity reaction to E. coli-derived proteins, Kineret, or the inactive components [147].
3.2 Canakinumab
Canakinumab is a human monoclonal antibody against IL-1β that was first approved by the FDA in 2009 for the treatment of cryopyrin-associated periodic syndromes (CAPS), and, subsequently, it was approved for the treatment of SJIA and JIA in 2013 [148, 149]. Canakinumab inhibits IL-1β by directly binding and neutralizing IL-1β signaling. The long-term effectiveness of canakinumab as a treatment for uveitis has not been studied. However, several case studies show canakinumab as a potential therapeutic for refractory uveitis. Successful resolution of inflammation with canakinumab treatment was seen in a case report of a 64-year-old patient with CAPS-associated uveitis [150]. Another case series by Brambilla et al. (2016) showed successful treatment of refractory uveitis with canakinumab in two children. The first patient in this study was a 9-year-old with recurrent uveitis associated with JIA intolerant to TNF-α inhibitors and refractory to other immune modulatory drugs. Clinical improvement was achieved within 12 months of initiating canakinumab [25]. The second patient, a 6-year-old boy with bilateral uveitis refractory to TNF-α inhibitors, showed a faster responsiveness with remarkable improvement to canakinumab within 2 months of treatment [25]. Another case study of a 16-year-old with severe Behcet’s disease associated refractory panuveitis, responded to a single dose of canakinumab with remission of uveitis for at least 8 weeks [151]. Overall, the case series provides evidence of the effectiveness of canakinumab for the treatment of uveitis. In addition, a retrospective study of 19 patients with BD-related uveitis showed an improvement of ocular symptoms after 12 months of treatment with canakinumab [142].
Additional prospective and retrospective studies in large patient groups are needed to validate the effects of canakinumab in uveitis.
Administration and dosing: Canakinumab is marketed as Ilaris (Novartis, East Hanover, NJ) and given at a dose of 150–300 mg subcutaneously every 4 weeks or 2–4 mg/kg every 4 weeks.
Adverse effects: Side effects of this drug include an increased risk of infection [152, 153]. Please see full prescribing information for complete list.
Contraindications: Serious hypersensitivity to Ilaris or the inactive components [154].
3.3 Gevokizumab
Gevokizumab is a humanized recombinant IgG2 monoclonal antibody with high affinity for IL-1β. Its ability to bind strongly to IL-1β prompted interest in its use as a biological agent for autoimmune uveitis. A prospective study of eight patients with anterior scleritis showed improvement in symptoms in seven of the patients following treatment with 60 mg SC of gevokizumab every 4 weeks for 12 weeks and continued to show improvement for 36 more weeks [155].
Gul et al. conducted a prospective study to test the efficacy of gevokizumab in patients with acute exacerbation of resistant uveitis in Behcet’s disease. Seven adult patients were given a single intravenous gevokizumab infusion at a dose of 0.3 mg/kg. All patients experienced a rapid clinical response and resolution of intraocular inflammation within a median duration of 14 days [156]. Gul et al. also conducted another prospective study to test the efficacy and safety of gevokizumab in 21 patients with Behcet’s disease-related uveitis; 3 patients were withdrawn from the study due to exacerbation of uveitis, but 14 patients showed responsiveness within 21 days [157]. These studies provide evidence of the effectiveness of gevokizumab in uveitis, especially the Behcet’s-related uveitis. However, the EYEGUARD clinical trials did not show efficacy of gevokizumab in the treatment of uveitis [158]. In the EYEGUARD study, 83 patients with Behcet’s disease-related uveitis were recruited into the study. Study groups were given 60 mg of gevokizumab every 4 weeks subcutaneously and were well tolerated. However, the results from this study did not show any treatment efficacy of gevokizumab compared to the placebo group [158]. The conflicting results from these two studies may be due to the route of administration with intravenous infusion being superior to subcutaneous administration. As such, further studies on the dosage, long-term efficacy, and safety of gevokizumab for uveitis treatment are necessary.
Administration and dosing: XOMA 052 (XOMA Corporation, Berkeley, CA, USA) is the brand name of gevokizumab. It has not been FDA approved but in trials has been administered at a dose of 60 mg IV or SC every 4 weeks.
Adverse effects: Gevokizumab is generally tolerated; however, it can result in mild side effects that include injection site reaction, neutropenia, and hypoglycemia [155, 159]. Please see full prescribing information for complete list.
Contraindications: None are listed with the FDA because it is not yet FDA approved.
3.4 Rilonacept
Rilonacept is a fully humanized IL-1 fusion protein, and it consists of the ligand-binding domain of the extracellular component of the IL-1 receptor and IL-1 receptor accessory protein. Rilonacept binds to IL-1β to prevent it from interacting with IL-1 receptor, thus preventing IL-1 signaling. This drug is FDA approved for the treatment of autoinflammatory diseases such as familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS) [160]. However, there are no clinical data on the use of rilonacept in uveitis, but it is currently being evaluated as a treatment for uveitis [161].
Administration and dosing: Rilonacept is marketed as Arcalyst by Regeneron Pharmaceuticals, Tarrytown, New York. It is given subcutaneously at a dose of two 160 mg injections at week 0 and then 160 mg/week.
Adverse effects: Local and/or hypersensitivity reaction [162, 163]. Other side effects reported include gastrointestinal bleeding and an increased risk for Streptococcus pneumoniae meningitis [160]. Please see full prescribing information for complete list.
Some autoimmune diseases such as rheumatic diseases respond to IL-1β inhibitors. However, the effects of these biologics in uveitis are not conclusive. Some IL-1β inhibitors such as anakinra have demonstrated efficacy in Behcet’s disease-related uveitis and autoinflammatory diseases such as NOMID that could be associated with uveitis [139]. Additional large clinical studies are required to evaluate the efficacy of IL-1β as a therapy for autoimmune uveitis.
Contraindications: None listed with the FDA [164].
4. IL-6 inhibitors
IL-6 is a powerful proinflammatory cytokine that is secreted by both innate and adaptive immune cells (B and T cells). Due to its pleiotropic effects including T-cell activation, IL-6 is implicated in many T-cell-mediated diseases [7]. Biological agents that inhibit IL-6 have been used as a treatment for autoimmune diseases such as RA and JIA. In spite of the proinflammatory effects, it has a role in tumor survival, so blockage of IL-6 is also effective as a cancer treatment, particularly large-cell lung cancer and ovarian cancer [165].
4.1 Tocilizumab
Tocilizumab is a fully humanized monoclonal antibody against both soluble and membrane-bound IL-6 receptors. It is currently FDA approved for the treatment of SJIA and RA, and it has profoundly improved disease outcomes [166]. A study by Tappeiner et al. has reported that two out of three patients with JIA-related uveitis responded to tocilizumab that was refractory to anti-TNF-α therapy [167]. Furthermore, a retrospective study that analyzed disease outcomes in five patients with refractory uveitis showed sustained remission after a mean follow-up period of 8.4 months [168]. A similar outcome was observed in another study testing the efficacy of tocilizumab to treat refractory uveitis with 10 out of 17 patients responding to IL-6 blockade [169]. A prospective STOP-UVEITIS study to test the safety, tolerability, and efficacy of tocilizumab in 37 patients with noninfectious uveitis was conducted by Quan et al. (2017); the result of this study shows tolerance at 6 months of drug initiation [170]. These studies and several case studies have reported that tocilizumab may be effective in the treatment of refractory uveitis [171, 172]. Also, Ruiz-Medrano et al. compiled data on the use of tocilizumab in the treatment of ocular conditions between 2011 and 2017. They found that tocilizumab is effective in the treatment of variety of ocular inflammatory conditions including refractory uveitis [173].
Administration and dosing: Tocilizumab (Actemra, Genentech, South San Francisco, CA, USA) is typically administered at a dose of 4–12 mg/kg every 2–4 weeks when given intravenously and 162 every 1–2 weeks when given subcutaneously.
Adverse effects: Side effects from Actemra include neutropenia with increased risk of fungal and bacterial infections and opportunistic infections [174]. Other side effects include hypersensitivity, increased risk of gastric perforation, and malignancies [175, 176, 177]. Please see full prescribing information for complete list.
Contraindications: Hypersensitivity to Actemra [178]. Tuberculosis reactivation has been reported in patients undergoing IL-6 inhibitor therapy [179], so patients should be initially tested for latent tuberculosis and should be routinely monitored for newly acquired tuberculosis.
4.2 Sarilumab
Sarilumab is another IL-6 receptor inhibitor, it is a fully humanized monoclonal antibody against the alpha subunit of the IL-6 receptor, and in 2017 it was FDA approved as a treatment for RA [180]. Sarilumab has shown some potential as an effective therapy for autoimmune uveitis in a prospective SATURN study [181]. In this randomized study, 57 patients with posterior uveitis on steroids with or without methotrexate were treated with 200 mg of sarilumab or placebo every 2 weeks. About 64% of the patients on sarilumab showed clinical improvement and steroid-sparing effects at 16 weeks after treatment initiation [181].
Administration and dosing: Sarilumab is marketed as Kevzara (Regeneron/Sanofi Tarrytown, NY, USA), and in the treatment of RA, sarilumab is typically given at 200 mg SC every 2 weeks.
Adverse effects: Increased risk of GI perforation and hepatitis [182]. Please see full prescribing information for complete list.
Contraindications: Hypersensitivity to Kevzara or the inactive ingredients [183]. Tuberculosis reactivation has been reported in patients undergoing IL-6 inhibitor therapy [179], so patients should be initially tested for latent tuberculosis and should be routinely monitored for newly acquired tuberculosis.
Other IL-6 inhibitors: Olokizumab (UCB, Brussels, Belgium) and clazakizumab (Alder Biopharma, Bothell, WA, USA) are currently being evaluated in clinical trials for the treatment of autoimmune diseases (which can be associated with uveitis) such as RA. Siltuximab (Janssen, Horsham, PA, USA) has been FDA approved for the treatment of Castleman’s disease [184, 185, 186, 187]. However, there are little or no data regarding the efficacy of these drugs in uveitis. See Table 1 for additional information regarding these drugs.
Table 1.
List of biologics discussed in sections 3–6.
5. IL-17 inhibitors
IL-17 is a proinflammatory cytokine produced by Th17 cells, a subset of inflammatory T cells, involved in an inflammatory response to self and certain extracellular bacteria and fungi. While IL-17 can be produced by other cells, it is the characteristic cytokine produced by Th17 cells. IL-17 is involved in the recruitment and activation of neutrophils [188, 189]. Animal and human studies have elucidated the critical role of IL-17 in the pathogenesis of autoimmune diseases including uveitis [190, 191]. Inhibitors of IL-17 have produced remarkable improvement in the outcome of autoimmune diseases especially rheumatoid diseases [192]. IL-17 inhibitors such as secukinumab (AIN457), ixekizumab (Taltz), and brodalumab (AMG 827) are FDA approved for the treatment of severe psoriasis [193]. Knowledge of the efficacies of these biological agents in autoimmune diseases provides the potential for use in uveitis, especially uveitis that is refractory to conventional drugs and other biologics. Blockade of IL-17 in animal models of autoimmune uveitis has produced significant improvement in uveitis symptoms [194].
5.1 Secukinumab
Secukinumab is a fully humanized monoclonal antibody that neutralizes IL-17A. It is FDA approved for treatment of moderate to severe plaque psoriasis [195]. Hueber et al. tested the efficacy of AIN457 in a prospective study with 104 uveitis patients, RA or psoriasis. About 50% of the uveitis patients showed a rapid response within 2 weeks and by 8 weeks of drug initiation; 13 out of 16 patients responded to AIN457 [196]. In a prospective study of 118 patients with Behcet’s disease (SHIELD study), the rate of recurrent ocular exacerbation of uveitis did not differ between the patients that received secukinumab or placebo. The study concluded that secukinumab did not demonstrate efficacy in the treatment of uveitis. Similar outcomes were concluded from the INSURE and ENDURE studies in which altering the dosing schedule of secukinumab did not improve the efficacy of secukinumab in uveitis patients [197, 198]. The outcome of these studies may have differed from the initial report by Hueber et al. because the differences were noted in the patient disease profile, concomitant immunosuppressive therapies, and route of administration [197]. One prospective study demonstrated that intravenous secukinumab (10 mg/kg or 30 mg/kg) had better efficacy than subcutaneous secukinumab (300 mg). Therefore, these studies demonstrate that patients responded better to secukinumab when it was administered IV [198].
Administration and dosing: Secukinumab was initially named AIN 457 and has been renamed Cosentyx (Novartis). It is given subcutaneously for plaque psoriasis at a dose of 150–300 mg weekly for 4 weeks and then every 4 weeks. However, it has been suggested that it is more effective given IV at 30 mg/kg for the treatment of noninfectious uveitis [198].
Adverse effects: Cosentyx is associated with an increased risk of infection, hypersensitivity reaction, and inflammatory bowel disease [199, 200]. Please see full prescribing information for complete list.
Contraindications: Hypersensitivity to Cosentyx or any of the inactive ingredients [201]. Tuberculosis reactivation is listed as a warning by the FDA, but it has been reported in a multicenter retrospective study by Novartis [202] and in a review of the literature [203] that there is no increased risk of tuberculosis reactivation.
Other IL-17 inhibitors: Additional biologics that target the IL-17 pathway include ixekizumab and brodalumab. Ixekizumab targets IL-17A and is FDA approved to treat plaque psoriasis and psoriatic arthritis. Brodalumab targets the IL-17 receptor and is FDA approved for the treatment of plaque psoriasis. At the time of this review, clinical trials for uveitis are underway, so there are no clinical reports regarding their efficacy in autoimmune uveitis. See Table 1 for additional information regarding these drugs.
6. Other biologics
Biological agents that target and inhibit cytokines such as TNF-α and IL-1β have been extensively studied and have resulted in improving clinical outcomes in many autoimmune diseases including uveitis. We chose to include a more in-depth discussion of biologics that target IL-6 and IL-17 because IL-6 is such a central inflammatory cytokine that bridges both innate and adaptive immunities, and IL-17 is the characteristic cytokine produced by Th17 T cells that are involved in autoimmune diseases. The efficacies of these biological agents have spurred the introduction of additional biologics that target other inflammatory mediators implicated in autoimmunity. Also, the heterogeneity of uveitis, non-responsiveness or adverse effects associated with the current biologics used for the treatment of uveitis, provides the need to examine the efficacy of other biological agents that target other mediators implicated in autoimmunity. Recombinant interferon and IVIG are biologics used for the treatment of refractory autoimmune uveitis and other inflammatory conditions [204, 205, 206]. However, the precise mechanism of action for these medications is not well understood. Rituximab targets CD20 on B cells and is used for the treatment of ocular cicatricial pemphigoid, scleritis, and uveitis associated with granulomatosis with polyangiitis [207, 208]. There are also additional biologics that target specific cytokines and cell surface proteins that are in development and undergoing clinical trials for autoimmune diseases that may include uveitis, rheumatoid arthritis, ulcerative colitis, psoriatic arthritis, and others. Since these other biologics are still in various phases of development, we will not go into the same level of detail as in the others discussed above. Because there are many medications that are not public knowledge, the following is not an exhaustive list. Some of the medications that may be available for the treatment of autoimmune uveitis in the near future target IL-15, IL-23 p40, interferon, and its receptors, CD52, CD4, VEGF, and VCAM. A fusion protein consisting of the B7-binding portion of CTLA4 and IgG is also available and is being evaluated for the treatment of autoimmune uveitis.
7. Switching biological therapies
The development of multiple biologics that target specific inflammatory pathways has greatly increased the treatment options available for patients with autoimmune uveitis. With so many options available, it is of interest to determine if there is an advantage to switching the biologic, either within the same class or to a different class. Large clinical studies have not been done with uveitis cohorts, but some have been done with rheumatoid arthritis patients. There is some evidence that switching biologics within the same class, specifically related to TNF-α inhibitors, for reasons related to adverse reactions rather than efficacy may be beneficial [209]. A more recent study found that switching from TNF-α inhibitors to another biological class showed a significantly greater benefit than switching to another TNF-α inhibitor [210]. Therefore, it is still not clear which is the best biological treatment strategy for autoimmune uveitis patients, but there is some indication based on RA patients that switching to a different class of biologics may have significantly better outcomes than switching to another biological within the same class.
8. Conclusions
In this review, we focus on biologics that target TNF-α, IL-β, IL-6, and IL-17. The rationale for this is that TNF-α, IL-β, and IL-6 cytokines are involved in key inflammatory pathways that target both the innate and adaptive arms of the immune response. We also include a brief discussion of IL-17 because it is produced by a specific T-cell subset, and Th17 cells have been demonstrated to be involved in autoimmune diseases [190, 191]. There are other biologics that target other cytokines and cell types, but these are in earlier phases of development and are not yet FDA approved. Additional options for therapy are constantly being studied. Biologics are a newer class of therapeutics that have the advantage over other medications in that they are extremely specific for one target molecule. This specificity makes them attractive as therapeutics because specific pathways and/or cell types can be blocked. Inhibition of a specific pathway or cell type has the advantage over other immunosuppressive therapies that suppress all leukocytes and lymphocytes. A drawback to biologics is the high economic burden associated with these drugs. Because of the high cost associated with biologics, it can be difficult to obtain insurance coverage until multiple therapies have failed. As such, the cost to the patient could be a permanent loss of vision with repeated relapses and the use of corticosteroids while transitioning to a new therapy. Importantly, because these therapies have efficacy in treatment of systemic autoimmune diseases such as RA, inflammatory bowel diseases, and Behcet’s disease with a uveitis manifestation they may be effective for the majority of uveitis patients that only have ocular involvement [2, 211]. Therefore, additional appropriately powered clinical studies are necessary to demonstrate the effectiveness of biologics for the treatment of chronic autoimmune uveitis.
Acknowledgments
Funding was provided by the National Institutes of Health/National Eye Institute grant EY024951 and in part by an unrestricted Research to Prevent Blindness grant (New York, NY, USA).
Conflict of interest declaration
The authors have no conflicts of interest to disclose.
\n',keywords:"uveitis, TNF-α, IL-1β, IL-6, IL-17, etanercept, adalimumab, infliximab, golimumab, certolizumab, anakinra, canakinumab, gevokizumab, rilonacept, tocilizumab, sarilumab, secukinumab",chapterPDFUrl:"https://cdn.intechopen.com/pdfs/64592.pdf",chapterXML:"https://mts.intechopen.com/source/xml/64592.xml",downloadPdfUrl:"/chapter/pdf-download/64592",previewPdfUrl:"/chapter/pdf-preview/64592",totalDownloads:1026,totalViews:135,totalCrossrefCites:2,dateSubmitted:"October 1st 2018",dateReviewed:"October 25th 2018",datePrePublished:"November 29th 2018",datePublished:"May 29th 2019",dateFinished:"November 29th 2018",readingETA:"0",abstract:"Uveitis is a leading cause of blindness that presents a considerable challenge given that our understanding of the mechanisms of disease is still evolving. Both innate and adaptive immunity play a role in disease and mediators of these responses can serve as therapeutic targets. TNF-α and IL-1β inflammatory cytokines are central mediators of immunity and are involved in the dysregulated inflammatory response during uveitis. Because toxicity limits the use of steroids and other steroid-sparing agents, biologics that target a specific cell type or pathway are being explored for the treatment of autoimmune uveitis. This chapter begins with a broad overview of the aberrant immune response resulting in uveitis, and highlights key mediators such as TNF-α, IL-1β, IL-6, and IL-17 and their potential use as therapeutic targets. Most biological agents discussed in this review have not been FDA-approved for uveitis. However, favorable outcomes in early trials and FDA approval of these drugs for the treatment of other autoimmune diseases associated with uveitis support the potential for these biological agents in the management of uveitis. This review aims to provide an updated report on the efficacy of biologics that target TNF-α, IL-1β, IL-6, and IL-17 for the treatment of autoimmune uveitis.",reviewType:"peer-reviewed",bibtexUrl:"/chapter/bibtex/64592",risUrl:"/chapter/ris/64592",signatures:"Ashvini Reddy, Fauziyya Muhammad and Darren J. Lee",book:{id:"7094",type:"book",title:"Advances in the Diagnosis and Management of Uveitis",subtitle:null,fullTitle:"Advances in the Diagnosis and Management of Uveitis",slug:"advances-in-the-diagnosis-and-management-of-uveitis",publishedDate:"May 29th 2019",bookSignature:"Alejandro Rodriguez-Garcia and C. Stephen Foster",coverURL:"https://cdn.intechopen.com/books/images_new/7094.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",isbn:"978-1-83880-543-2",printIsbn:"978-1-83880-542-5",pdfIsbn:"978-1-83880-712-2",isAvailableForWebshopOrdering:!0,editors:[{id:"209514",title:"Dr.",name:"Alejandro",middleName:null,surname:"Rodriguez-Garcia",slug:"alejandro-rodriguez-garcia",fullName:"Alejandro Rodriguez-Garcia"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:[{id:"264148",title:"Prof.",name:"Darren",middleName:null,surname:"Lee",fullName:"Darren Lee",slug:"darren-lee",email:"darren-lee@ouhsc.edu",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",institution:{name:"University of Oklahoma Health Sciences Center",institutionURL:null,country:{name:"United States of America"}}},{id:"278741",title:"Prof.",name:"Ashvini",middleName:null,surname:"Reddy",fullName:"Ashvini Reddy",slug:"ashvini-reddy",email:"ashvini-reddy@dmei.org",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",institution:null},{id:"278742",title:"Dr.",name:"Fauziyya",middleName:null,surname:"Muhammad",fullName:"Fauziyya Muhammad",slug:"fauziyya-muhammad",email:"fauziyya-muhammad@ouhsc.edu",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",institution:null}],sections:[{id:"sec_1",title:"1. Introduction",level:"1"},{id:"sec_1_2",title:"1.1 Biologics in uveitis",level:"2"},{id:"sec_2_2",title:"1.2 Basic immunology of uveitis",level:"2"},{id:"sec_4",title:"2. TNF-α inhibitors",level:"1"},{id:"sec_4_2",title:"2.1 Etanercept",level:"2"},{id:"sec_5_2",title:"2.2 Adalimumab",level:"2"},{id:"sec_6_2",title:"2.3 Infliximab",level:"2"},{id:"sec_7_2",title:"2.4 Golimumab",level:"2"},{id:"sec_8_2",title:"2.5 Certolizumab",level:"2"},{id:"sec_10",title:"3. IL-1 inhibitors",level:"1"},{id:"sec_10_2",title:"3.1 Anakinra",level:"2"},{id:"sec_11_2",title:"3.2 Canakinumab",level:"2"},{id:"sec_12_2",title:"3.3 Gevokizumab",level:"2"},{id:"sec_13_2",title:"3.4 Rilonacept",level:"2"},{id:"sec_15",title:"4. IL-6 inhibitors",level:"1"},{id:"sec_15_2",title:"4.1 Tocilizumab",level:"2"},{id:"sec_16_2",title:"4.2 Sarilumab",level:"2"},{id:"sec_18",title:"5. IL-17 inhibitors",level:"1"},{id:"sec_18_2",title:"5.1 Secukinumab",level:"2"},{id:"sec_20",title:"6. Other biologics",level:"1"},{id:"sec_21",title:"7. Switching biological therapies",level:"1"},{id:"sec_22",title:"8. Conclusions",level:"1"},{id:"sec_23",title:"Acknowledgments",level:"1"},{id:"sec_23",title:"Conflict of interest declaration",level:"1"},{id:"sec_24",title:"List of abbreviations",level:"1"}],chapterReferences:[{id:"B1",body:'Lee DJ, Taylor AW. Following EAU recovery there is an associated MC5r-dependent APC induction of regulatory immunity in the spleen. Investigative Ophthalmology & Visual Science. 2011;52:8862-8867'},{id:"B2",body:'Pasadhika S, Rosenbaum JT. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biologics. 2014;8:67-81'},{id:"B3",body:'Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature Working G. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. American Journal of Ophthalmology. 2005;140:509-516'},{id:"B4",body:'Lerman MA, Rabinovich CE. The future is now: Biologics for non-infectious pediatric anterior uveitis. Paediatric Drugs. 2015;17:283-301'},{id:"B5",body:'Brezin AP. Semiology and classification of uveitis. La Revue du Praticien. 1999;49:1982-1988'},{id:"B6",body:'Rathinam SR, Babu M. Algorithmic approach in the diagnosis of uveitis. Indian Journal of Ophthalmology. 2013;61:255-262'},{id:"B7",body:'Barry RJ, Nguyen QD, Lee RW, Murray PI, Denniston AK. Pharmacotherapy for uveitis: Current management and emerging therapy. Clinical Ophthalmology. 2014;8:1891-1911'},{id:"B8",body:'Curnow SJ, Scheel-Toellner D, Jenkinson W, Raza K, Durrani OM, Faint JM, et al. Inhibition of T cell apoptosis in the aqueous humor of patients with uveitis by IL-6/soluble IL-6 receptor trans-signaling. Journal of Immunology. 2004;173:5290-5297'},{id:"B9",body:'Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI. Degree, duration, and causes of visual loss in uveitis. The British Journal of Ophthalmology. 2004;88:1159-1162'},{id:"B10",body:'Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: A literature survey. The British Journal of Ophthalmology. 1996;80:844-848'},{id:"B11",body:'You C, Sahawneh HF, Ma L, Kubaisi B, Schmidt A, Foster CS. A review and update on orphan drugs for the treatment of noninfectious uveitis. Clinical Ophthalmology. 2017;11:257-265'},{id:"B12",body:'Babu K, Mahendradas P. Medical management of uveitis - current trends. Indian Journal of Ophthalmology. 2013;61:277-283'},{id:"B13",body:'Suhler EB, Thorne JE, Mittal M, Betts KA, Tari S, Camez A, et al. Corticosteroid-related adverse events systematically increase with corticosteroid dose in noninfectious intermediate, posterior, or panuveitis: Post hoc analyses from the VISUAL-1 and VISUAL-2 trials. Ophthalmology. 2017;12:1799-1807'},{id:"B14",body:'Merida S, Palacios E, Navea A, Bosch-Morell F. New immunosuppressive therapies in uveitis treatment. International Journal of Molecular Sciences. 2015;16:18778-18795'},{id:"B15",body:'Smith JR. Management of uveitis. Clinical and Experimental Medicine. 2004;4:21-29'},{id:"B16",body:'Hunter RS, Lobo AM. Dexamethasone intravitreal implant for the treatment of noninfectious uveitis. Clinical Ophthalmology. 2011;5:1613-1621'},{id:"B17",body:'Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: Recommendations of an expert panel. American Journal of Ophthalmology. 2000;130:492-513'},{id:"B18",body:'Jabs DA. Immunosuppression for the uveitides. Ophthalmology. 2018;125:193-202'},{id:"B19",body:'Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47:85-118'},{id:"B20",body:'Arellano B, Graber DJ, Sentman CL. Regulatory T cell-based therapies for autoimmunity. Discovery Medicine. 2016;22:73-80'},{id:"B21",body:'Dejaco C, Duftner C, Grubeck-Loebenstein B, Schirmer M. Imbalance of regulatory T cells in human autoimmune diseases. Immunology. 2006;117:289-300'},{id:"B22",body:'Li J, Kim SG, Blenis J. Rapamycin: One drug, many effects. Cell Metabolism. 2014;19:373-379'},{id:"B23",body:'Imrie FR, Dick AD. Biologics in the treatment of uveitis. Current Opinion in Ophthalmology. 2007;18:481-486'},{id:"B24",body:'Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121:785-796.e3'},{id:"B25",body:'Brambilla A, Caputo R, Cimaz R, Simonini G. Canakinumab for childhood sight-threatening refractory uveitis: A case series. The Journal of Rheumatology. 2016;43:1445-1447'},{id:"B26",body:'Jaffe GJ, Dick AD, Brezin AP, Nguyen QD, Thorne JE, Kestelyn P, et al. Adalimumab in patients with active noninfectious uveitis. The New England Journal of Medicine. 2016;375:932-943'},{id:"B27",body:'Barisani-Asenbauer T, Maca SM, Mejdoubi L, Emminger W, Machold K, Auer H. Uveitis–A rare disease often associated with systemic diseases and infections- a systematic review of 2619 patients. Orphanet Journal of Rare Diseases. 2012;7:57'},{id:"B28",body:'Wildner G, Diedrichs-Mohring M. Autoimmune uveitis induced by molecular mimicry of peptides from rotavirus, bovine casein and retinal S-antigen. European Journal of Immunology. 2003;33:2577-2587'},{id:"B29",body:'Cusick MF, Libbey JE, Fujinami RS. Molecular mimicry as a mechanism of autoimmune disease. Clinical Reviews in Allergy and Immunology. 2012;42:102-111'},{id:"B30",body:'Willermain F, Rosenbaum JT, Bodaghi B, Rosenzweig HL, Childers S, Behrend T, et al. Interplay between innate and adaptive immunity in the development of non-infectious uveitis. Progress in Retinal and Eye Research. 2012;31:182-194'},{id:"B31",body:'Caspi RR. Understanding autoimmune uveitis through animal models. The Friedenwald Lecture. Investigative Ophthalmology & Visual Science. 2011;52:1872-1879'},{id:"B32",body:'Feltkamp TE. HLA and uveitis. International Ophthalmology. 1990;14:327-333'},{id:"B33",body:'Shenavandeh S, Jahanshahi KA, Aflaki E, Tavassoli A. Frequency of HLA-B5, HLA-B51 and HLA-B27 in patients with idiopathic uveitis and Behcet\'s disease: A case-control study. Reumatologia. 2018;56:67-72'},{id:"B34",body:'Caspi RR. A look at autoimmunity and inflammation in the eye. The Journal of Clinical Investigation. 2010;120:3073-3083'},{id:"B35",body:'Martin TM, Rosenbaum JT. An update on the genetics of HLA B27-associated acute anterior uveitis. Ocular Immunology and Inflammation. 2011;19:108-114'},{id:"B36",body:'Colmegna I, Cuchacovich R, Espinoza LR. HLA-B27-associated reactive arthritis: Pathogenetic and clinical considerations. Clinical Microbiology Reviews. 2004;17:348-369'},{id:"B37",body:'Takeuchi M, Kastner DL, Remmers EF. The immunogenetics of Behcet\'s disease: A comprehensive review. Journal of Autoimmunity. 2015;64:137-148'},{id:"B38",body:'Forrester JV, Kuffova L, Dick AD. Autoimmunity, autoinflammation, and infection in uveitis. American Journal of Ophthalmology. 2018;189:77-85'},{id:"B39",body:'Mattapallil MJ, Sahin A, Silver PB, Sun SH, Chan CC, Remmers EF, et al. Common genetic determinants of uveitis shared with other autoimmune disorders. Journal of Immunology. 2008;180:6751-6759'},{id:"B40",body:'Martin TM, Kurz DE, Rosenbaum JT. Genetics of uveitis. Ophthalmology Clinics of North America. 2003;16:555-565'},{id:"B41",body:'Bi HS, Liu ZF, Cui Y. Pathogenesis of innate immunity and adaptive immunity in the mouse model of experimental autoimmune uveitis. Journal of the Chinese Medical Association. 2015;78:276-282'},{id:"B42",body:'Huhtinen M, Repo H, Laasila K, Jansson SE, Kautiainen H, Karma A, et al. Systemic inflammation and innate immune response in patients with previous anterior uveitis. The British Journal of Ophthalmology. 2002;86:412-417'},{id:"B43",body:'Perez VL, Caspi RR. Immune mechanisms in inflammatory and degenerative eye disease. Trends in Immunology. 2015;36:354-363'},{id:"B44",body:'Kasper M, Walscheid K, Laffer B, Bauer D, Busch M, Wildschutz L, et al. The phenotype of monocytes in anterior uveitis depends on the HLA-B27 status. Frontiers in Immunology. 2018;9:1773'},{id:"B45",body:'Horai R, Caspi RR. Cytokines in autoimmune uveitis. Journal of Interferon & Cytokine Research. 2011;31:733-744'},{id:"B46",body:'Caspi RR, Silver PB, Luger D, Tang J, Cortes LM, Pennesi G, et al. Mouse models of experimental autoimmune uveitis. Ophthalmic Research. 2008;40:169-174'},{id:"B47",body:'Dick AD, Forrester JV, Liversidge J, Cope AP. The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Progress in Retinal and Eye Research. 2004;23:617-637'},{id:"B48",body:'Weinstein JE, Pepple KL. Cytokines in uveitis. Current Opinion in Ophthalmology. 2018;29:267-274'},{id:"B49",body:'Zhao R, Zhou H, Zhang J, Liu X, Su SB. Interleukin-1beta promotes the induction of retinal autoimmune disease. International Immunopharmacology. 2014;22:285-292'},{id:"B50",body:'Jain A, Pasare C. Innate control of adaptive immunity: Beyond the three-signal paradigm. Journal of Immunology. 2017;198:3791-3800'},{id:"B51",body:'Banyer JL, Hamilton NH, Ramshaw IA, Ramsay AJ. Cytokines in innate and adaptive immunity. Reviews in Immunogenetics. 2000;2:359-373'},{id:"B52",body:'Kuwabara T, Ishikawa F, Kondo M, Kakiuchi T. The role of IL-17 and related cytokines in inflammatory autoimmune diseases. Mediators of Inflammation. 2017;2017:3908061'},{id:"B53",body:'Jawad S, Liu B, Agron E, Nussenblatt RB, Sen HN. Elevated serum levels of interleukin-17A in uveitis patients. Ocular Immunology and Inflammation. 2013;21:434-439'},{id:"B54",body:'Kuiper JJ, Mutis T, de Jager W, de Groot-Mijnes JD, Rothova A. Intraocular interleukin-17 and proinflammatory cytokines in HLA-A29-associated birdshot chorioretinopathy. American Journal of Ophthalmology. 2011;152:177-182.e1'},{id:"B55",body:'Ooi KG, Galatowicz G, Calder VL, Lightman SL. Cytokines and chemokines in uveitis: Is there a correlation with clinical phenotype? Clinical Medicine & Research. 2006;4:294-309'},{id:"B56",body:'He Y, Jia SB, Zhang W, Shi JM. New options for uveitis treatment. International Journal of Ophthalmology. 2013;6:702-707'},{id:"B57",body:'Khalili H, Lee RW, Khaw PT, Brocchini S, Dick AD, Copland DA. An anti-TNF-alpha antibody mimetic to treat ocular inflammation. Scientific Reports. 2016;6:36905'},{id:"B58",body:'Cordero-Coma M, Calleja S, Llorente M, Rodriguez E, Franco M, Ruiz de Morales JG. Serum cytokine profile in adalimumab-treated refractory uveitis patients: Decreased IL-22 correlates with clinical responses. Ocular Immunology and Inflammation. 2013;21:212-219'},{id:"B59",body:'Monaco C, Nanchahal J, Taylor P, Feldmann M. Anti-TNF therapy: Past, present and future. International Immunology. 2015;27:55-62'},{id:"B60",body:'Bradley JR. TNF-mediated inflammatory disease. The Journal of Pathology. 2008;214:149-160'},{id:"B61",body:'Parameswaran N, Patial S. Tumor necrosis factor-alpha signaling in macrophages. Critical Reviews in Eukaryotic Gene Expression. 2010;20:87-103'},{id:"B62",body:'Butler DM, Maini RN, Feldmann M, Brennan FM. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. European Cytokine Network. 1995;6:225-230'},{id:"B63",body:'Sugita S, Takase H, Taguchi C, Mochizuki M. The role of soluble TNF receptors for TNF-alpha in uveitis. Investigative Ophthalmology & Visual Science. 2007;48:3246-3252'},{id:"B64",body:'Kollias G, Kontoyiannis D, Douni E, Kassiotis G. The role of TNF/TNFR in organ-specific and systemic autoimmunity: Implications for the design of optimized ‘anti-TNF’ therapies. Current Directions in Autoimmunity. 2002;5:30-50'},{id:"B65",body:'Agrawal R, Iyer J, Connolly J, Iwata D, Teoh S. Cytokines and biologics in non-infectious autoimmune uveitis: Bench to bedside. Indian Journal of Ophthalmology. 2014;62:74-81'},{id:"B66",body:'Busch M, Bauer D, Hennig M, Wasmuth S, Thanos S, Heiligenhaus A. Effects of systemic and intravitreal TNF-alpha inhibition in experimental autoimmune uveoretinitis. Investigative Ophthalmology & Visual Science. 2013;54:39-46'},{id:"B67",body:'Lis K, Kuzawinska O, Balkowiec-Iskra E. Tumor necrosis factor inhibitors - state of knowledge. Archives of Medical Science. 2014;10:1175-1185'},{id:"B68",body:'Haraoui B, Bykerk V. Etanercept in the treatment of rheumatoid arthritis. Therapeutics and Clinical Risk Management. 2007;3:99-105'},{id:"B69",body:'Ardestani S, Li B, Deskins DL, Wu H, Massion PP, Young PP. Membrane versus soluble isoforms of TNF-alpha exert opposing effects on tumor growth and survival of tumor-associated myeloid cells. Cancer Research. 2013;73:3938-3950'},{id:"B70",body:'Scott LJ. Etanercept: A review of its use in autoimmune inflammatory diseases. Drugs. 2014;74:1379-1410'},{id:"B71",body:'Reiff A, Takei S, Sadeghi S, Stout A, Shaham B, Bernstein B, et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis and Rheumatism. 2001;44:1411-1415'},{id:"B72",body:'Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis and Rheumatism. 2003;48:1093-1101'},{id:"B73",body:'Smith JA, Thompson DJ, Whitcup SM, Suhler E, Clarke G, Smith S, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis and Rheumatism. 2005;53:18-23'},{id:"B74",body:'Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A. Etanercept for refractory ocular sarcoidosis: Results of a double-blind randomized trial. Chest. 2005;128:1062-1047'},{id:"B75",body:'Foster CS, Tufail F, Waheed NK, Chu D, Miserocchi E, Baltatzis S, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Archives of Ophthalmology. 2003;121:437-440'},{id:"B76",body:'Raffeiner B, Ometto F, Bernardi L, Botsios C, Punzi L. Inefficacy or paradoxical effect? Uveitis in ankylosing spondylitis treated with etanercept. Case Reports in Medicine. 2014;2014:4'},{id:"B77",body:'Wendling D, Joshi A, Reilly P, Jalundhwala YJ, Mittal M, Bao Y. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: An analysis of a large US claims database. Current Medical Research and Opinion. 2014;30:2515-2521'},{id:"B78",body:'Reddy AR, Backhouse OC. Does etanercept induce uveitis? The British Journal of Ophthalmology. 2003;87:925'},{id:"B79",body:'Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology. 2006;113:2317-2323'},{id:"B80",body:'Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis and Rheumatism. 2007;56:3248-3252'},{id:"B81",body:'Scheinfeld N. The medical uses and side effects of etanercept with a focus on cutaneous disease. Journal of Drugs in Dermatology. 2004;3:653-659'},{id:"B82",body:'Fallahi-Sichani M, Flynn JL, Linderman JJ, Kirschner DE. Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability. Journal of Immunology. 2012;188:3169-3178'},{id:"B83",body:'Ramos-Casals M, Roberto Perez A, Diaz-Lagares C, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by biological agents: A double-edged sword? Autoimmunity Reviews. 2010;9:188-193'},{id:"B84",body:'Ibrahim WH, Hammoudah M, Akhtar N, Al-Hail H, Deleu D. Central nervous system demyelination associated with etanercept in a 51 years old woman. Libyan Journal of Medicine. 2007;2:99-102'},{id:"B85",body:'ENBREL. FDA Approved Drug Products [Internet]. 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103795s5569lbl.pdf'},{id:"B86",body:'Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Annals of the Rheumatic Diseases. 2011;70:616-623'},{id:"B87",body:'Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clinical Infectious Diseases. 2004;38:1261-1265'},{id:"B88",body:'Gottlieb AB. Tumor necrosis factor blockade: Mechanism of action. The Journal of Investigative Dermatology. Symposium Proceedings. 2007;12:1-4'},{id:"B89",body:'Reimold AM. The role of adalimumab in rheumatic and autoimmune disorders: Comparison with other biologic agents. Open Access Rheumatology. 2012;4:33-47'},{id:"B90",body:'Sheppard J, Joshi A, Betts KA, Hudgens S, Tari S, Chen N, et al. Effect of adalimumab on visual functioning in patients with noninfectious intermediate uveitis, posterior uveitis, and panuveitis in the VISUAL-1 and VISUAL-2 trials. JAMA Ophthalmology. 2017;135:511-518'},{id:"B91",body:'Perra D, Alba MA, Callejas JL, Mesquida M, Rios-Fernandez R, Adan A, et al. Adalimumab for the treatment of Behcet\'s disease: Experience in 19 patients. Rheumatology (Oxford). 2012;51:1825-1831'},{id:"B92",body:'van Denderen JC, Visman IM, Nurmohamed MT, Suttorp-Schulten MS, van der Horst-Bruinsma IE. Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis. The Journal of Rheumatology. 2014;41:1843-1848'},{id:"B93",body:'Suhler EB, Lowder CY, Goldstein DA, Giles T, Lauer AK, Kurz PA, et al. Adalimumab therapy for refractory uveitis: Results of a multicentre, open-label, prospective trial. The British Journal of Ophthalmology. 2013;97:481-486'},{id:"B94",body:'Fabiani C, Vitale A, Emmi G, Vannozzi L, Lopalco G, Guerriero S, et al. Efficacy and safety of adalimumab in Behcet\'s disease-related uveitis: A multicenter retrospective observational study. Clinical Rheumatology. 2017;36:183-189'},{id:"B95",body:'Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, et al. Adalimumab in the therapy of uveitis in childhood. The British Journal of Ophthalmology. 2007;91:319-324'},{id:"B96",body:'Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S, et al. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. The New England Journal of Medicine. 2017;376:1637-1646'},{id:"B97",body:'LaMattina KC, Goldstein DA. Adalimumab for the treatment of uveitis. Expert Review of Clinical Immunology. 2017;13:181-188'},{id:"B98",body:'Neri P, Lettieri M, Fortuna C, Zucchi M, Manoni M, Celani S, et al. Adalimumab (humira) in ophthalmology: A review of the literature. Middle East African Journal of Ophthalmology. 2010;17:290-296'},{id:"B99",body:'Alnasser Alsukhni R, Jriekh Z, Aboras Y. Adalimumab induced or provoked MS in patient with autoimmune uveitis: A case report and review of the literature. Case Reports in Medicine. 2016;2016:1423131'},{id:"B100",body:'Sim JK, Lee SY, Shim JJ, Kang KH. Pulmonary sarcoidosis induced by adalimumab: A case report and literature review. Yonsei Medical Journal. 2016;57:272-273'},{id:"B101",body:'Humira. FDA Approved Drug Products [Internet]. 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125057s409lbl.pdf'},{id:"B102",body:'Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clinical Immunology. 2009;131:308-316'},{id:"B103",body:'Bickston SJ. Infliximab for ulcerative colitis induction of remission and maintenance therapy. Gastroenterol Hepatol (N Y). 2007;3:55-56'},{id:"B104",body:'Scheinfeld N. Off-label uses and side effects of infliximab. Journal of Drugs in Dermatology. 2004;3:273-284'},{id:"B105",body:'Benitez-del-Castillo JM, Martinez-de-la-Casa JM, Pato-Cour E, Mendez-Fernandez R, Lopez-Abad C, Matilla M, et al. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab). Eye (London, England). 2005;19:841-845'},{id:"B106",body:'Lopez-Gonzalez R, Loza E, Jover JA, Benitez Del Castillo JM, Mendez R, Hernandez-Garcia C, et al. Treatment of refractory posterior uveitis with infliximab: A 7-year follow-up study. Scandinavian Journal of Rheumatology. 2009;38:58-62'},{id:"B107",body:'Ardoin SP, Kredich D, Rabinovich E, Schanberg LE, Jaffe GJ. Infliximab to treat chronic noninfectious uveitis in children: Retrospective case series with long-term follow-up. American Journal of Ophthalmology. 2007;144:844-849'},{id:"B108",body:'Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. 2006;113:860-864.e2'},{id:"B109",body:'Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, et al. A prospective trial of infliximab therapy for refractory uveitis: Preliminary safety and efficacy outcomes. Archives of Ophthalmology. 2005;123:903-912'},{id:"B110",body:'Vallet H, Seve P, Biard L, Baptiste Fraison J, Bielefeld P, Perard L, et al. Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: A Multicenter Study From the French Uveitis Network. Arthritis & Rhematology. 2016;68:1522-1530'},{id:"B111",body:'Hoshino M, Yoshio T, Onishi S, Minota S. Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis. Modern Rheumatology. 2012;22:532-540'},{id:"B112",body:'Napolitano M, Balato N, Ayala F, Cirillo T, Balato A. Multiple sclerosis following anti-tumor necrosis factor-alpha therapy for psoriasis: First case in Italy? Giornale Italiano di Dermatologia e Venereologia. 2018;153:567-572'},{id:"B113",body:'Signore SC, Brauns B, Schutze G, Dohm CP, Bahr M, Mossner R, et al. Infliximab-associated chronic inflammatory central nervous system disease and peroneal nerve injury in a psoriatic patient refractory to treatment: Case report with 10-year follow-up. Case Reports in Neurological Medicine. 2018;10:12-17'},{id:"B114",body:'Remicade. FDA Approved Drug Products [Internet]. 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103772s5385lbl.pdf'},{id:"B115",body:'Shealy DJ, Cai A, Staquet K, Baker A, Lacy ER, Johns L, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. MAbs. 2010;2:428-439'},{id:"B116",body:'Lowenberg M, de Boer N, Hoentjen F. Golimumab for the treatment of ulcerative colitis. Clinical and Experimental Gastroenterology. 2014;7:53-59'},{id:"B117",body:'Rifkin LM, Birnbaum AD, Goldstein DA. TNF inhibition for ophthalmic indications: Current status and outlook. BioDrugs. 2013;27:347-357'},{id:"B118",body:'Yazgan S, Celik U, Isik M, Yesil NK, Baki AE, Sahin H, et al. Efficacy of golimumab on recurrent uveitis in HLA-B27-positive ankylosing spondylitis. International Ophthalmology. 2017;37:139-145'},{id:"B119",body:'Calvo-Rio V, Blanco R, Santos-Gomez M, Rubio-Romero E, Cordero-Coma M, Gallego-Flores A, et al. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. Seminars in Arthritis and Rheumatism. 2016;46:95-101'},{id:"B120",body:'Zhang Z, Fan W, Yang G, Xu Z, Wang J, Cheng Q, et al. Risk of tuberculosis in patients treated with TNF-alpha antagonists: A systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2017;7:e012567'},{id:"B121",body:'Chovel-Sella A, Karplus R, Sella T, Amital H. Clinical efficacy and adverse effects of golimumab in the treatment of rheumatoid arthritis. The Israel Medical Association Journal. 2012;14:390-394'},{id:"B122",body:'Michelon MA, Gottlieb AB. Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis. Clinical, Cosmetic and Investigational Dermatology. 2010;3:79-84'},{id:"B123",body:'Duica I, Voinea LM, Mitulescu C, Istrate S, Coman IC, Ciuluvica R. The use of biologic therapies in uveitis. Romanian Journal of Ophthalmology. 2018;62:105-113'},{id:"B124",body:'Simponi. FDA Approved Drug Products [Internet]. 2009. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125289s000lbl.pdf'},{id:"B125",body:'Lang L. FDA approves Cimzia to treat Crohn\'s disease. Gastroenterology. 2008;134:1819'},{id:"B126",body:'Llorenc V, Mesquida M, Sainz de la Maza M, Blanco R, Calvo V, Maiz O, et al. Certolizumab Pegol, a New Anti-TNF-alpha in the Armamentarium against Ocular Inflammation. Ocular Immunology and Inflammation. 2016;24:167-172'},{id:"B127",body:'Rudwaleit M, Rosenbaum JT, Landewe R, Marzo-Ortega H, Sieper J, van der Heijde D, et al. Observed incidence of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis. Arthritis Care & Research (Hoboken). 2016;68:838-844'},{id:"B128",body:'Moisseiev E, Shulman S. Certolizumab-induced uveitis: A case report and review of the literature. Case Reports in Ophthalmology. 2014;5:54-59'},{id:"B129",body:'Acosta-Felquer ML, Rosa J, Soriano ER. An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: Place in therapy. Open Access Rheumatology. 2016;8:37-44'},{id:"B130",body:'Cimzia. FDA Approved Drug Products [Internet]. 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125160s283lbl.pdf'},{id:"B131",body:'Wan CK, He C, Sun L, Egwuagu CE, Leonard WJ. Cutting edge: IL-1 receptor signaling is critical for the development of autoimmune uveitis. Journal of Immunology. 2016;196:543-546'},{id:"B132",body:'Lopez-Castejon G, Brough D. Understanding the mechanism of IL-1beta secretion. Cytokine & Growth Factor Reviews. 2011;22:189-195'},{id:"B133",body:'Lin CC, Edelson BT. New insights into the role of IL-1beta in experimental autoimmune encephalomyelitis and multiple sclerosis. Journal of Immunology. 2017;198:4553-4560'},{id:"B134",body:'Sha Y, Markovic-Plese S. A role of IL-1R1 signaling in the differentiation of Th17 cells and the development of autoimmune diseases. Self Nonself. 2011;2:35-42'},{id:"B135",body:'Carreno E, Portero A, Herreras JM, Garcia-Vazquez C, Whitcup SM, Stern ME, et al. Cytokine and chemokine tear levels in patients with uveitis. Acta Ophthalmologica. 2017;95:e405-ee14'},{id:"B136",body:'Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine & Growth Factor Reviews. 2002;13:323-340'},{id:"B137",body:'Goh AX, Bertin-Maghit S, Ping Yeo S, Ho AW, Derks H, Mortellaro A, et al. A novel human anti-interleukin-1beta neutralizing monoclonal antibody showing in vivo efficacy. MAbs. 2014;6:765-773'},{id:"B138",body:'Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nature Reviews. Drug Discovery. 2012;11:633-652'},{id:"B139",body:'Cohen SB. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis. Rheumatic Diseases Clinics of North America. 2004;30:365-380, vii'},{id:"B140",body:'Teoh SC, Sharma S, Hogan A, Lee R, Ramanan AV, Dick AD. Tailoring biological treatment: Anakinra treatment of posterior uveitis associated with the CINCA syndrome. The British Journal of Ophthalmology. 2007;91:263-264'},{id:"B141",body:'Botsios C, Sfriso P, Ostuni PA, Todesco S, Punzi L. Efficacy of the IL-1 receptor antagonist, anakinra, for the treatment of diffuse anterior scleritis in rheumatoid arthritis. Report of two cases. Rheumatology (Oxford). 2007;46:1042-1043'},{id:"B142",body:'Fabiani C, Vitale A, Emmi G, Lopalco G, Vannozzi L, Guerriero S, et al. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behcet\'s disease-related uveitis: A multicenter retrospective observational study. Clinical Rheumatology. 2017;36:191-197'},{id:"B143",body:'Kaiser C, Knight A, Nordstrom D, Pettersson T, Fransson J, Florin-Robertsson E, et al. Injection-site reactions upon Kineret (anakinra) administration: Experiences and explanations. Rheumatology International. 2012;32:295-299'},{id:"B144",body:'Kullenberg T, Lofqvist M, Leinonen M, Goldbach-Mansky R, Olivecrona H. Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes. Rheumatology (Oxford). 2016;55:1499-1506'},{id:"B145",body:'Ahmed O, Brahmania M, Alsahafi M, Alkhowaiter S, Erb S. Anakinra hepatotoxicity in a patient with adult-onset still’s disease. ACG Case Reports Journal. 2015;2:173-174'},{id:"B146",body:'Fleischmann RM, Tesser J, Schiff MH, Schechtman J, Burmester GR, Bennett R, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 2006;65:1006-1012'},{id:"B147",body:'Kineret. FDA Approved Drug Products [Internet]. 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103950s5182lbl.pdf'},{id:"B148",body:'Dhimolea E. Canakinumab. MAbs. 2010;2:3-13'},{id:"B149",body:'Orrock JE, Ilowite NT. Canakinumab for the treatment of active systemic juvenile idiopathic arthritis. Expert Review of Clinical Pharmacology. 2016;9:1015-1024'},{id:"B150",body:'Hirano M, Seguchi J, Yamamura M, Narita A, Okanobu H, Nishikomori R, et al. Successful resolution of stromal keratitis and uveitis using canakinumab in a patient with chronic infantile neurologic, cutaneous, and articular syndrome: A case study. Journal of Ophthalmic Inflammation and Infection. 2015;5:34'},{id:"B151",body:'Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S. Canakinumab in a patient with juvenile Behcet’s syndrome with refractory eye disease. Annals of the Rheumatic Diseases. 2012;71:1589-1591'},{id:"B152",body:'Hoy SM. Canakinumab: A review of its use in the management of systemic juvenile idiopathic arthritis. BioDrugs. 2015;29:133-142'},{id:"B153",body:'Dubois EA, Rissmann R, Cohen AF. Rilonacept and canakinumab. British Journal of Clinical Pharmacology. 2011;71:639-641'},{id:"B154",body:'ILaris. FDA Approved Drug Products [Internet]. 2016. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125319s088lbl.pdf'},{id:"B155",body:'Knickelbein JE, Tucker WR, Bhatt N, Armbrust K, Valent D, Obiyor D, et al. Gevokizumab in the treatment of autoimmune non-necrotizing anterior scleritis: Results of a phase I/II clinical trial. American Journal of Ophthalmology. 2016;172:104-110'},{id:"B156",body:'Gul A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A, et al. Interleukin-1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: An open-label pilot study. Annals of the Rheumatic Diseases. 2012;71:563-566'},{id:"B157",body:'Tugal-Tutkun IM, Kadayifcilar SM, Khairallah MM, Lee SCMP, Ozdal P, Ozyazgan Y, et al. Safety and efficacy of gevokizumab in patients with Behcet’s disease uveitis: Results of an exploratory phase 2 study. Ocular Immunology and Inflammation. 2017;25:62-70'},{id:"B158",body:'Tugal-Tutkun I, Pavesio C, De Cordoue A, Bernard-Poenaru O, Gul A. Use of gevokizumab in patients with Behcet’s disease uveitis: An international, randomized, double-masked, placebo-controlled study and open-label extension study. Ocular Immunology and Inflammation. 2018:1-11'},{id:"B159",body:'Cavelti-Weder C, Babians-Brunner A, Keller C, Stahel MA, Kurz-Levin M, Zayed H, et al. Effects of gevokizumab on glycemia and inflammatory markers in typ. 2 diabetes. Diabetes Care. 2012;35:1654-1662'},{id:"B160",body:'Kapur S, Bonk ME. Rilonacept (arcalyst), an interleukin-1 trap for the treatment of cryopyrin-associated periodic syndromes. P T. 2009;34:138-141'},{id:"B161",body:'Gomes Bittencourt M, Sepah YJ, Do DV, Agbedia O, Akhtar A, Liu H, et al. New treatment options for noninfectious uveitis. Developments in Ophthalmology. 2012;51:134-161'},{id:"B162",body:'Gillespie J, Mathews R, McDermott MF. Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS). Journal of Inflammation Research. 2010;3:1-8'},{id:"B163",body:'Vitale A, Rigante D, Lucherini OM, Caso F, Muscari I, Magnotti F, et al. Biological treatments: New weapons in the management of monogenic autoinflammatory disorders. Mediators of Inflammation. 2013;2013:939847'},{id:"B164",body:'Arcalyst. FDA Approved Drug Products [Internet]. 2008. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125249lbl.pdf'},{id:"B165",body:'Maccio A, Madeddu C. The role of interleukin-6 in the evolution of ovarian cancer: Clinical and prognostic implications–A review. Journal of Molecular Medicine (Berlin). 2013;91:1355-1368'},{id:"B166",body:'Grevich S, Shenoi S. Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition. Adolescent Health, Medicine and Therapeutics. 2017;8:125-135'},{id:"B167",body:'Tappeiner C, Heinz C, Ganser G, Heiligenhaus A. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? The Journal of Rheumatology. 2012;39:1294-1295'},{id:"B168",body:'Adan A, Mesquida M, Llorenc V, Espinosa G, Molins B, Hernandez MV, et al. Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2013;251:2627-2632'},{id:"B169",body:'Tappeiner C, Mesquida M, Adan A, Anton J, Ramanan AV, Carreno E, et al. Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. The Journal of Rheumatology. 2016;43:2183-2188'},{id:"B170",body:'Sepah YJ, Sadiq MA, Chu DS, Dacey M, Gallemore R, Dayani P, et al. Primary (month-6) outcomes of the STOP-uveitis study: Evaluating the safety, tolerability, and efficacy of tocilizumab in patients with noninfectious uveitis. American Journal of Ophthalmology. 2017;183:71-80'},{id:"B171",body:'Chen J, Chen S, He J. A case of refractory intestinal Behcet’s disease treated with tocilizumab, a humanised anti-interleukin-6 receptor antibody. 2017. Clinical and Experimental Rheumatology;108(35 Suppl):116-118'},{id:"B172",body:'Oshitari T, Kajita F, Tobe A, Itami M, Yotsukura J, Baba T, et al. Refractory uveitis in patient with castleman disease successfully treated with tocilizumab. Case Reports in Ophthalmological Medicine. 2012;2012:968180'},{id:"B173",body:'Ruiz-Medrano J, Diaz-Valle D, Cuina R, Gegundez JA, Chhablani J, Majumder PD, et al. The role of tocilizumab in the treatment of inflammatory diseases of the eye and orbit: A useful alternative. Journal Français d\'Ophtalmologie. 2018;8:759-766'},{id:"B174",body:'Jones G, Ding C. Tocilizumab: A review of its safety and efficacy in rheumatoid arthritis. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders. 2010;3:81-89'},{id:"B175",body:'Monemi S, Berber E, Sarsour K, Wang J, Lampl K, Bharucha K, et al. Incidence of gastrointestinal perforations in patients with rheumatoid arthritis treated with tocilizumab from clinical trial, postmarketing, and real-world data sources. Rheumatology and Theraphy. 2016;3:337-352'},{id:"B176",body:'Xie F, Yun H, Bernatsky S, Curtis JR. Brief report: Risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments. Arthritis & Rhematology. 2016;68:2612-2617'},{id:"B177",body:'Rubbert-Roth A, Sebba A, Brockwell L, Kelman A, Porter-Brown B, Pulley J, et al. Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab. RMD Open. 2016;2:e000213'},{id:"B178",body:'Actemra. FDA Approved Drug Products [Internet]. 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125276s122,125472s031lbl.pdf'},{id:"B179",body:'Takayanagi N. Biological agents and respiratory infections: Causative mechanisms and practice management. Respiratory Investigation. 2015;53:185-200'},{id:"B180",body:'McCarty D, Robinson A. Efficacy and safety of sarilumab in patients with active rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease. 2018;10:61-67'},{id:"B181",body:'Maya JR, Sadiq MA, Zapata LJ, Hanout M, Sarwar S, Rajagopalan N, et al. Emerging therapies for noninfectious uveitis: What may be coming to the clinics. Journal of Ophthalmology. 2014;2014:310329'},{id:"B182",body:'Boyce EG, Rogan EL, Vyas D, Prasad N, Mai Y. Sarilumab: Review of a second IL-6 receptor antagonist indicated for the treatment of rheumatoid arthritis. The Annals of Pharmacotherapy. 2018;52:780-791'},{id:"B183",body:'Kevzara. FDA Approved Drug Products [Internet]. 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761037s001lbl.pdf'},{id:"B184",body:'Mease P, Strand V, Shalamberidze L, Dimic A, Raskina T, Xu LA, et al. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Annals of the Rheumatic Diseases. 2012;71:1183-1189'},{id:"B185",body:'Genovese MC, Fleischmann R, Furst D, Janssen N, Carter J, Dasgupta B, et al. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: Outcomes of a randomised Phase IIb study. Annals of the Rheumatic Diseases. 2014;73:1607-1615'},{id:"B186",body:'Smolen JS, Weinblatt ME, Sheng S, Zhuang Y, Hsu B. Sirukumab, a human anti-interleukin-6 monoclonal antibody: A randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Annals of the Rheumatic Diseases. 2014;73:1616-1625'},{id:"B187",body:'Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clinical Cancer Research. 2013;19:3659-3670'},{id:"B188",body:'Correction to Lancet HIV 2017. Lancet HIV. 2017;4:e122-e133. 4: e102'},{id:"B189",body:'Veldhoen M. Interleukin 17 is a chief orchestrator of immunity. Nature Immunology. 2017;18:612-621'},{id:"B190",body:'Guedes MC, Borrego LM, Proenca RD. Roles of interleukin-17 in uveitis. Indian Journal of Ophthalmology. 2016;64:628-634'},{id:"B191",body:'Kellner H. Targeting interleukin-17 in patients with active rheumatoid arthritis: Rationale and clinical potential. Therapeutic Advances in Musculoskeletal Disease. 2013;5:141-152'},{id:"B192",body:'Kunwar S, Dahal K, Sharma S. Anti-IL-17 therapy in treatment of rheumatoid arthritis: A systematic literature review and meta-analysis of randomized controlled trials. Rheumatology International. 2016;36:1065-1075'},{id:"B193",body:'Thomas LW, Lee EB, Wu JJ. Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis. The Journal of Dermatological Treatment. 2018:1-7'},{id:"B194",body:'Luger D, Silver PB, Tang J, Cua D, Chen Z, Iwakura Y, et al. Either a Th17 or a Th1 effector response can drive autoimmunity: Conditions of disease induction affect dominant effector category. The Journal of Experimental Medicine. 2008;205:799-810'},{id:"B195",body:'Fala L. Cosentyx (Secukinumab): First IL-17A antagonist receives FDA approval for moderate-to-severe plaque psoriasis. American Health & Drug Benefits. 2016;9:60-63'},{id:"B196",body:'Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Science Translational Medicine. 2010;2:52ra72'},{id:"B197",body:'Dick AD, Tugal-Tutkun I, Foster S, Zierhut M, Melissa Liew SH, Bezlyak V, et al. Secukinumab in the treatment of noninfectious uveitis: Results of three randomized, controlled clinical trials. Ophthalmology. 2013;120:777-787'},{id:"B198",body:'Letko E, Yeh S, Foster CS, Pleyer U, Brigell M, Grosskreutz CL, et al. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology. 2015;122:939-948'},{id:"B199",body:'Fobelo Lozano MJ, Serrano Gimenez R, Castro Fernandez M. Emergence of inflammatory bowel disease during treatment with secukinumab. Journal of Crohn’s & Colitis. 2018;12:1131-1133'},{id:"B200",body:'Frieder J, Kivelevitch D, Menter A. Secukinumab: A review of the anti-IL-17A biologic for the treatment of psoriasis. Therapeutic Advances in Chronic Disease. 2018;9:5-21'},{id:"B201",body:'Cosentyx. FDA Approved Drug Products [Internet]. 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125504s013lbl.pdf'},{id:"B202",body:'Kammuller M, Tsai TF, Griffiths CE, Kapoor N, Kolattukudy PE, Brees D, et al. Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections. Clinical & Translational Immunology. 2017;6:e152'},{id:"B203",body:'Blauvelt A. Safety of secukinumab in the treatment of psoriasis. Expert Opinion on Drug Safety. 2016;15:1413-1420'},{id:"B204",body:'Butler NJ, Suhler EB, Rosenbaum JT. Interferon alpha 2b in the treatment of uveitic cystoid macular edema. Ocular Immunology and Inflammation. 2012;20:86-90'},{id:"B205",body:'Kivity S, Katz U, Daniel N, Nussinovitch U, Papageorgiou N, Shoenfeld Y. Evidence for the use of intravenous immunoglobulins–A review of the literature. Clinical Reviews in Allergy and Immunology. 2010;38:201-269'},{id:"B206",body:'Garcia-Geremias M, Carreno E, Epps SJ, Lee RW, Dick AD. Clinical outcomes of intravenous immunoglobulin therapy in refractory uveitis. International Ophthalmology. 2015;35:281-285'},{id:"B207",body:'You C, Lamba N, Lasave AF, Ma L, Diaz MH, Foster CS. Rituximab in the treatment of ocular cicatricial pemphigoid: A retrospective cohort study. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2017;255:1221-1228'},{id:"B208",body:'Ahmed A, Foster CS. Cyclophosphamide or rituximab treatment of scleritis and uveitis for patients with granulomatosis with polyangiitis. Ophthalmic Research. 2018. DOI: 10.1159/000486791'},{id:"B209",body:'Reynolds A, Koenig AS, Bananis E, Singh A. When is switching warranted among biologic therapies in rheumatoid arthritis? Expert Review of Pharmacoeconomics & Outcomes Research. 2012;12:319-333'},{id:"B210",body:'Wei W, Knapp K, Wang L, Chen CI, Craig GL, Ferguson K, et al. Treatment persistence and clinical outcomes of tumor necrosis factor inhibitor cycling or switching to a new mechanism of action therapy: Real-world observational study of rheumatoid arthritis patients in the United States with prior tumor necrosis factor inhibitor therapy. Advances in Therapy. 2017;34:1936-1952'},{id:"B211",body:'Kraus CL, Culican SM. Use of biologic agents in ocular manifestations of rheumatic disease. International Journal of Clinical Rheumatology. 2012;2012:203819'}],footnotes:[],contributors:[{corresp:null,contributorFullName:"Ashvini Reddy",address:null,affiliation:'
Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, USA
Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, USA
'},{corresp:"yes",contributorFullName:"Darren J. Lee",address:"darren-lee@ouhsc.edu",affiliation:'
Department of Ophthalmology, Dean McGee Eye Institute, Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, USA
'}],corrections:null},book:{id:"7094",type:"book",title:"Advances in the Diagnosis and Management of Uveitis",subtitle:null,fullTitle:"Advances in the Diagnosis and Management of Uveitis",slug:"advances-in-the-diagnosis-and-management-of-uveitis",publishedDate:"May 29th 2019",bookSignature:"Alejandro Rodriguez-Garcia and C. Stephen Foster",coverURL:"https://cdn.intechopen.com/books/images_new/7094.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",isbn:"978-1-83880-543-2",printIsbn:"978-1-83880-542-5",pdfIsbn:"978-1-83880-712-2",isAvailableForWebshopOrdering:!0,editors:[{id:"209514",title:"Dr.",name:"Alejandro",middleName:null,surname:"Rodriguez-Garcia",slug:"alejandro-rodriguez-garcia",fullName:"Alejandro Rodriguez-Garcia"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}}},profile:{item:{id:"62365",title:"Dr.",name:"Eliana",middleName:null,surname:"Badiale-Furlong",email:"dqmebf@furg.br",fullName:"Eliana Badiale-Furlong",slug:"eliana-badiale-furlong",position:null,biography:null,institutionString:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",totalCites:0,totalChapterViews:"0",outsideEditionCount:0,totalAuthoredChapters:"1",totalEditedBooks:"0",personalWebsiteURL:null,twitterURL:null,linkedinURL:null,institution:null},booksEdited:[],chaptersAuthored:[{id:"20401",title:"Aflatoxins: Contamination, Analysis and Control",slug:"aflatoxins-contamination-analysis-and-control",abstract:null,signatures:"Giniani Carla Dors, Sergiane Souza Caldas, Vivian Feddern, Renata Heidtmann Bemvenuti, Helen Cristina dos Santos Hackbart, Michele Moraes de Souza, Melissa dos Santos Oliveira, Jaqueline Garda-Buffon, Ednei Gilberto Primel and Eliana Badiale-Furlong",authors:[{id:"15462",title:"Dr.",name:"Ednei",surname:"Primel",fullName:"Ednei Primel",slug:"ednei-primel",email:"eprimelfurg@gmail.com"},{id:"15463",title:"MSc.",name:"Sergiane",surname:"Caldas",fullName:"Sergiane Caldas",slug:"sergiane-caldas",email:"sergianecaldas@hotmail.com"},{id:"60264",title:"Dr.",name:"Giniani Carla",surname:"Dors",fullName:"Giniani Carla Dors",slug:"giniani-carla-dors",email:"dorsgi@yahoo.com.br"},{id:"62365",title:"Dr.",name:"Eliana",surname:"Badiale-Furlong",fullName:"Eliana Badiale-Furlong",slug:"eliana-badiale-furlong",email:"dqmebf@furg.br"},{id:"87217",title:"MSc",name:"Helen Cristina",surname:"Dos Santos Hackbart",fullName:"Helen Cristina Dos Santos Hackbart",slug:"helen-cristina-dos-santos-hackbart",email:"hhackbart@yahoo.com.br"},{id:"87219",title:"Dr.",name:"Vivian",surname:"Feddern",fullName:"Vivian Feddern",slug:"vivian-feddern",email:"vivian.feddern@embrapa.br"},{id:"87221",title:"MSc",name:"Michele",surname:"Moraes De Souza",fullName:"Michele Moraes De Souza",slug:"michele-moraes-de-souza",email:"michele.moraesdesouza@gmail.com"},{id:"87223",title:"MSc.",name:"Renata",surname:"Heidtmann Bemvenuti",fullName:"Renata Heidtmann Bemvenuti",slug:"renata-heidtmann-bemvenuti",email:"reheidtmann@yahoo.com.br"},{id:"87232",title:"Dr.",name:"Jaqueline",surname:"Garda Buffon",fullName:"Jaqueline Garda Buffon",slug:"jaqueline-garda-buffon",email:"jaquelinegarda@yahoo.com.br"},{id:"87236",title:"Dr.",name:"Melissa",surname:"Dos Santos Oliveira",fullName:"Melissa Dos Santos Oliveira",slug:"melissa-dos-santos-oliveira",email:"mel_olisa@yahoo.com.br"}],book:{id:"372",title:"Aflatoxins",slug:"aflatoxins-biochemistry-and-molecular-biology",productType:{id:"1",title:"Edited Volume"}}}],collaborators:[{id:"46279",title:"Prof.",name:"Gonzalo",surname:"Diaz",slug:"gonzalo-diaz",fullName:"Gonzalo Diaz",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"46391",title:"Dr.",name:"Kenneth",surname:"Ehrlich",slug:"kenneth-ehrlich",fullName:"Kenneth Ehrlich",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Agricultural Research Service",institutionURL:null,country:{name:"United States of America"}}},{id:"46479",title:"Dr.",name:"Robert",surname:"Brown",slug:"robert-brown",fullName:"Robert Brown",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"50275",title:"Dr.",name:"Jiujiang",surname:"Yu",slug:"jiujiang-yu",fullName:"Jiujiang Yu",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"59126",title:"Dr.",name:"Perng-Kuang",surname:"Chang",slug:"perng-kuang-chang",fullName:"Perng-Kuang Chang",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"61089",title:"Prof.",name:"Ana M.",surname:"Calvo",slug:"ana-m.-calvo",fullName:"Ana M. Calvo",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Northern Illinois University",institutionURL:null,country:{name:"United States of America"}}},{id:"62331",title:"Prof.",name:"Sourabh",surname:"Dhingra",slug:"sourabh-dhingra",fullName:"Sourabh Dhingra",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"85971",title:"MSc.",name:"Hansen",surname:"Murcia",slug:"hansen-murcia",fullName:"Hansen Murcia",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/85971/images/453_n.jpg",biography:null,institutionString:null,institution:{name:"Universidad Manuela Beltrán",institutionURL:null,country:{name:"Colombia"}}},{id:"136752",title:"Prof.",name:"Abebe",surname:"Menkir",slug:"abebe-menkir",fullName:"Abebe Menkir",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"International Institute of Tropical Agriculture",institutionURL:null,country:{name:"Benin"}}},{id:"136753",title:"Prof.",name:"Zhi-Yuan",surname:"Chen",slug:"zhi-yuan-chen",fullName:"Zhi-Yuan Chen",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Louisiana State University",institutionURL:null,country:{name:"United States of America"}}}]},generic:{page:{slug:"open-access-funding-institutions-list",title:"List of Institutions by Country",intro:"
If you are associated with any of the institutions in our list below, you can apply to receive OA publication funds by following the instructions provided in the links.
",metaTitle:"List of Institutions by Country",metaDescription:"If you are associated with any of the institutions in our list below, you can apply to receive OA publication funds by following the instructions provided in the links. However, if your research is financed through any of the below-mentioned funders, please consult their Open Access policies or grant ‘terms and conditions’ to explore ways to cover your publication costs (also accessible by clicking on the link in their title).",metaKeywords:null,canonicalURL:"open-access-funding-institutions-list",contentRaw:'[{"type":"htmlEditorComponent","content":"
Corresponding authors will receive a 25% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters. A 20% discount for publishing a long-form monographs, 25% for compacts and 23% for short-form monographs.
\\n\\n
CSIC affiliated authors can also take advantage of a central Open Access fund (amounting to 10,000 EUR) to cover up to 50% of the rest of the OAPF until it expires. Effective for chapters accepted from January 1, 2020.
Corresponding authors will receive a 25% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters. A 20% discount for publishing a long-form monographs, 25% for compacts and 23% for short-form monographs.
Corresponding authors will receive a 25% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters. A 20% discount for publishing a long-form monographs, 25% for compacts and 23% for short-form monographs.
Corresponding authors will receive a 25% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters. A 20% discount for publishing a long-form monographs, 25% for compacts and 23% for short-form monographs.
The Claremont Colleges are pledging funds via the Knowledge Unlatched program to ensure academics can publish Open Access content more easily.
\\n\\n
Corresponding authors will receive a 15% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters or monograph publications. To use the discount you will need to verify your institutional email address. These discounts are valid from 2020 to 2022.
The University of Massachusetts, Amherst is pledging funds via the Knowledge Unlatched program to ensure academics can publish Open Access content more easily.
\\n\\n
Corresponding authors will receive a 10% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters or monograph publications. To use the discount you will need to verify your institutional email address. These discounts are valid from 2020 to 2022.
The University of Surrey is pledging funds via the Knowledge Unlatched program to ensure academics can publish Open Access content more easily.
\\n\\n
Corresponding authors will receive a 10% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters or monograph publications. To use the discount you will need to verify your institutional email address. These discounts are valid from 2020 to 2022.
\\n\\n
\\n\\t
Virginia Polytechnic Institute and State University
Corresponding authors will receive a 25% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters. A 20% discount for publishing a long-form monographs, 25% for compacts and 23% for short-form monographs.
\n\n
CSIC affiliated authors can also take advantage of a central Open Access fund (amounting to 10,000 EUR) to cover up to 50% of the rest of the OAPF until it expires. Effective for chapters accepted from January 1, 2020.
Corresponding authors will receive a 25% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters. A 20% discount for publishing a long-form monographs, 25% for compacts and 23% for short-form monographs.
Corresponding authors will receive a 25% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters. A 20% discount for publishing a long-form monographs, 25% for compacts and 23% for short-form monographs.
Corresponding authors will receive a 25% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters. A 20% discount for publishing a long-form monographs, 25% for compacts and 23% for short-form monographs.
The Claremont Colleges are pledging funds via the Knowledge Unlatched program to ensure academics can publish Open Access content more easily.
\n\n
Corresponding authors will receive a 15% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters or monograph publications. To use the discount you will need to verify your institutional email address. These discounts are valid from 2020 to 2022.
The University of Massachusetts, Amherst is pledging funds via the Knowledge Unlatched program to ensure academics can publish Open Access content more easily.
\n\n
Corresponding authors will receive a 10% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters or monograph publications. To use the discount you will need to verify your institutional email address. These discounts are valid from 2020 to 2022.
The University of Surrey is pledging funds via the Knowledge Unlatched program to ensure academics can publish Open Access content more easily.
\n\n
Corresponding authors will receive a 10% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters or monograph publications. To use the discount you will need to verify your institutional email address. These discounts are valid from 2020 to 2022.
\n\n
\n\t
Virginia Polytechnic Institute and State University
Important: You must be a member or grantee of the above listed institutions in order to apply for their Open Access publication funds.
\n'}]},successStories:{items:[]},authorsAndEditors:{filterParams:{},profiles:[{id:"58592",title:"Dr.",name:"Arun",middleName:null,surname:"Shanker",slug:"arun-shanker",fullName:"Arun Shanker",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/58592/images/1664_n.jpg",biography:"Arun K. Shanker is serving as a Principal Scientist (Plant Physiology) with the Indian Council of Agricultural Research (ICAR) at the Central Research Institute for Dryland Agriculture in Hyderabad, India. He is working with the ICAR as a full time researcher since 1993 and has since earned his Advanced degree in Crop Physiology while in service. He has been awarded the prestigious Member of the Royal Society of Chemistry (MRSC), by the Royal Society of Chemistry, London in 2015. Presently he is working on systems biology approach to study the mechanism of abiotic stress tolerance in crops. His main focus now is to unravel the mechanism of drought and heat stress response in plants to tackle climate change related threats in agriculture.",institutionString:null,institution:{name:"Indian Council of Agricultural Research",country:{name:"India"}}},{id:"4782",title:"Prof.",name:"Bishnu",middleName:"P",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/4782/images/system/4782.jpg",biography:"Bishnu P. Pal is Professor of Physics at Mahindra École\nCentrale Hyderabad India since July 1st 2014 after retirement\nas Professor of Physics from IIT Delhi; Ph.D.’1975 from IIT\nDelhi; Fellow of OSA and SPIE; Senior Member IEEE;\nHonorary Foreign Member Royal Norwegian Society for\nScience and Arts; Member OSA Board of Directors (2009-\n11); Distinguished Lecturer IEEE Photonics Society (2005-\n07).",institutionString:null,institution:{name:"Indian Institute of Technology Delhi",country:{name:"India"}}},{id:"69653",title:"Dr.",name:"Chusak",middleName:null,surname:"Limsakul",slug:"chusak-limsakul",fullName:"Chusak Limsakul",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Prince of Songkla University",country:{name:"Thailand"}}},{id:"23804",title:"Dr.",name:"Hamzah",middleName:null,surname:"Arof",slug:"hamzah-arof",fullName:"Hamzah Arof",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/23804/images/5492_n.jpg",biography:"Hamzah Arof received his BSc from Michigan State University, and PhD from the University of Wales. Both degrees were in electrical engineering. His current research interests include signal processing and photonics. Currently he is affiliated with the Department of Electrical Engineering, University of Malaya, Malaysia.",institutionString:null,institution:{name:"University of Malaya",country:{name:"Malaysia"}}},{id:"41989",title:"Prof.",name:"He",middleName:null,surname:"Tian",slug:"he-tian",fullName:"He Tian",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"East China University of Science and Technology",country:{name:"China"}}},{id:"33351",title:null,name:"Hendra",middleName:null,surname:"Hermawan",slug:"hendra-hermawan",fullName:"Hendra Hermawan",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/33351/images/168_n.jpg",biography:null,institutionString:null,institution:{name:"Institut Teknologi Bandung",country:{name:"Indonesia"}}},{id:"11981",title:"Prof.",name:"Hiroshi",middleName:null,surname:"Ishiguro",slug:"hiroshi-ishiguro",fullName:"Hiroshi Ishiguro",position:null,profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRglaQAC/Profile_Picture_1626411846553",biography:"Hiroshi Ishiguro is an award-winning roboticist and innovator. As the Director of the Intelligent Robotics Laboratory, which is part of the Department of Systems Innovation in the Graduate School of Engineering Science at Osaka University, Japan, Ishiguro concentrates on making robots that are similar as possible to humans to understand the human species. A notable project of his laboratory is the Actroid, a humanoid robot with a lifelike appearance and observable behavior such as facial movements. (Sources: http://www.geminoid.jp/en/index.html, https://en.wikipedia.org/wiki/Hiroshi_Ishiguro)",institutionString:null,institution:{name:"Osaka University",country:{name:"Japan"}}},{id:"45747",title:"Dr.",name:"Hsin-I",middleName:null,surname:"Chang",slug:"hsin-i-chang",fullName:"Hsin-I Chang",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"National Chiayi University",country:{name:"Taiwan"}}},{id:"61581",title:"Dr.",name:"Joy Rizki Pangestu",middleName:null,surname:"Djuansjah",slug:"joy-rizki-pangestu-djuansjah",fullName:"Joy Rizki Pangestu Djuansjah",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/61581/images/237_n.jpg",biography:null,institutionString:null,institution:{name:"University of Technology Malaysia",country:{name:"Malaysia"}}},{id:"94249",title:"Prof.",name:"Junji",middleName:null,surname:"Kido",slug:"junji-kido",fullName:"Junji Kido",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Yamagata University",country:{name:"Japan"}}},{id:"12009",title:"Dr.",name:"Ki Young",middleName:null,surname:"Kim",slug:"ki-young-kim",fullName:"Ki Young Kim",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/12009/images/system/12009.jpg",biography:"Http://m80.knu.ac.kr/~doors",institutionString:null,institution:{name:"National Cheng Kung University",country:{name:"Taiwan"}}},{id:"132595",title:"Prof.",name:"Long",middleName:null,surname:"Wang",slug:"long-wang",fullName:"Long Wang",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Peking University",country:{name:"China"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:6581},{group:"region",caption:"Middle and South America",value:2,count:5888},{group:"region",caption:"Africa",value:3,count:2381},{group:"region",caption:"Asia",value:4,count:12507},{group:"region",caption:"Australia and Oceania",value:5,count:1006},{group:"region",caption:"Europe",value:6,count:17529}],offset:12,limit:12,total:12507},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{hasNoEditors:"0",sort:"dateEndThirdStepPublish",topicId:"7,21,23"},books:[{type:"book",id:"11481",title:"Active Learning - Research and Practice",subtitle:null,isOpenForSubmission:!0,hash:"3aba1eb3600a8c9ff880c628f70b3298",slug:null,bookSignature:"Ph.D. Delfín Ortega-Sánchez",coverURL:"https://cdn.intechopen.com/books/images_new/11481.jpg",editedByType:null,editors:[{id:"302925",title:"Ph.D.",name:"Delfín",surname:"Ortega-Sánchez",slug:"delfin-ortega-sanchez",fullName:"Delfín Ortega-Sánchez"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11603",title:"People Management - Highlighting Futures",subtitle:null,isOpenForSubmission:!0,hash:"982c56a5fb4684d966f8f5e76b2638f5",slug:null,bookSignature:"Dr. Diana Dias and Dr. Carla Magalhães",coverURL:"https://cdn.intechopen.com/books/images_new/11603.jpg",editedByType:null,editors:[{id:"450553",title:"Dr.",name:"Diana",surname:"Dias",slug:"diana-dias",fullName:"Diana Dias"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11440",title:"Aggression and Violent Behaviour",subtitle:null,isOpenForSubmission:!0,hash:"7f1d671b6a9e4df140f63d940ee2a1e1",slug:null,bookSignature:"Dr. Catherine Athanasiadou-Lewis",coverURL:"https://cdn.intechopen.com/books/images_new/11440.jpg",editedByType:null,editors:[{id:"287692",title:"Dr.",name:"Catherine",surname:"Lewis",slug:"catherine-lewis",fullName:"Catherine Lewis"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11476",title:"Globalization and Sustainability - Recent Advances, New Perspectives and Emerging Issues",subtitle:null,isOpenForSubmission:!0,hash:"8d41fa5f3a5da07469bbc121594bfd3e",slug:null,bookSignature:"Prof. Margherita Mori",coverURL:"https://cdn.intechopen.com/books/images_new/11476.jpg",editedByType:null,editors:[{id:"335401",title:"Prof.",name:"Margherita",surname:"Mori",slug:"margherita-mori",fullName:"Margherita Mori"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11439",title:"Crisis Management - Principles, Roles and Application",subtitle:null,isOpenForSubmission:!0,hash:"89fd49a084aea68bc39838042bdfce66",slug:null,bookSignature:"Ph.D. Carine J. Yi",coverURL:"https://cdn.intechopen.com/books/images_new/11439.jpg",editedByType:null,editors:[{id:"200332",title:"Ph.D.",name:"Carine",surname:"Yi",slug:"carine-yi",fullName:"Carine Yi"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11479",title:"Social Aspects of Ageing - Selected Challenges, Analyses, and Solutions",subtitle:null,isOpenForSubmission:!0,hash:"dbf515446deb32a56696801cd224984d",slug:null,bookSignature:"Ph.D. Andrzej Klimczuk",coverURL:"https://cdn.intechopen.com/books/images_new/11479.jpg",editedByType:null,editors:[{id:"320017",title:"Ph.D.",name:"Andrzej",surname:"Klimczuk",slug:"andrzej-klimczuk",fullName:"Andrzej Klimczuk"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11441",title:"Psychometrics - New Insights",subtitle:null,isOpenForSubmission:!0,hash:"c0fb1dfb98e0ae76496610595407145e",slug:null,bookSignature:" Sandro Misciagna",coverURL:"https://cdn.intechopen.com/books/images_new/11441.jpg",editedByType:null,editors:[{id:"103586",title:null,name:"Sandro",surname:"Misciagna",slug:"sandro-misciagna",fullName:"Sandro Misciagna"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11480",title:"Second Language Acquisition - Learning Theories and Recent Approaches",subtitle:null,isOpenForSubmission:!0,hash:"353e6f5278b4862f1f610fe7f1842125",slug:null,bookSignature:"Assistant Prof. Tabassum Maqbool",coverURL:"https://cdn.intechopen.com/books/images_new/11480.jpg",editedByType:null,editors:[{id:"450261",title:"Assistant Prof.",name:"Tabassum",surname:"Maqbool",slug:"tabassum-maqbool",fullName:"Tabassum Maqbool"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11772",title:"Corruption - New Insights",subtitle:null,isOpenForSubmission:!0,hash:"9cda6d2feaa52a6d523da74f2e2d7ffb",slug:null,bookSignature:"Dr. Josiane Fahed-Sreih",coverURL:"https://cdn.intechopen.com/books/images_new/11772.jpg",editedByType:null,editors:[{id:"103784",title:"Dr.",name:"Josiane",surname:"Fahed-Sreih",slug:"josiane-fahed-sreih",fullName:"Josiane Fahed-Sreih"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11434",title:"Indigenous Populations - Perspectives From Scholars and Practitioners in Contemporary Times",subtitle:null,isOpenForSubmission:!0,hash:"c0d1c1c93a36fd9d726445966316a373",slug:null,bookSignature:"Dr. Sylvanus Gbendazhi Barnabas",coverURL:"https://cdn.intechopen.com/books/images_new/11434.jpg",editedByType:null,editors:[{id:"293764",title:"Dr.",name:"Sylvanus",surname:"Barnabas",slug:"sylvanus-barnabas",fullName:"Sylvanus Barnabas"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11782",title:"Personality Traits - The Role in Psychopathology",subtitle:null,isOpenForSubmission:!0,hash:"d3a491e5194cad4c59b900dd57a11842",slug:null,bookSignature:" Vladimir V. Kalinin",coverURL:"https://cdn.intechopen.com/books/images_new/11782.jpg",editedByType:null,editors:[{id:"31572",title:null,name:"Vladimir V.",surname:"Kalinin",slug:"vladimir-v.-kalinin",fullName:"Vladimir V. Kalinin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11601",title:"Econometrics - Recent Advances and Applications",subtitle:null,isOpenForSubmission:!0,hash:"bc8ab49e2cf436c217a49ca8c12a22eb",slug:null,bookSignature:"Dr. Brian Sloboda",coverURL:"https://cdn.intechopen.com/books/images_new/11601.jpg",editedByType:null,editors:[{id:"452331",title:"Dr.",name:"Brian",surname:"Sloboda",slug:"brian-sloboda",fullName:"Brian Sloboda"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:41},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:11},{group:"topic",caption:"Business, Management and Economics",value:7,count:6},{group:"topic",caption:"Chemistry",value:8,count:20},{group:"topic",caption:"Computer and Information Science",value:9,count:20},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:15},{group:"topic",caption:"Engineering",value:11,count:60},{group:"topic",caption:"Environmental Sciences",value:12,count:8},{group:"topic",caption:"Immunology and Microbiology",value:13,count:9},{group:"topic",caption:"Materials Science",value:14,count:27},{group:"topic",caption:"Mathematics",value:15,count:9},{group:"topic",caption:"Medicine",value:16,count:122},{group:"topic",caption:"Nanotechnology and Nanomaterials",value:17,count:9},{group:"topic",caption:"Neuroscience",value:18,count:3},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:6},{group:"topic",caption:"Physics",value:20,count:11},{group:"topic",caption:"Psychology",value:21,count:10},{group:"topic",caption:"Robotics",value:22,count:4},{group:"topic",caption:"Social Sciences",value:23,count:9},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:4}],offset:12,limit:12,total:25},popularBooks:{featuredBooks:[{type:"book",id:"10584",title:"Engineered Wood Products for Construction",subtitle:null,isOpenForSubmission:!1,hash:"421757c56a3735986055250821275a51",slug:"engineered-wood-products-for-construction",bookSignature:"Meng Gong",coverURL:"https://cdn.intechopen.com/books/images_new/10584.jpg",editors:[{id:"274242",title:"Dr.",name:"Meng",middleName:null,surname:"Gong",slug:"meng-gong",fullName:"Meng Gong"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10222",title:"Demyelination Disorders",subtitle:null,isOpenForSubmission:!1,hash:"b6c26ceccacdde70c41c587361bd5558",slug:"demyelination-disorders",bookSignature:"Stavros J. Baloyannis, Fabian H. Rossi and Welwin Liu",coverURL:"https://cdn.intechopen.com/books/images_new/10222.jpg",editors:[{id:"156098",title:"Emeritus Prof.",name:"Stavros J.",middleName:"J.",surname:"Baloyannis",slug:"stavros-j.-baloyannis",fullName:"Stavros J. Baloyannis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9544",title:"Global Trade in the Emerging Business Environment",subtitle:null,isOpenForSubmission:!1,hash:"fb8cb09b9599246add78d508a98273d5",slug:"global-trade-in-the-emerging-business-environment",bookSignature:"Muhammad Mohiuddin, Jingbin Wang , Md. Samim Al Azad and Selim Ahmed",coverURL:"https://cdn.intechopen.com/books/images_new/9544.jpg",editors:[{id:"418514",title:"Dr.",name:"Muhammad",middleName:null,surname:"Mohiuddin",slug:"muhammad-mohiuddin",fullName:"Muhammad Mohiuddin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10979",title:"Parenting",subtitle:"Challenges of Child Rearing in a Changing Society",isOpenForSubmission:!1,hash:"6f345ebcf4fd61e73643c69063a12c7b",slug:"parenting-challenges-of-child-rearing-in-a-changing-society",bookSignature:"Sayyed Ali Samadi",coverURL:"https://cdn.intechopen.com/books/images_new/10979.jpg",editors:[{id:"52145",title:"Dr.",name:"Sayyed Ali",middleName:null,surname:"Samadi",slug:"sayyed-ali-samadi",fullName:"Sayyed Ali Samadi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9808",title:"Contemporary Topics in Patient Safety",subtitle:"Volume 1",isOpenForSubmission:!1,hash:"fb6371607c2c6c02c6a2af8892765aba",slug:"contemporary-topics-in-patient-safety-volume-1",bookSignature:"Stanislaw P. Stawicki and Michael S. Firstenberg",coverURL:"https://cdn.intechopen.com/books/images_new/9808.jpg",editors:[{id:"181694",title:"Dr.",name:"Stanislaw P.",middleName:null,surname:"Stawicki",slug:"stanislaw-p.-stawicki",fullName:"Stanislaw P. Stawicki"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10681",title:"Biodegradation Technology of Organic and Inorganic Pollutants",subtitle:null,isOpenForSubmission:!1,hash:"9a6e10e02788092872fd249436898e97",slug:"biodegradation-technology-of-organic-and-inorganic-pollutants",bookSignature:"Kassio Ferreira Mendes, Rodrigo Nogueira de Sousa and Kamila Cabral Mielke",coverURL:"https://cdn.intechopen.com/books/images_new/10681.jpg",editors:[{id:"197720",title:"Ph.D.",name:"Kassio",middleName:null,surname:"Ferreira Mendes",slug:"kassio-ferreira-mendes",fullName:"Kassio Ferreira Mendes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10764",title:"Antenna Systems",subtitle:null,isOpenForSubmission:!1,hash:"2fbf1c7a5d92723f08198fc9b526a8ad",slug:"antenna-systems",bookSignature:"Hussain Al-Rizzo and Said Abushamleh",coverURL:"https://cdn.intechopen.com/books/images_new/10764.jpg",editors:[{id:"153384",title:"Prof.",name:"Hussain",middleName:null,surname:"Al-Rizzo",slug:"hussain-al-rizzo",fullName:"Hussain Al-Rizzo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10668",title:"Sustainability of Concrete With Synthetic and Recycled Aggregates",subtitle:null,isOpenForSubmission:!1,hash:"55856c6a8bc3a5b21dae5a1af09a56b6",slug:"sustainability-of-concrete-with-synthetic-and-recycled-aggregates",bookSignature:"Hosam M. Saleh",coverURL:"https://cdn.intechopen.com/books/images_new/10668.jpg",editors:[{id:"144691",title:"Prof.",name:"Hosam",middleName:null,surname:"Saleh",slug:"hosam-saleh",fullName:"Hosam Saleh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10803",title:"Reactive Oxygen Species",subtitle:null,isOpenForSubmission:!1,hash:"176adcf090fdd1f93cb8ce3146e79ca1",slug:"reactive-oxygen-species",bookSignature:"Rizwan Ahmad",coverURL:"https://cdn.intechopen.com/books/images_new/10803.jpg",editors:[{id:"40482",title:null,name:"Rizwan",middleName:null,surname:"Ahmad",slug:"rizwan-ahmad",fullName:"Rizwan Ahmad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9032",title:"Corporate Social Responsibility",subtitle:null,isOpenForSubmission:!1,hash:"f609bf3251d7cc7bae0099a4374adfc3",slug:"corporate-social-responsibility",bookSignature:"Beatrice Orlando",coverURL:"https://cdn.intechopen.com/books/images_new/9032.jpg",editors:[{id:"232969",title:"Prof.",name:"Beatrice",middleName:null,surname:"Orlando",slug:"beatrice-orlando",fullName:"Beatrice Orlando"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10351",title:"Enhanced Liposuction",subtitle:"New Perspectives and Techniques",isOpenForSubmission:!1,hash:"f08ed6de16da357614586c5b58ed4dfa",slug:"enhanced-liposuction-new-perspectives-and-techniques",bookSignature:"Diane Irvine Duncan",coverURL:"https://cdn.intechopen.com/books/images_new/10351.jpg",editors:[{id:"279869",title:"Dr.",name:"Diane Irvine",middleName:null,surname:"Duncan",slug:"diane-irvine-duncan",fullName:"Diane Irvine Duncan"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10779",title:"21st Century Nanostructured Materials",subtitle:"Physics, Chemistry, Classification, and Emerging Applications in Industry, Biomedicine, and Agriculture",isOpenForSubmission:!1,hash:"72c67f97f9bef68200df115b5fd79884",slug:"21st-century-nanostructured-materials-physics-chemistry-classification-and-emerging-applications-in-industry-biomedicine-and-agriculture",bookSignature:"Phuong V. Pham",coverURL:"https://cdn.intechopen.com/books/images_new/10779.jpg",editors:[{id:"236073",title:"Dr.",name:"Phuong",middleName:"Viet",surname:"Pham",slug:"phuong-pham",fullName:"Phuong Pham"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:4386},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"10584",title:"Engineered Wood Products for Construction",subtitle:null,isOpenForSubmission:!1,hash:"421757c56a3735986055250821275a51",slug:"engineered-wood-products-for-construction",bookSignature:"Meng Gong",coverURL:"https://cdn.intechopen.com/books/images_new/10584.jpg",publishedDate:"April 28th 2022",numberOfDownloads:3665,editors:[{id:"274242",title:"Dr.",name:"Meng",middleName:null,surname:"Gong",slug:"meng-gong",fullName:"Meng Gong"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10222",title:"Demyelination Disorders",subtitle:null,isOpenForSubmission:!1,hash:"b6c26ceccacdde70c41c587361bd5558",slug:"demyelination-disorders",bookSignature:"Stavros J. Baloyannis, Fabian H. Rossi and Welwin Liu",coverURL:"https://cdn.intechopen.com/books/images_new/10222.jpg",publishedDate:"May 4th 2022",numberOfDownloads:1713,editors:[{id:"156098",title:"Emeritus Prof.",name:"Stavros J.",middleName:"J.",surname:"Baloyannis",slug:"stavros-j.-baloyannis",fullName:"Stavros J. Baloyannis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9544",title:"Global Trade in the Emerging Business Environment",subtitle:null,isOpenForSubmission:!1,hash:"fb8cb09b9599246add78d508a98273d5",slug:"global-trade-in-the-emerging-business-environment",bookSignature:"Muhammad Mohiuddin, Jingbin Wang , Md. Samim Al Azad and Selim Ahmed",coverURL:"https://cdn.intechopen.com/books/images_new/9544.jpg",publishedDate:"April 28th 2022",numberOfDownloads:2481,editors:[{id:"418514",title:"Dr.",name:"Muhammad",middleName:null,surname:"Mohiuddin",slug:"muhammad-mohiuddin",fullName:"Muhammad Mohiuddin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10979",title:"Parenting",subtitle:"Challenges of Child Rearing in a Changing Society",isOpenForSubmission:!1,hash:"6f345ebcf4fd61e73643c69063a12c7b",slug:"parenting-challenges-of-child-rearing-in-a-changing-society",bookSignature:"Sayyed Ali Samadi",coverURL:"https://cdn.intechopen.com/books/images_new/10979.jpg",publishedDate:"May 4th 2022",numberOfDownloads:1107,editors:[{id:"52145",title:"Dr.",name:"Sayyed Ali",middleName:null,surname:"Samadi",slug:"sayyed-ali-samadi",fullName:"Sayyed Ali Samadi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9808",title:"Contemporary Topics in Patient Safety",subtitle:"Volume 1",isOpenForSubmission:!1,hash:"fb6371607c2c6c02c6a2af8892765aba",slug:"contemporary-topics-in-patient-safety-volume-1",bookSignature:"Stanislaw P. Stawicki and Michael S. Firstenberg",coverURL:"https://cdn.intechopen.com/books/images_new/9808.jpg",publishedDate:"April 20th 2022",numberOfDownloads:3307,editors:[{id:"181694",title:"Dr.",name:"Stanislaw P.",middleName:null,surname:"Stawicki",slug:"stanislaw-p.-stawicki",fullName:"Stanislaw P. Stawicki"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10681",title:"Biodegradation Technology of Organic and Inorganic Pollutants",subtitle:null,isOpenForSubmission:!1,hash:"9a6e10e02788092872fd249436898e97",slug:"biodegradation-technology-of-organic-and-inorganic-pollutants",bookSignature:"Kassio Ferreira Mendes, Rodrigo Nogueira de Sousa and Kamila Cabral Mielke",coverURL:"https://cdn.intechopen.com/books/images_new/10681.jpg",publishedDate:"April 20th 2022",numberOfDownloads:3266,editors:[{id:"197720",title:"Ph.D.",name:"Kassio",middleName:null,surname:"Ferreira Mendes",slug:"kassio-ferreira-mendes",fullName:"Kassio Ferreira Mendes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10764",title:"Antenna Systems",subtitle:null,isOpenForSubmission:!1,hash:"2fbf1c7a5d92723f08198fc9b526a8ad",slug:"antenna-systems",bookSignature:"Hussain Al-Rizzo and Said Abushamleh",coverURL:"https://cdn.intechopen.com/books/images_new/10764.jpg",publishedDate:"April 28th 2022",numberOfDownloads:1868,editors:[{id:"153384",title:"Prof.",name:"Hussain",middleName:null,surname:"Al-Rizzo",slug:"hussain-al-rizzo",fullName:"Hussain Al-Rizzo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10668",title:"Sustainability of Concrete With Synthetic and Recycled Aggregates",subtitle:null,isOpenForSubmission:!1,hash:"55856c6a8bc3a5b21dae5a1af09a56b6",slug:"sustainability-of-concrete-with-synthetic-and-recycled-aggregates",bookSignature:"Hosam M. Saleh",coverURL:"https://cdn.intechopen.com/books/images_new/10668.jpg",publishedDate:"May 4th 2022",numberOfDownloads:856,editors:[{id:"144691",title:"Prof.",name:"Hosam",middleName:null,surname:"Saleh",slug:"hosam-saleh",fullName:"Hosam Saleh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10803",title:"Reactive Oxygen Species",subtitle:null,isOpenForSubmission:!1,hash:"176adcf090fdd1f93cb8ce3146e79ca1",slug:"reactive-oxygen-species",bookSignature:"Rizwan Ahmad",coverURL:"https://cdn.intechopen.com/books/images_new/10803.jpg",publishedDate:"April 28th 2022",numberOfDownloads:1704,editors:[{id:"40482",title:null,name:"Rizwan",middleName:null,surname:"Ahmad",slug:"rizwan-ahmad",fullName:"Rizwan Ahmad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9032",title:"Corporate Social Responsibility",subtitle:null,isOpenForSubmission:!1,hash:"f609bf3251d7cc7bae0099a4374adfc3",slug:"corporate-social-responsibility",bookSignature:"Beatrice Orlando",coverURL:"https://cdn.intechopen.com/books/images_new/9032.jpg",publishedDate:"March 16th 2022",numberOfDownloads:7489,editors:[{id:"232969",title:"Prof.",name:"Beatrice",middleName:null,surname:"Orlando",slug:"beatrice-orlando",fullName:"Beatrice Orlando"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"8737",title:"Rabies Virus at the Beginning of 21st Century",subtitle:null,isOpenForSubmission:!1,hash:"49cce3f548da548c718c865feb343509",slug:"rabies-virus-at-the-beginning-of-21st-century",bookSignature:"Sergey Tkachev",coverURL:"https://cdn.intechopen.com/books/images_new/8737.jpg",editedByType:"Edited by",publishedDate:"May 11th 2022",editors:[{id:"61139",title:"Dr.",name:"Sergey",middleName:null,surname:"Tkachev",slug:"sergey-tkachev",fullName:"Sergey Tkachev"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10861",title:"Furan Derivatives",subtitle:"Recent Advances and Applications",isOpenForSubmission:!1,hash:"fdfc39cecd82f91b0effac994f75c877",slug:"furan-derivatives-recent-advances-and-applications",bookSignature:"Anish Khan, Mohammed Muzibur Rahman, M. Ramesh, Salman Ahmad Khan and Abdullah Mohammed Ahmed Asiri",coverURL:"https://cdn.intechopen.com/books/images_new/10861.jpg",editedByType:"Edited by",publishedDate:"May 11th 2022",editors:[{id:"293058",title:"Dr.",name:"Anish",middleName:null,surname:"Khan",slug:"anish-khan",fullName:"Anish Khan"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10356",title:"Natural Medicinal Plants",subtitle:null,isOpenForSubmission:!1,hash:"943e56ccaaf19ff696d25aa638ae37d6",slug:"natural-medicinal-plants",bookSignature:"Hany A. El-Shemy",coverURL:"https://cdn.intechopen.com/books/images_new/10356.jpg",editedByType:"Edited by",publishedDate:"May 11th 2022",editors:[{id:"54719",title:"Prof.",name:"Hany",middleName:null,surname:"El-Shemy",slug:"hany-el-shemy",fullName:"Hany El-Shemy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10870",title:"Ultrasound Imaging",subtitle:"Current Topics",isOpenForSubmission:!1,hash:"2f0bc3733ab226d67fa73759ef0e12ad",slug:"ultrasound-imaging-current-topics",bookSignature:"Felix Okechukwu Erondu",coverURL:"https://cdn.intechopen.com/books/images_new/10870.jpg",editedByType:"Edited by",publishedDate:"May 11th 2022",editors:[{id:"68312",title:"Prof.",name:"Felix",middleName:null,surname:"Okechukwu Erondu",slug:"felix-okechukwu-erondu",fullName:"Felix Okechukwu Erondu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11392",title:"Leadership in a Changing World",subtitle:"A Multidimensional Perspective",isOpenForSubmission:!1,hash:"86a6d33cf601587e591064ce92effc02",slug:"leadership-in-a-changing-world-a-multidimensional-perspective",bookSignature:"Muhammad Mohiuddin, Bilal Khalid, Md. Samim Al Azad and Slimane Ed-dafali",coverURL:"https://cdn.intechopen.com/books/images_new/11392.jpg",editedByType:"Edited by",publishedDate:"May 11th 2022",editors:[{id:"418514",title:"Dr.",name:"Muhammad",middleName:null,surname:"Mohiuddin",slug:"muhammad-mohiuddin",fullName:"Muhammad Mohiuddin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10400",title:"The Application of Ant Colony Optimization",subtitle:null,isOpenForSubmission:!1,hash:"f4fdfd07ee1ab99fb7c740d6d0c144c6",slug:"the-application-of-ant-colony-optimization",bookSignature:"Ali Soofastaei",coverURL:"https://cdn.intechopen.com/books/images_new/10400.jpg",editedByType:"Edited by",publishedDate:"May 11th 2022",editors:[{id:"257455",title:"Dr.",name:"Ali",middleName:null,surname:"Soofastaei",slug:"ali-soofastaei",fullName:"Ali Soofastaei"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10915",title:"Leadership",subtitle:"New Insights",isOpenForSubmission:!1,hash:"0d72e79892f2a020cee66a52d09de5a4",slug:"leadership-new-insights",bookSignature:"Mário Franco",coverURL:"https://cdn.intechopen.com/books/images_new/10915.jpg",editedByType:"Edited by",publishedDate:"May 11th 2022",editors:[{id:"105529",title:"Dr.",name:"Mário",middleName:null,surname:"Franco",slug:"mario-franco",fullName:"Mário Franco"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10683",title:"Technological Innovations and Advances in Hydropower Engineering",subtitle:null,isOpenForSubmission:!1,hash:"7ce7ad8768bd2cad155470fe1fd883f4",slug:"technological-innovations-and-advances-in-hydropower-engineering",bookSignature:"Yizi Shang, Ling Shang and Xiaofei Li",coverURL:"https://cdn.intechopen.com/books/images_new/10683.jpg",editedByType:"Edited by",publishedDate:"May 11th 2022",editors:[{id:"349630",title:"Dr.",name:"Yizi",middleName:null,surname:"Shang",slug:"yizi-shang",fullName:"Yizi Shang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7102",title:"Pneumonia",subtitle:null,isOpenForSubmission:!1,hash:"9fd70142814192dcec58a176749f1b60",slug:"pneumonia",bookSignature:"Nima Rezaei",coverURL:"https://cdn.intechopen.com/books/images_new/7102.jpg",editedByType:"Edited by",publishedDate:"May 11th 2022",editors:[{id:"116250",title:"Dr.",name:"Nima",middleName:null,surname:"Rezaei",slug:"nima-rezaei",fullName:"Nima Rezaei"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9670",title:"Current Trends in Wheat Research",subtitle:null,isOpenForSubmission:!1,hash:"89d795987f1747a76eee532700d2093d",slug:"current-trends-in-wheat-research",bookSignature:"Mahmood-ur-Rahman Ansari",coverURL:"https://cdn.intechopen.com/books/images_new/9670.jpg",editedByType:"Edited by",publishedDate:"May 11th 2022",editors:[{id:"185476",title:"Dr.",name:"Mahmood-ur-Rahman",middleName:null,surname:"Ansari",slug:"mahmood-ur-rahman-ansari",fullName:"Mahmood-ur-Rahman Ansari"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"582",title:"Machine Learning and Data Mining",slug:"information-and-knowledge-engineering-machine-learning-and-data-mining",parent:{id:"92",title:"Information and Knowledge Engineering",slug:"information-and-knowledge-engineering"},numberOfBooks:4,numberOfSeries:0,numberOfAuthorsAndEditors:155,numberOfWosCitations:159,numberOfCrossrefCitations:152,numberOfDimensionsCitations:289,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicId:"582",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"8141",title:"Social Media and Machine Learning",subtitle:null,isOpenForSubmission:!1,hash:"155aa6c54dc411b5d2a1498f10f9417e",slug:"social-media-and-machine-learning",bookSignature:"Alberto Cano",coverURL:"https://cdn.intechopen.com/books/images_new/8141.jpg",editedByType:"Edited by",editors:[{id:"200724",title:"Dr.",name:"Alberto",middleName:null,surname:"Cano",slug:"alberto-cano",fullName:"Alberto Cano"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2746",title:"Theory and Applications for Advanced Text Mining",subtitle:null,isOpenForSubmission:!1,hash:"ed74b8719e654014932e764fe1e57816",slug:"theory-and-applications-for-advanced-text-mining",bookSignature:"Shigeaki Sakurai",coverURL:"https://cdn.intechopen.com/books/images_new/2746.jpg",editedByType:"Edited by",editors:[{id:"150787",title:"Prof.",name:"Shigeaki",middleName:null,surname:"Sakurai",slug:"shigeaki-sakurai",fullName:"Shigeaki Sakurai"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"30",title:"New Fundamental Technologies in Data Mining",subtitle:null,isOpenForSubmission:!1,hash:null,slug:"new-fundamental-technologies-in-data-mining",bookSignature:"Kimito Funatsu",coverURL:"https://cdn.intechopen.com/books/images_new/30.jpg",editedByType:"Edited by",editors:[{id:"16715",title:"Prof.",name:"Kimito",middleName:null,surname:"Funatsu",slug:"kimito-funatsu",fullName:"Kimito Funatsu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1358",title:"Knowledge-Oriented Applications in Data Mining",subtitle:null,isOpenForSubmission:!1,hash:"ab9e02a9453e1c7bd85182eb3f322e11",slug:"knowledge-oriented-applications-in-data-mining",bookSignature:"Kimito Funatsu",coverURL:"https://cdn.intechopen.com/books/images_new/1358.jpg",editedByType:"Edited by",editors:[{id:"16715",title:"Prof.",name:"Kimito",middleName:null,surname:"Funatsu",slug:"kimito-funatsu",fullName:"Kimito Funatsu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:4,seriesByTopicCollection:[],seriesByTopicTotal:0,mostCitedChapters:[{id:"38735",doi:"10.5772/51066",title:"Biomedical Named Entity Recognition: A Survey of Machine-Learning Tools",slug:"biomedical-named-entity-recognition-a-survey-of-machine-learning-tools",totalDownloads:5085,totalCrossrefCites:23,totalDimensionsCites:44,abstract:null,book:{id:"2746",slug:"theory-and-applications-for-advanced-text-mining",title:"Theory and Applications for Advanced Text Mining",fullTitle:"Theory and Applications for Advanced Text Mining"},signatures:"David Campos, Sérgio Matos and José Luís Oliveira",authors:[{id:"72193",title:"Dr.",name:"Jose Luis",middleName:null,surname:"Oliveira",slug:"jose-luis-oliveira",fullName:"Jose Luis Oliveira"},{id:"152991",title:"Dr.",name:"Sérgio",middleName:null,surname:"Matos",slug:"sergio-matos",fullName:"Sérgio Matos"},{id:"152992",title:"MSc.",name:"David",middleName:null,surname:"Campos",slug:"david-campos",fullName:"David Campos"}]},{id:"65993",doi:"10.5772/intechopen.84856",title:"Automatic Speech Emotion Recognition Using Machine Learning",slug:"automatic-speech-emotion-recognition-using-machine-learning",totalDownloads:4535,totalCrossrefCites:21,totalDimensionsCites:42,abstract:"This chapter presents a comparative study of speech emotion recognition (SER) systems. Theoretical definition, categorization of affective state and the modalities of emotion expression are presented. To achieve this study, an SER system, based on different classifiers and different methods for features extraction, is developed. Mel-frequency cepstrum coefficients (MFCC) and modulation spectral (MS) features are extracted from the speech signals and used to train different classifiers. Feature selection (FS) was applied in order to seek for the most relevant feature subset. Several machine learning paradigms were used for the emotion classification task. A recurrent neural network (RNN) classifier is used first to classify seven emotions. Their performances are compared later to multivariate linear regression (MLR) and support vector machines (SVM) techniques, which are widely used in the field of emotion recognition for spoken audio signals. Berlin and Spanish databases are used as the experimental data set. This study shows that for Berlin database all classifiers achieve an accuracy of 83% when a speaker normalization (SN) and a feature selection are applied to the features. For Spanish database, the best accuracy (94 %) is achieved by RNN classifier without SN and with FS.",book:{id:"8141",slug:"social-media-and-machine-learning",title:"Social Media and Machine Learning",fullTitle:"Social Media and Machine Learning"},signatures:"Leila Kerkeni, Youssef Serrestou, Mohamed Mbarki, Kosai Raoof, Mohamed Ali Mahjoub and Catherine Cleder",authors:[{id:"247090",title:"Ph.D. Student",name:"Leila",middleName:null,surname:"Kerkeni",slug:"leila-kerkeni",fullName:"Leila Kerkeni"}]},{id:"13173",doi:"10.5772/13222",title:"Glucose Prediction in Type 1 and Type 2 Diabetic Patients Using Data Driven Techniques",slug:"glucose-prediction-in-type-1-and-type-2-diabetic-patients-using-data-driven-techniques",totalDownloads:3623,totalCrossrefCites:0,totalDimensionsCites:27,abstract:null,book:{id:"1358",slug:"knowledge-oriented-applications-in-data-mining",title:"Knowledge-Oriented Applications in Data Mining",fullTitle:"Knowledge-Oriented Applications in Data Mining"},signatures:"Eleni I. Georga, Vasilios C. Protopappas and Dimitrios I. Fotiadis",authors:[{id:"14138",title:"Prof.",name:"Eleni",middleName:null,surname:"Georga",slug:"eleni-georga",fullName:"Eleni Georga"},{id:"16827",title:"Dr.",name:"Vasilios C.",middleName:null,surname:"Protopappas",slug:"vasilios-c.-protopappas",fullName:"Vasilios C. Protopappas"},{id:"16828",title:"Prof",name:"Dimitrios",middleName:null,surname:"Fotiadis",slug:"dimitrios-fotiadis",fullName:"Dimitrios Fotiadis"}]},{id:"13162",doi:"10.5772/13683",title:"Data Mining Using RFM Analysis",slug:"data-mining-using-rfm-analysis",totalDownloads:21720,totalCrossrefCites:17,totalDimensionsCites:26,abstract:null,book:{id:"1358",slug:"knowledge-oriented-applications-in-data-mining",title:"Knowledge-Oriented Applications in Data Mining",fullTitle:"Knowledge-Oriented Applications in Data Mining"},signatures:"Derya Birant",authors:[{id:"15609",title:"Dr.",name:"Derya",middleName:null,surname:"Birant",slug:"derya-birant",fullName:"Derya Birant"}]},{id:"13261",doi:"10.5772/13124",title:"Parallel and Distributed Data Mining",slug:"parallel-and-distributed-data-mining",totalDownloads:4346,totalCrossrefCites:8,totalDimensionsCites:10,abstract:null,book:{id:"30",slug:"new-fundamental-technologies-in-data-mining",title:"New Fundamental Technologies in Data Mining",fullTitle:"New Fundamental Technologies in Data Mining"},signatures:"Sujni Paul",authors:[{id:"13871",title:"Dr.",name:"Sujni",middleName:null,surname:"Paul",slug:"sujni-paul",fullName:"Sujni Paul"}]}],mostDownloadedChaptersLast30Days:[{id:"65993",title:"Automatic Speech Emotion Recognition Using Machine Learning",slug:"automatic-speech-emotion-recognition-using-machine-learning",totalDownloads:4556,totalCrossrefCites:21,totalDimensionsCites:42,abstract:"This chapter presents a comparative study of speech emotion recognition (SER) systems. Theoretical definition, categorization of affective state and the modalities of emotion expression are presented. To achieve this study, an SER system, based on different classifiers and different methods for features extraction, is developed. Mel-frequency cepstrum coefficients (MFCC) and modulation spectral (MS) features are extracted from the speech signals and used to train different classifiers. Feature selection (FS) was applied in order to seek for the most relevant feature subset. Several machine learning paradigms were used for the emotion classification task. A recurrent neural network (RNN) classifier is used first to classify seven emotions. Their performances are compared later to multivariate linear regression (MLR) and support vector machines (SVM) techniques, which are widely used in the field of emotion recognition for spoken audio signals. Berlin and Spanish databases are used as the experimental data set. This study shows that for Berlin database all classifiers achieve an accuracy of 83% when a speaker normalization (SN) and a feature selection are applied to the features. For Spanish database, the best accuracy (94 %) is achieved by RNN classifier without SN and with FS.",book:{id:"8141",slug:"social-media-and-machine-learning",title:"Social Media and Machine Learning",fullTitle:"Social Media and Machine Learning"},signatures:"Leila Kerkeni, Youssef Serrestou, Mohamed Mbarki, Kosai Raoof, Mohamed Ali Mahjoub and Catherine Cleder",authors:[{id:"247090",title:"Ph.D. Student",name:"Leila",middleName:null,surname:"Kerkeni",slug:"leila-kerkeni",fullName:"Leila Kerkeni"}]},{id:"13162",title:"Data Mining Using RFM Analysis",slug:"data-mining-using-rfm-analysis",totalDownloads:21725,totalCrossrefCites:17,totalDimensionsCites:26,abstract:null,book:{id:"1358",slug:"knowledge-oriented-applications-in-data-mining",title:"Knowledge-Oriented Applications in Data Mining",fullTitle:"Knowledge-Oriented Applications in Data Mining"},signatures:"Derya Birant",authors:[{id:"15609",title:"Dr.",name:"Derya",middleName:null,surname:"Birant",slug:"derya-birant",fullName:"Derya Birant"}]},{id:"38914",title:"Ontology Learning Using Word Net Lexical Expansion and Text Mining",slug:"ontology-learning-using-word-net-lexical-expansion-and-text-mining",totalDownloads:5415,totalCrossrefCites:6,totalDimensionsCites:6,abstract:null,book:{id:"2746",slug:"theory-and-applications-for-advanced-text-mining",title:"Theory and Applications for Advanced Text Mining",fullTitle:"Theory and Applications for Advanced Text Mining"},signatures:"Hiep Luong, Susan Gauch and Qiang Wang",authors:[{id:"151702",title:"Dr.",name:"Hiep",middleName:null,surname:"Luong",slug:"hiep-luong",fullName:"Hiep Luong"},{id:"162908",title:"Prof.",name:"Susan",middleName:null,surname:"Gauch",slug:"susan-gauch",fullName:"Susan Gauch"},{id:"162909",title:"MSc.",name:"Qiang",middleName:null,surname:"Wang",slug:"qiang-wang",fullName:"Qiang Wang"}]},{id:"38385",title:"Survey on Kernel-Based Relation Extraction",slug:"survey-on-kernel-based-relation-extraction",totalDownloads:6999,totalCrossrefCites:1,totalDimensionsCites:2,abstract:null,book:{id:"2746",slug:"theory-and-applications-for-advanced-text-mining",title:"Theory and Applications for Advanced Text Mining",fullTitle:"Theory and Applications for Advanced Text Mining"},signatures:"Hanmin Jung, Sung-Pil Choi, Seungwoo Lee and Sa-Kwang Song",authors:[{id:"152081",title:"Dr.",name:"Hanmin",middleName:null,surname:"Jung",slug:"hanmin-jung",fullName:"Hanmin Jung"},{id:"153590",title:"Dr.",name:"Sa-Kwang",middleName:null,surname:"Song",slug:"sa-kwang-song",fullName:"Sa-Kwang Song"},{id:"153591",title:"Dr.",name:"Seungwoo",middleName:null,surname:"Lee",slug:"seungwoo-lee",fullName:"Seungwoo Lee"},{id:"153592",title:"Dr.",name:"Sung-Pil",middleName:null,surname:"Choi",slug:"sung-pil-choi",fullName:"Sung-Pil Choi"}]},{id:"40461",title:"Automatic Compilation of Travel Information from Texts: A Survey",slug:"automatic-compilation-of-travel-information-from-texts-a-survey",totalDownloads:4678,totalCrossrefCites:1,totalDimensionsCites:1,abstract:null,book:{id:"2746",slug:"theory-and-applications-for-advanced-text-mining",title:"Theory and Applications for Advanced Text Mining",fullTitle:"Theory and Applications for Advanced Text Mining"},signatures:"Hidetsugu Nanba, Aya Ishino and Toshiyuki Takezawa",authors:[{id:"153069",title:"Dr.",name:"Hidetsugu",middleName:null,surname:"Nanba",slug:"hidetsugu-nanba",fullName:"Hidetsugu Nanba"},{id:"155243",title:"MSc.",name:"Aya",middleName:null,surname:"Ishino",slug:"aya-ishino",fullName:"Aya Ishino"},{id:"155244",title:"Prof.",name:"Toshiyuki",middleName:null,surname:"Takezawa",slug:"toshiyuki-takezawa",fullName:"Toshiyuki Takezawa"}]}],onlineFirstChaptersFilter:{topicId:"582",limit:6,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},subscriptionForm:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[],offset:8,limit:8,total:0},allSeries:{pteSeriesList:[{id:"14",title:"Artificial Intelligence",numberOfPublishedBooks:8,numberOfPublishedChapters:87,numberOfOpenTopics:6,numberOfUpcomingTopics:0,issn:"2633-1403",doi:"10.5772/intechopen.79920",isOpenForSubmission:!0},{id:"7",title:"Biomedical Engineering",numberOfPublishedBooks:12,numberOfPublishedChapters:98,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2631-5343",doi:"10.5772/intechopen.71985",isOpenForSubmission:!0}],lsSeriesList:[{id:"11",title:"Biochemistry",numberOfPublishedBooks:27,numberOfPublishedChapters:285,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2632-0983",doi:"10.5772/intechopen.72877",isOpenForSubmission:!0},{id:"25",title:"Environmental Sciences",numberOfPublishedBooks:1,numberOfPublishedChapters:9,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2754-6713",doi:"10.5772/intechopen.100362",isOpenForSubmission:!0},{id:"10",title:"Physiology",numberOfPublishedBooks:11,numberOfPublishedChapters:139,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2631-8261",doi:"10.5772/intechopen.72796",isOpenForSubmission:!0}],hsSeriesList:[{id:"3",title:"Dentistry",numberOfPublishedBooks:8,numberOfPublishedChapters:129,numberOfOpenTopics:0,numberOfUpcomingTopics:2,issn:"2631-6218",doi:"10.5772/intechopen.71199",isOpenForSubmission:!1},{id:"6",title:"Infectious Diseases",numberOfPublishedBooks:13,numberOfPublishedChapters:105,numberOfOpenTopics:3,numberOfUpcomingTopics:1,issn:"2631-6188",doi:"10.5772/intechopen.71852",isOpenForSubmission:!0},{id:"13",title:"Veterinary Medicine and Science",numberOfPublishedBooks:9,numberOfPublishedChapters:101,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2632-0517",doi:"10.5772/intechopen.73681",isOpenForSubmission:!0}],sshSeriesList:[{id:"22",title:"Business, Management and Economics",numberOfPublishedBooks:1,numberOfPublishedChapters:11,numberOfOpenTopics:2,numberOfUpcomingTopics:1,issn:null,doi:"10.5772/intechopen.100359",isOpenForSubmission:!0},{id:"23",title:"Education and Human Development",numberOfPublishedBooks:0,numberOfPublishedChapters:0,numberOfOpenTopics:2,numberOfUpcomingTopics:0,issn:null,doi:"10.5772/intechopen.100360",isOpenForSubmission:!1},{id:"24",title:"Sustainable Development",numberOfPublishedBooks:0,numberOfPublishedChapters:9,numberOfOpenTopics:4,numberOfUpcomingTopics:1,issn:null,doi:"10.5772/intechopen.100361",isOpenForSubmission:!0}],testimonialsList:[{id:"13",text:"The collaboration with and support of the technical staff of IntechOpen is fantastic. The whole process of submitting an article and editing of the submitted article goes extremely smooth and fast, the number of reads and downloads of chapters is high, and the contributions are also frequently cited.",author:{id:"55578",name:"Antonio",surname:"Jurado-Navas",institutionString:null,profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRisIQAS/Profile_Picture_1626166543950",slug:"antonio-jurado-navas",institution:{id:"720",name:"University of Malaga",country:{id:null,name:"Spain"}}}},{id:"6",text:"It is great to work with the IntechOpen to produce a worthwhile collection of research that also becomes a great educational resource and guide for future research endeavors.",author:{id:"259298",name:"Edward",surname:"Narayan",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/259298/images/system/259298.jpeg",slug:"edward-narayan",institution:{id:"3",name:"University of Queensland",country:{id:null,name:"Australia"}}}}]},series:{item:{id:"24",title:"Sustainable Development",doi:"10.5772/intechopen.100361",issn:null,scope:"
\r\n\tTransforming our World: the 2030 Agenda for Sustainable Development endorsed by United Nations and 193 Member States, came into effect on Jan 1, 2016, to guide decision making and actions to the year 2030 and beyond. Central to this Agenda are 17 Goals, 169 associated targets and over 230 indicators that are reviewed annually. The vision envisaged in the implementation of the SDGs is centered on the five Ps: People, Planet, Prosperity, Peace and Partnership. This call for renewed focused efforts ensure we have a safe and healthy planet for current and future generations.
\r\n
\r\n\t
\r\n
\r\n\tThis Series focuses on covering research and applied research involving the five Ps through the following topics:
\r\n
\r\n\t
\r\n
\r\n\t1. Sustainable Economy and Fair Society that relates to SDG 1 on No Poverty, SDG 2 on Zero Hunger, SDG 8 on Decent Work and Economic Growth, SDG 10 on Reduced Inequalities, SDG 12 on Responsible Consumption and Production, and SDG 17 Partnership for the Goals
\r\n
\r\n\t
\r\n
\r\n\t2. Health and Wellbeing focusing on SDG 3 on Good Health and Wellbeing and SDG 6 on Clean Water and Sanitation
\r\n
\r\n\t
\r\n
\r\n\t3. Inclusivity and Social Equality involving SDG 4 on Quality Education, SDG 5 on Gender Equality, and SDG 16 on Peace, Justice and Strong Institutions
\r\n
\r\n\t
\r\n
\r\n\t4. Climate Change and Environmental Sustainability comprising SDG 13 on Climate Action, SDG 14 on Life Below Water, and SDG 15 on Life on Land
\r\n
\r\n\t
\r\n
\r\n\t5. Urban Planning and Environmental Management embracing SDG 7 on Affordable Clean Energy, SDG 9 on Industry, Innovation and Infrastructure, and SDG 11 on Sustainable Cities and Communities.
\r\n
\r\n\t
\r\n
\r\n\tThe series also seeks to support the use of cross cutting SDGs, as many of the goals listed above, targets and indicators are all interconnected to impact our lives and the decisions we make on a daily basis, making them impossible to tie to a single topic.
",coverUrl:"https://cdn.intechopen.com/series/covers/24.jpg",latestPublicationDate:"April 24th, 2022",hasOnlineFirst:!0,numberOfPublishedBooks:0,editor:{id:"262440",title:"Prof.",name:"Usha",middleName:null,surname:"Iyer-Raniga",slug:"usha-iyer-raniga",fullName:"Usha Iyer-Raniga",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRYSXQA4/Profile_Picture_2022-02-28T13:55:36.jpeg",biography:"Usha Iyer-Raniga is a professor in the School of Property and Construction Management at RMIT University. Usha co-leads the One Planet Network’s Sustainable Buildings and Construction Programme (SBC), a United Nations 10 Year Framework of Programmes on Sustainable Consumption and Production (UN 10FYP SCP) aligned with Sustainable Development Goal 12. The work also directly impacts SDG 11 on Sustainable Cities and Communities. She completed her undergraduate degree as an architect before obtaining her Masters degree from Canada and her Doctorate in Australia. Usha has been a keynote speaker as well as an invited speaker at national and international conferences, seminars and workshops. Her teaching experience includes teaching in Asian countries. She has advised Austrade, APEC, national, state and local governments. She serves as a reviewer and a member of the scientific committee for national and international refereed journals and refereed conferences. She is on the editorial board for refereed journals and has worked on Special Issues. Usha has served and continues to serve on the Boards of several not-for-profit organisations and she has also served as panel judge for a number of awards including the Premiers Sustainability Award in Victoria and the International Green Gown Awards. Usha has published over 100 publications, including research and consulting reports. Her publications cover a wide range of scientific and technical research publications that include edited books, book chapters, refereed journals, refereed conference papers and reports for local, state and federal government clients. She has also produced podcasts for various organisations and participated in media interviews. She has received state, national and international funding worth over USD $25 million. Usha has been awarded the Quarterly Franklin Membership by London Journals Press (UK). Her biography has been included in the Marquis Who's Who in the World® 2018, 2016 (33rd Edition), along with approximately 55,000 of the most accomplished men and women from around the world, including luminaries as U.N. Secretary-General Ban Ki-moon. In 2017, Usha was awarded the Marquis Who’s Who Lifetime Achiever Award.",institutionString:null,institution:{name:"RMIT University",institutionURL:null,country:{name:"Australia"}}},editorTwo:null,editorThree:null},subseries:{paginationCount:5,paginationItems:[{id:"91",title:"Sustainable Economy and Fair Society",coverUrl:"https://cdn.intechopen.com/series_topics/covers/91.jpg",isOpenForSubmission:!0,editor:{id:"181603",title:"Dr.",name:"Antonella",middleName:null,surname:"Petrillo",slug:"antonella-petrillo",fullName:"Antonella Petrillo",profilePictureURL:"https://mts.intechopen.com/storage/users/181603/images/system/181603.jpg",biography:"Antonella Petrillo is a Professor at the Department of Engineering of the University of Naples “Parthenope”, Italy. She received her Ph.D. in Mechanical Engineering from the University of Cassino. Her research interests include multi-criteria decision analysis, industrial plant, logistics, manufacturing and safety. She serves as an Associate Editor for the International Journal of the Analytic Hierarchy Process. She is a member of AHP Academy and a member of several editorial boards. She has over 160 Scientific Publications in International Journals and Conferences and she is the author of 5 books on Innovation and Decision Making in Industrial Applications and Engineering.",institutionString:null,institution:{name:"Parthenope University of Naples",institutionURL:null,country:{name:"Italy"}}},editorTwo:null,editorThree:null},{id:"92",title:"Health and Wellbeing",coverUrl:"https://cdn.intechopen.com/series_topics/covers/92.jpg",isOpenForSubmission:!0,editor:{id:"348225",title:"Prof.",name:"Ann",middleName:null,surname:"Hemingway",slug:"ann-hemingway",fullName:"Ann Hemingway",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0033Y000035LZFoQAO/Profile_Picture_2022-04-11T14:55:40.jpg",biography:"Professor Hemingway is a public health researcher, Bournemouth University, undertaking international and UK research focused on reducing inequalities in health outcomes for marginalised and excluded populations and more recently focused on equine assisted interventions.",institutionString:null,institution:{name:"Bournemouth University",institutionURL:null,country:{name:"United Kingdom"}}},editorTwo:null,editorThree:null},{id:"93",title:"Inclusivity and Social Equity",coverUrl:"https://cdn.intechopen.com/series_topics/covers/93.jpg",isOpenForSubmission:!0,editor:{id:"210060",title:"Prof. Dr.",name:"Ebba",middleName:null,surname:"Ossiannilsson",slug:"ebba-ossiannilsson",fullName:"Ebba Ossiannilsson",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002g6LkBQAU/Profile_Picture_2022-02-28T13:31:48.png",biography:'Professor Dr. Ebba Ossiannilsson is an independent researcher, expert, consultant, quality auditor and influencer in the fields of open, flexible online and distance learning (OFDL) and the "new normal". Her focus is on quality, innovation, leadership, and personalised learning. She works primarily at the strategic and policy levels, both nationally and internationally, and with key international organisations. She is committed to promoting and improving OFDL in the context of SDG4 and the future of education. Ossiannilsson has more than 20 years of experience in her current field, but more than 40 years in the education sector. She works as a reviewer and expert for the European Commission and collaborates with the Joint Research Centre for Quality in Open Education. Ossiannilsson also collaborates with ITCILO and ICoBC (International Council on Badges and Credentials). She is a member of the ICDE Board of Directors and has previously served on the boards of EDEN and EUCEN. Ossiannilsson is a quality expert and reviewer for ICDE, EDEN and the EADTU. She chairs the ICDE OER Advocacy Committee and is a member of the ICDE Quality Network. She is regularly invited as a keynote speaker at conferences. She is a guest editor for several special issues and a member of the editorial board of several scientific journals. She has published more than 200 articles and is currently working on book projects in the field of OFDL. Ossiannilsson is a visiting professor at several international universities and was recently appointed Professor and Research Fellow at Victoria University of Wellington, NZ. Ossiannilsson has been awarded the following fellowships: EDEN Fellows, EDEN Council of Fellows, and Open Education Europe. She is a ICDE OER Ambassador, Open Education Europe Ambassador, GIZ Ambassador for Quality in Digital Learning, and part of the Globe-Community of Digital Learning and Champion of SPARC Europe. On a national level, she is a quality developer at the Swedish Institute for Standards (SIS) and for ISO. She is a member of the Digital Skills and Jobs Coalition Sweden and Vice President of the Swedish Association for Distance Education. She is currently working on a government initiative on quality in distance education at the National Council for Higher Education. She holds a Ph.D. from the University of Oulu, Finland.',institutionString:"Swedish Association for Distance Education, Sweden",institution:null},editorTwo:null,editorThree:null},{id:"94",title:"Climate Change and Environmental Sustainability",coverUrl:"https://cdn.intechopen.com/series_topics/covers/94.jpg",isOpenForSubmission:!1,editor:null,editorTwo:null,editorThree:null},{id:"95",title:"Urban Planning and Environmental Management",coverUrl:"https://cdn.intechopen.com/series_topics/covers/95.jpg",isOpenForSubmission:!0,editor:{id:"181079",title:"Dr.",name:"Christoph",middleName:null,surname:"Lüthi",slug:"christoph-luthi",fullName:"Christoph Lüthi",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRHSqQAO/Profile_Picture_2022-04-12T15:51:33.png",biography:"Dr. Christoph Lüthi is an urban infrastructure planner with over 25 years of experience in planning and design of urban infrastructure in middle and low-income countries. He holds a Master’s Degree in Urban Development Planning from the University College of London (UCL), and a Ph.D. in Urban Planning & Engineering from TU Berlin. He has conducted applied research on urban planning and infrastructure issues in over 20 countries in Africa and Asia. In 2005 he joined Eawag-Sandec as Leader of the Strategic Environmental Sanitation Planning Group. Since 2015 he heads the research department Sanitation, Water and Solid Waste for Development (Sandec) at the Swiss Federal Institute of Aquatic Research and Technology (Eawag).",institutionString:"Swiss Federal Institute of Aquatic Science and Technology, Switzerland",institution:null},editorTwo:{id:"290571",title:"Dr.",name:"Rui Alexandre",middleName:null,surname:"Castanho",slug:"rui-alexandre-castanho",fullName:"Rui Alexandre Castanho",profilePictureURL:"https://mts.intechopen.com/storage/users/290571/images/system/290571.jpg",biography:"Rui Alexandre Castanho has a master\\'s degree in Planning, Audit, and Control in Urban Green Spaces and an international Ph.D. in Sustainable Planning in Borderlands. Currently, he is a professor at WSB University, Poland, and a visiting professor at the University of Johannesburg, South Africa. Dr. Castanho is a post-doc researcher on the GREAT Project, University of Azores, Ponta Delgada, Portugal. He collaborates with the Environmental Resources Analysis Research Group (ARAM), University of Extremadura (UEx), Spain; VALORIZA - Research Center for the Enhancement of Endogenous Resources, Polytechnic Institute of Portalegre (IPP), Portugal; Centre for Tourism Research, Development and Innovation (CITUR), Madeira, Portugal; and AQUAGEO Research Group, University of Campinas (UNICAMP), Brazil.",institutionString:"University of Johannesburg, South Africa and WSB University, Poland",institution:{name:"University of Johannesburg",institutionURL:null,country:{name:"South Africa"}}},editorThree:null}]},overviewPageOFChapters:{paginationCount:9,paginationItems:[{id:"81493",title:"Rust Disease Classification Using Deep Learning Based Algorithm: The Case of Wheat",doi:"10.5772/intechopen.104426",signatures:"Shivani Sood, Harjeet Singh and Suruchi Jindal",slug:"rust-disease-classification-using-deep-learning-based-algorithm-the-case-of-wheat",totalDownloads:35,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Food Systems Resilience",coverURL:"https://cdn.intechopen.com/books/images_new/10897.jpg",subseries:{id:"91",title:"Sustainable Economy and Fair Society"}}},{id:"81428",title:"Observatory of Sustainable Development in Postgraduate Study Programs in Baja California",doi:"10.5772/intechopen.104641",signatures:"Rodolfo Martinez-Gutierrez, Maria Marcela Solis-Quinteros, Maria Esther Ibarra-Estrada and Angel Ernesto Jimenez-Bernardino",slug:"observatory-of-sustainable-development-in-postgraduate-study-programs-in-baja-california",totalDownloads:8,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Globalization and Sustainability - Recent Advances, New Perspectives and Emerging Issues",coverURL:"https://cdn.intechopen.com/books/images_new/11476.jpg",subseries:{id:"91",title:"Sustainable Economy and Fair Society"}}},{id:"81235",title:"Global Food System Transformation for Resilience",doi:"10.5772/intechopen.102749",signatures:"Jasper Okoro Godwin Elechi, Ikechukwu U. Nwiyi and Cornelius Smah Adamu",slug:"global-food-system-transformation-for-resilience",totalDownloads:30,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Food Systems Resilience",coverURL:"https://cdn.intechopen.com/books/images_new/10897.jpg",subseries:{id:"91",title:"Sustainable Economy and Fair Society"}}},{id:"80749",title:"Analysis of the Nexus Between Coping Strategies and Resilience to Food Insecurity Shocks: The Case of Rural Households in Boricha Woreda, Sidama National Regional State, Ethiopia",doi:"10.5772/intechopen.102613",signatures:"Adane Atara Debessa, Degefa Tolossa and Berhanu Denu",slug:"analysis-of-the-nexus-between-coping-strategies-and-resilience-to-food-insecurity-shocks-the-case-of",totalDownloads:45,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Food Systems Resilience",coverURL:"https://cdn.intechopen.com/books/images_new/10897.jpg",subseries:{id:"91",title:"Sustainable Economy and Fair Society"}}}]},overviewPagePublishedBooks:{paginationCount:0,paginationItems:[]},openForSubmissionBooks:{paginationCount:5,paginationItems:[{id:"11576",title:"Malaria - Recent Advances, and New Perspectives",coverURL:"https://cdn.intechopen.com/books/images_new/11576.jpg",hash:"5a01644fb0b4ce24c2f947913d154abe",secondStepPassed:!0,currentStepOfPublishingProcess:3,submissionDeadline:"April 26th 2022",isOpenForSubmission:!0,editors:[{id:"76041",title:"Prof.",name:"Pier Paolo",surname:"Piccaluga",slug:"pier-paolo-piccaluga",fullName:"Pier Paolo Piccaluga"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{id:"11577",title:"Tick-Borne Diseases - A Review and an Update of Knowledge on Infections in Human and Animal Population",coverURL:"https://cdn.intechopen.com/books/images_new/11577.jpg",hash:"3d72ae651ee2a04b2368bf798a3183ca",secondStepPassed:!0,currentStepOfPublishingProcess:3,submissionDeadline:"April 29th 2022",isOpenForSubmission:!0,editors:[{id:"51521",title:"Prof.",name:"Elisa",surname:"Pieragostini",slug:"elisa-pieragostini",fullName:"Elisa Pieragostini"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{id:"11570",title:"Influenza - New Approaches",coverURL:"https://cdn.intechopen.com/books/images_new/11570.jpg",hash:"157b379b9d7a4bf5e2cc7a742f155a44",secondStepPassed:!0,currentStepOfPublishingProcess:3,submissionDeadline:"May 10th 2022",isOpenForSubmission:!0,editors:[{id:"139889",title:"Dr.",name:"Seyyed Shamsadin",surname:"Athari",slug:"seyyed-shamsadin-athari",fullName:"Seyyed Shamsadin Athari"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{id:"11569",title:"Bacterial Sexually Transmitted Infections - New Findings, Diagnosis, Treatment, and Prevention",coverURL:"https://cdn.intechopen.com/books/images_new/11569.jpg",hash:"069d6142ecb0d46d14920102d48c0e9d",secondStepPassed:!1,currentStepOfPublishingProcess:2,submissionDeadline:"May 31st 2022",isOpenForSubmission:!0,editors:[{id:"189561",title:"Dr.",name:"Mihaela Laura",surname:"Vica",slug:"mihaela-laura-vica",fullName:"Mihaela Laura Vica"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{id:"11568",title:"Staphylococcal Infections - Recent Advances and Perspectives",coverURL:"https://cdn.intechopen.com/books/images_new/11568.jpg",hash:"92c881664d1921c7f2d0fee34b78cd08",secondStepPassed:!1,currentStepOfPublishingProcess:2,submissionDeadline:"June 1st 2022",isOpenForSubmission:!0,editors:[{id:"59719",title:"Dr.",name:"Jaime",surname:"Bustos-Martínez",slug:"jaime-bustos-martinez",fullName:"Jaime Bustos-Martínez"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null}]},onlineFirstChapters:{paginationCount:48,paginationItems:[{id:"81799",title:"Cross Talk of Purinergic and Immune Signaling: Implication in Inflammatory and Pathogenic Diseases",doi:"10.5772/intechopen.104978",signatures:"Richa Rai",slug:"cross-talk-of-purinergic-and-immune-signaling-implication-in-inflammatory-and-pathogenic-diseases",totalDownloads:0,totalCrossrefCites:null,totalDimensionsCites:0,authors:null,book:{title:"Purinergic System",coverURL:"https://cdn.intechopen.com/books/images_new/10801.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"81764",title:"Involvement of the Purinergic System in Cell Death in Models of Retinopathies",doi:"10.5772/intechopen.103935",signatures:"Douglas Penaforte Cruz, Marinna Garcia Repossi and Lucianne Fragel Madeira",slug:"involvement-of-the-purinergic-system-in-cell-death-in-models-of-retinopathies",totalDownloads:1,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Purinergic System",coverURL:"https://cdn.intechopen.com/books/images_new/10801.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"81756",title:"Alteration of Cytokines Level and Oxidative Stress Parameters in COVID-19",doi:"10.5772/intechopen.104950",signatures:"Marija Petrusevska, Emilija Atanasovska, Dragica Zendelovska, Aleksandar Eftimov and Katerina Spasovska",slug:"alteration-of-cytokines-level-and-oxidative-stress-parameters-in-covid-19",totalDownloads:1,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Chemokines Updates",coverURL:"https://cdn.intechopen.com/books/images_new/11672.jpg",subseries:{id:"18",title:"Proteomics"}}},{id:"81681",title:"Immunomodulatory Effects of a M2-Conditioned Medium (PRS® CK STORM): Theory on the Possible Complex Mechanism of Action through Anti-Inflammatory Modulation of the TLR System and the Purinergic System",doi:"10.5772/intechopen.104486",signatures:"Juan Pedro Lapuente",slug:"immunomodulatory-effects-of-a-m2-conditioned-medium-prs-ck-storm-theory-on-the-possible-complex-mech",totalDownloads:5,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Purinergic System",coverURL:"https://cdn.intechopen.com/books/images_new/10801.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"81647",title:"Diabetes and Epigenetics",doi:"10.5772/intechopen.104653",signatures:"Rasha A. Alhazzaa, Thomas Heinbockel and Antonei B. Csoka",slug:"diabetes-and-epigenetics",totalDownloads:9,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Epigenetics to Optogenetics - A New Paradigm in the Study of Biology",coverURL:"https://cdn.intechopen.com/books/images_new/9672.jpg",subseries:{id:"14",title:"Cell and Molecular Biology"}}},{id:"81580",title:"Graft-Versus-Host Disease: Pathogenesis and Treatment",doi:"10.5772/intechopen.104450",signatures:"Shin Mukai",slug:"graft-versus-host-disease-pathogenesis-and-treatment",totalDownloads:11,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Purinergic System",coverURL:"https://cdn.intechopen.com/books/images_new/10801.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"81533",title:"Prenylation of Natural Products: An Overview",doi:"10.5772/intechopen.104636",signatures:"Kantharaju Kamanna and Aravind Kamath",slug:"prenylation-of-natural-products-an-overview",totalDownloads:18,totalCrossrefCites:0,totalDimensionsCites:0,authors:[{name:"Kantharaju",surname:"Kamanna"}],book:{title:"Modifications of Biomolecules",coverURL:"https://cdn.intechopen.com/books/images_new/11098.jpg",subseries:null}},{id:"81067",title:"Encapsulation of Essential Oils and Their Use in Food Applications",doi:"10.5772/intechopen.103147",signatures:"Hamdy A. Shaaban and Amr Farouk",slug:"encapsulation-of-essential-oils-and-their-use-in-food-applications",totalDownloads:44,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Essential Oils - Advances in Extractions and Biological Applications",coverURL:"https://cdn.intechopen.com/books/images_new/11332.jpg",subseries:{id:"15",title:"Chemical Biology"}}},{id:"81099",title:"SK Channels and Heart Disease",doi:"10.5772/intechopen.104115",signatures:"Katherine Zhong, Shawn Kant, Frank Sellke and Jun Feng",slug:"sk-channels-and-heart-disease",totalDownloads:16,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Ion Channels - From Basic Properties to Medical Treatment",coverURL:"https://cdn.intechopen.com/books/images_new/10838.jpg",subseries:{id:"14",title:"Cell and Molecular Biology"}}},{id:"81188",title:"Structure- and Design-Based Difficulties in Recombinant Protein Purification in Bacterial Expression",doi:"10.5772/intechopen.103958",signatures:"Kubra Acikalin Coskun, Nazlıcan Yurekli, Elif Cansu Abay, Merve Tutar, Mervenur Al and Yusuf Tutar",slug:"structure-and-design-based-difficulties-in-recombinant-protein-purification-in-bacterial-expression",totalDownloads:20,totalCrossrefCites:0,totalDimensionsCites:0,authors:[{name:"Yusuf",surname:"Tutar"},{name:"Nazlican",surname:"Yurekli"},{name:"Merve",surname:"Tutar"},{name:"Mervenur",surname:"Al"},{name:"Elif Cansu",surname:"Abay"},{name:"Kubra",surname:"Acikalin Coskun"}],book:{title:"Protein Detection",coverURL:"https://cdn.intechopen.com/books/images_new/10839.jpg",subseries:{id:"18",title:"Proteomics"}}}]},subseriesFiltersForOFChapters:[{caption:"Proteomics",value:18,count:3,group:"subseries"},{caption:"Metabolism",value:17,count:8,group:"subseries"},{caption:"Cell and Molecular Biology",value:14,count:17,group:"subseries"},{caption:"Chemical Biology",value:15,count:19,group:"subseries"}],publishedBooks:{paginationCount:8,paginationItems:[{type:"book",id:"10859",title:"Data Mining",subtitle:"Concepts and Applications",coverURL:"https://cdn.intechopen.com/books/images_new/10859.jpg",slug:"data-mining-concepts-and-applications",publishedDate:"March 30th 2022",editedByType:"Edited by",bookSignature:"Ciza Thomas",hash:"63a4e514e537d3962cf53ef1c6b9d5eb",volumeInSeries:8,fullTitle:"Data Mining - Concepts and Applications",editors:[{id:"43680",title:"Prof.",name:"Ciza",middleName:null,surname:"Thomas",slug:"ciza-thomas",fullName:"Ciza Thomas",profilePictureURL:"https://mts.intechopen.com/storage/users/43680/images/system/43680.jpeg",institutionString:null,institution:{name:"Government of Kerala",institutionURL:null,country:{name:"India"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"10651",title:"Machine Learning",subtitle:"Algorithms, Models and Applications",coverURL:"https://cdn.intechopen.com/books/images_new/10651.jpg",slug:"machine-learning-algorithms-models-and-applications",publishedDate:"December 22nd 2021",editedByType:"Edited by",bookSignature:"Jaydip Sen",hash:"6208156401c496e0a4ca5ff4265324cc",volumeInSeries:7,fullTitle:"Machine Learning - Algorithms, Models and Applications",editors:[{id:"4519",title:"Prof.",name:"Jaydip",middleName:null,surname:"Sen",slug:"jaydip-sen",fullName:"Jaydip Sen",profilePictureURL:"https://mts.intechopen.com/storage/users/4519/images/system/4519.jpeg",institutionString:"Praxis Business School",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9869",title:"Self-Driving Vehicles and Enabling Technologies",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/9869.jpg",slug:"self-driving-vehicles-and-enabling-technologies",publishedDate:"September 22nd 2021",editedByType:"Edited by",bookSignature:"Marian Găiceanu",hash:"fd451ca2e4785ef098e04b7d695a18d9",volumeInSeries:6,fullTitle:"Self-Driving Vehicles and Enabling Technologies",editors:[{id:"169608",title:"Prof.",name:"Marian",middleName:null,surname:"Găiceanu",slug:"marian-gaiceanu",fullName:"Marian Găiceanu",profilePictureURL:"https://mts.intechopen.com/storage/users/169608/images/system/169608.png",institutionString:'"Dunarea de Jos" University of Galati',institution:{name:'"Dunarea de Jos" University of Galati',institutionURL:null,country:{name:"Romania"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9958",title:"Artificial Intelligence",subtitle:"Latest Advances, New Paradigms and Novel Applications",coverURL:"https://cdn.intechopen.com/books/images_new/9958.jpg",slug:"artificial-intelligence-latest-advances-new-paradigms-and-novel-applications",publishedDate:"September 1st 2021",editedByType:"Edited by",bookSignature:"Eneko Osaba, Esther Villar, Jesús L. Lobo and Ibai Laña",hash:"39648fbfdaa11385097d62b1f13aad54",volumeInSeries:5,fullTitle:"Artificial Intelligence - Latest Advances, New Paradigms and Novel Applications",editors:[{id:"221364",title:"Dr.",name:"Eneko",middleName:null,surname:"Osaba",slug:"eneko-osaba",fullName:"Eneko Osaba",profilePictureURL:"https://mts.intechopen.com/storage/users/221364/images/system/221364.jpg",institutionString:"TECNALIA Research & Innovation",institution:{name:"Tecnalia",institutionURL:null,country:{name:"Spain"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9963",title:"Advances and Applications in Deep Learning",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/9963.jpg",slug:"advances-and-applications-in-deep-learning",publishedDate:"December 9th 2020",editedByType:"Edited by",bookSignature:"Marco Antonio Aceves-Fernandez",hash:"0d51ba46f22e55cb89140f60d86a071e",volumeInSeries:4,fullTitle:"Advances and Applications in Deep Learning",editors:[{id:"24555",title:"Dr.",name:"Marco Antonio",middleName:null,surname:"Aceves Fernandez",slug:"marco-antonio-aceves-fernandez",fullName:"Marco Antonio Aceves Fernandez",profilePictureURL:"https://mts.intechopen.com/storage/users/24555/images/system/24555.jpg",institutionString:null,institution:{name:"Autonomous University of Queretaro",institutionURL:null,country:{name:"Mexico"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"7656",title:"Fuzzy Logic",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/7656.jpg",slug:"fuzzy-logic",publishedDate:"February 5th 2020",editedByType:"Edited by",bookSignature:"Constantin Volosencu",hash:"54f092d4ffe0abf5e4172a80025019bc",volumeInSeries:3,fullTitle:"Fuzzy Logic",editors:[{id:"1063",title:"Prof.",name:"Constantin",middleName:null,surname:"Volosencu",slug:"constantin-volosencu",fullName:"Constantin Volosencu",profilePictureURL:"https://mts.intechopen.com/storage/users/1063/images/system/1063.png",institutionString:"Polytechnic University of Timişoara",institution:{name:"Polytechnic University of Timişoara",institutionURL:null,country:{name:"Romania"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"7726",title:"Swarm Intelligence",subtitle:"Recent Advances, New Perspectives and Applications",coverURL:"https://cdn.intechopen.com/books/images_new/7726.jpg",slug:"swarm-intelligence-recent-advances-new-perspectives-and-applications",publishedDate:"December 4th 2019",editedByType:"Edited by",bookSignature:"Javier Del Ser, Esther Villar and Eneko Osaba",hash:"e7ea7e74ce7a7a8e5359629e07c68d31",volumeInSeries:2,fullTitle:"Swarm Intelligence - Recent Advances, New Perspectives and Applications",editors:[{id:"49813",title:"Dr.",name:"Javier",middleName:null,surname:"Del Ser",slug:"javier-del-ser",fullName:"Javier Del Ser",profilePictureURL:"https://mts.intechopen.com/storage/users/49813/images/system/49813.png",institutionString:"Tecnalia Research & Innovation",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"7723",title:"Artificial Intelligence",subtitle:"Applications in Medicine and Biology",coverURL:"https://cdn.intechopen.com/books/images_new/7723.jpg",slug:"artificial-intelligence-applications-in-medicine-and-biology",publishedDate:"July 31st 2019",editedByType:"Edited by",bookSignature:"Marco Antonio Aceves-Fernandez",hash:"a3852659e727f95c98c740ed98146011",volumeInSeries:1,fullTitle:"Artificial Intelligence - Applications in Medicine and Biology",editors:[{id:"24555",title:"Dr.",name:"Marco Antonio",middleName:null,surname:"Aceves Fernandez",slug:"marco-antonio-aceves-fernandez",fullName:"Marco Antonio Aceves Fernandez",profilePictureURL:"https://mts.intechopen.com/storage/users/24555/images/system/24555.jpg",institutionString:null,institution:{name:"Autonomous University of Queretaro",institutionURL:null,country:{name:"Mexico"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null}]},subseriesFiltersForPublishedBooks:[{group:"subseries",caption:"Evolutionary Computation",value:25,count:1},{group:"subseries",caption:"Machine Learning and Data Mining",value:26,count:3},{group:"subseries",caption:"Applied Intelligence",value:22,count:4}],publicationYearFilters:[{group:"publicationYear",caption:"2022",value:2022,count:1},{group:"publicationYear",caption:"2021",value:2021,count:3},{group:"publicationYear",caption:"2020",value:2020,count:2},{group:"publicationYear",caption:"2019",value:2019,count:2}],authors:{paginationCount:25,paginationItems:[{id:"429683",title:"Dr.",name:"Bilal",middleName:null,surname:"Khalid",slug:"bilal-khalid",fullName:"Bilal Khalid",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/429683/images/system/429683.png",biography:"Dr. Bilal Khalid received a Ph.D. in Industrial Business Administration from KMITL Business School, Bangkok, in 2021, and a master’s in International Business Management from Stamford International University, Bangkok, in 2017. Dr. Khalid\\'s research interests include leadership and negotiations, digital transformations, gamification, eLearning, blockchain, Big Data, and management of information technology. Dr. Bilal Khalid also serves as an academic editor at Education Research International and a reviewer for international journals.",institutionString:"KMITL Business School",institution:{name:"King Mongkut's Institute of Technology Ladkrabang",country:{name:"Thailand"}}},{id:"418514",title:"Dr.",name:"Muhammad",middleName:null,surname:"Mohiuddin",slug:"muhammad-mohiuddin",fullName:"Muhammad Mohiuddin",position:null,profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0033Y000038UqSfQAK/Profile_Picture_2022-05-13T10:39:03.jpg",biography:"Dr. Muhammad Mohiuddin is an Associate Professor of International Business at Laval University, Canada. He has taught at Thompson Rivers University, Canada; University of Paris-Est, France; Osnabruck University of Applied Science, Germany; and Shanghai Institute of Technology and Tianjin University of Technology, China. He has published research in Research Policy, Applied Economics, Review of Economic Philosophy, Strategic Change, International Journal of Logistics, Sustainability, Journal of Environmental Management, Journal of Global Information Management, Journal of Cleaner Production, M@N@GEMENT, and more. He is a member of CEDIMES Institut (France), Academy of International Business (AIB), Strategic Management Society (SMS), Academy of Management (AOM), Administrative Science Association of Canada (ASAC), and Canadian council of small business and entrepreneurship (CCSBE). He is currently the director of the Research Group on Contemporary Asia (GERAC) at Laval University. He is also co-managing editor of Transnational Corporations Review and a guest editor for Electronic Commerce Research and Journal of Internet Technology.",institutionString:null,institution:{name:"Université Laval",country:{name:"Canada"}}},{id:"189147",title:"Dr.",name:"Hailan",middleName:null,surname:"Salamun",slug:"hailan-salamun",fullName:"Hailan Salamun",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/189147/images/19274_n.jpeg",biography:"Hailan Salamun, (Dr.) was born in Selangor, Malaysia and graduated from Tunku Ampuan Jamaah Religious High School at Shah Alam. Obtained a degree from the International Islamic University (UIA), Gombak in the field of Islamic Revealed Knowledge and Heritage. Next, I furthered my studies to the professional level to obtain a Diploma in Education at UIA. After serving for several years in school, I furthered my studies to the Master of Dakwah and Leadership at Universiti Kebangsaan Malaysia (UKM), Bangi. I graduated with a Doctor of Philosophy in Principalship Leadership from the University of Malaya (UM) in 2010. I am currently a senior lecturer in the Department of Nationalism and Civilization, Center for Basic and Continuing Education, Universiti Malaysia Terengganu. Prior to that, I had served in several educational institutions such as schools, the Institute of Teacher Education (IPG), and also the University of Malaya. I am also actively involved in paper presentation, writing and publishing. My research interests are focused on leadership, education, society and Islamic civilization. This area of research requires a detailed understanding of Islamic studies and research studies in leadership. Another research interest that I have explored recently is the politics of the Malay community and also the leadership of the mosque.",institutionString:null,institution:{name:"Universiti Malaysia Terengganu",country:{name:"Malaysia"}}},{id:"442081",title:"Dr.",name:"Audrey",middleName:null,surname:"Addy",slug:"audrey-addy",fullName:"Audrey Addy",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Kwame Nkrumah University of Science and Technology",country:{name:"Ghana"}}},{id:"437993",title:"Mr.",name:"Job",middleName:null,surname:"Jackson",slug:"job-jackson",fullName:"Job Jackson",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Management College of Southern Africa",country:{name:"South Africa"}}},{id:"428495",title:"Prof.",name:"Asyraf",middleName:null,surname:"Ab Rahman",slug:"asyraf-ab-rahman",fullName:"Asyraf Ab Rahman",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universiti Malaysia Terengganu",country:{name:"Malaysia"}}},{id:"429650",title:"Dr.",name:"Jacqueline",middleName:null,surname:"Kareem",slug:"jacqueline-kareem",fullName:"Jacqueline Kareem",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Christ University",country:{name:"India"}}},{id:"421041",title:"Dr.",name:"Sunil",middleName:null,surname:"Kumar Ramdas",slug:"sunil-kumar-ramdas",fullName:"Sunil Kumar Ramdas",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Jain University",country:{name:"India"}}},{id:"421833",title:"Mr.",name:"Eugene",middleName:null,surname:"Owusu-Acheampong",slug:"eugene-owusu-acheampong",fullName:"Eugene Owusu-Acheampong",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Ghana",country:{name:"Ghana"}}},{id:"239876",title:"Ph.D.",name:"Luciana",middleName:null,surname:"Mourão",slug:"luciana-mourao",fullName:"Luciana Mourão",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universidade Salgado de Oliveira",country:{name:"Brazil"}}},{id:"421735",title:"Dr.",name:"elizabeth",middleName:null,surname:"addy",slug:"elizabeth-addy",fullName:"elizabeth addy",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"442083",title:"Dr.",name:"James",middleName:null,surname:"Addy",slug:"james-addy",fullName:"James Addy",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"437991",title:"Prof.",name:"Muhammad",middleName:null,surname:"Hoque",slug:"muhammad-hoque",fullName:"Muhammad Hoque",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"421006",title:"Dr.",name:"Anna",middleName:null,surname:"Uster",slug:"anna-uster",fullName:"Anna Uster",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"470243",title:"Dr.",name:"Md Samim",middleName:null,surname:"Al Azad",slug:"md-samim-al-azad",fullName:"Md Samim Al Azad",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"470244",title:"Dr.",name:"Slimane",middleName:null,surname:"Ed-dafali",slug:"slimane-ed-dafali",fullName:"Slimane Ed-dafali",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"421011",title:"Dr.",name:"Afatakpa",middleName:null,surname:"Fortune",slug:"afatakpa-fortune",fullName:"Afatakpa Fortune",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"446057",title:"Mr.",name:"Okedare",middleName:null,surname:"David Olubukunmi",slug:"okedare-david-olubukunmi",fullName:"Okedare David Olubukunmi",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"421778",title:"Dr.",name:"Fatimah",middleName:"Saeed",surname:"AlAhmari",slug:"fatimah-alahmari",fullName:"Fatimah AlAhmari",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"421024",title:"Prof.",name:"Harold Andrew",middleName:null,surname:"Patrick",slug:"harold-andrew-patrick",fullName:"Harold Andrew Patrick",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"421065",title:"Ms.",name:"Euzália",middleName:null,surname:"do Rosário Botelho Tomé",slug:"euzalia-do-rosario-botelho-tome",fullName:"Euzália do Rosário Botelho Tomé",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"421053",title:"Associate Prof.",name:"Ken",middleName:null,surname:"Kalala Ndalamba",slug:"ken-kalala-ndalamba",fullName:"Ken Kalala Ndalamba",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"421826",title:"Dr.",name:"Inusah",middleName:null,surname:"Salifu",slug:"inusah-salifu",fullName:"Inusah Salifu",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"420823",title:"Prof.",name:"Gardênia da Silva",middleName:null,surname:"Abbad",slug:"gardenia-da-silva-abbad",fullName:"Gardênia da Silva Abbad",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"437613",title:"MSc.",name:"Juliana",middleName:null,surname:"Legentil",slug:"juliana-legentil",fullName:"Juliana Legentil",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null}]}},subseries:{item:{id:"9",type:"subseries",title:"Biotechnology - Biosensors, Biomaterials and Tissue Engineering",keywords:"Biotechnology, Biosensors, Biomaterials, Tissue Engineering",scope:"The Biotechnology - Biosensors, Biomaterials and Tissue Engineering topic within the Biomedical Engineering Series aims to rapidly publish contributions on all aspects of biotechnology, biosensors, biomaterial and tissue engineering. We encourage the submission of manuscripts that provide novel and mechanistic insights that report significant advances in the fields. Topics can include but are not limited to: Biotechnology such as biotechnological products and process engineering; Biotechnologically relevant enzymes and proteins; Bioenergy and biofuels; Applied genetics and molecular biotechnology; Genomics, transcriptomics, proteomics; Applied microbial and cell physiology; Environmental biotechnology; Methods and protocols. Moreover, topics in biosensor technology, like sensors that incorporate enzymes, antibodies, nucleic acids, whole cells, tissues and organelles, and other biological or biologically inspired components will be considered, and topics exploring transducers, including those based on electrochemical and optical piezoelectric, thermal, magnetic, and micromechanical elements. Chapters exploring biomaterial approaches such as polymer synthesis and characterization, drug and gene vector design, biocompatibility, immunology and toxicology, and self-assembly at the nanoscale, are welcome. Finally, the tissue engineering subcategory will support topics such as the fundamentals of stem cells and progenitor cells and their proliferation, differentiation, bioreactors for three-dimensional culture and studies of phenotypic changes, stem and progenitor cells, both short and long term, ex vivo and in vivo implantation both in preclinical models and also in clinical trials.",coverUrl:"https://cdn.intechopen.com/series_topics/covers/9.jpg",hasOnlineFirst:!1,hasPublishedBooks:!0,annualVolume:11405,editor:{id:"126286",title:"Dr.",name:"Luis",middleName:"Jesús",surname:"Villarreal-Gómez",slug:"luis-villarreal-gomez",fullName:"Luis Villarreal-Gómez",profilePictureURL:"https://mts.intechopen.com/storage/users/126286/images/system/126286.jpg",biography:"Dr. Luis Villarreal is a research professor from the Facultad de Ciencias de la Ingeniería y Tecnología, Universidad Autónoma de Baja California, Tijuana, Baja California, México. Dr. Villarreal is the editor in chief and founder of the Revista de Ciencias Tecnológicas (RECIT) (https://recit.uabc.mx/) and is a member of several editorial and reviewer boards for numerous international journals. He has published more than thirty international papers and reviewed more than ninety-two manuscripts. His research interests include biomaterials, nanomaterials, bioengineering, biosensors, drug delivery systems, and tissue engineering.",institutionString:null,institution:{name:"Autonomous University of Baja California",institutionURL:null,country:{name:"Mexico"}}},editorTwo:null,editorThree:null,series:{id:"7",title:"Biomedical Engineering",doi:"10.5772/intechopen.71985",issn:"2631-5343"},editorialBoard:[{id:"35539",title:"Dr.",name:"Cecilia",middleName:null,surname:"Cristea",slug:"cecilia-cristea",fullName:"Cecilia Cristea",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002aYQ65QAG/Profile_Picture_1621007741527",institutionString:null,institution:{name:"Iuliu Hațieganu University of Medicine and Pharmacy",institutionURL:null,country:{name:"Romania"}}},{id:"40735",title:"Dr.",name:"Gil",middleName:"Alberto Batista",surname:"Gonçalves",slug:"gil-goncalves",fullName:"Gil Gonçalves",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002aYRLGQA4/Profile_Picture_1628492612759",institutionString:null,institution:{name:"University of Aveiro",institutionURL:null,country:{name:"Portugal"}}},{id:"211725",title:"Associate Prof.",name:"Johann F.",middleName:null,surname:"Osma",slug:"johann-f.-osma",fullName:"Johann F. Osma",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bSDv7QAG/Profile_Picture_1626602531691",institutionString:null,institution:{name:"Universidad de Los Andes",institutionURL:null,country:{name:"Colombia"}}},{id:"69697",title:"Dr.",name:"Mani T.",middleName:null,surname:"Valarmathi",slug:"mani-t.-valarmathi",fullName:"Mani T. Valarmathi",profilePictureURL:"https://mts.intechopen.com/storage/users/69697/images/system/69697.jpg",institutionString:"Religen Inc. | A Life Science Company, United States of America",institution:null},{id:"205081",title:"Dr.",name:"Marco",middleName:"Vinícius",surname:"Chaud",slug:"marco-chaud",fullName:"Marco Chaud",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bSDGeQAO/Profile_Picture_1622624307737",institutionString:null,institution:{name:"Universidade de Sorocaba",institutionURL:null,country:{name:"Brazil"}}}]},onlineFirstChapters:{paginationCount:9,paginationItems:[{id:"81493",title:"Rust Disease Classification Using Deep Learning Based Algorithm: The Case of Wheat",doi:"10.5772/intechopen.104426",signatures:"Shivani Sood, Harjeet Singh and Suruchi Jindal",slug:"rust-disease-classification-using-deep-learning-based-algorithm-the-case-of-wheat",totalDownloads:35,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Food Systems Resilience",coverURL:"https://cdn.intechopen.com/books/images_new/10897.jpg",subseries:{id:"91",title:"Sustainable Economy and Fair Society"}}},{id:"81428",title:"Observatory of Sustainable Development in Postgraduate Study Programs in Baja California",doi:"10.5772/intechopen.104641",signatures:"Rodolfo Martinez-Gutierrez, Maria Marcela Solis-Quinteros, Maria Esther Ibarra-Estrada and Angel Ernesto Jimenez-Bernardino",slug:"observatory-of-sustainable-development-in-postgraduate-study-programs-in-baja-california",totalDownloads:8,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Globalization and Sustainability - Recent Advances, New Perspectives and Emerging Issues",coverURL:"https://cdn.intechopen.com/books/images_new/11476.jpg",subseries:{id:"91",title:"Sustainable Economy and Fair Society"}}},{id:"81235",title:"Global Food System Transformation for Resilience",doi:"10.5772/intechopen.102749",signatures:"Jasper Okoro Godwin Elechi, Ikechukwu U. Nwiyi and Cornelius Smah Adamu",slug:"global-food-system-transformation-for-resilience",totalDownloads:30,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Food Systems Resilience",coverURL:"https://cdn.intechopen.com/books/images_new/10897.jpg",subseries:{id:"91",title:"Sustainable Economy and Fair Society"}}},{id:"80749",title:"Analysis of the Nexus Between Coping Strategies and Resilience to Food Insecurity Shocks: The Case of Rural Households in Boricha Woreda, Sidama National Regional State, Ethiopia",doi:"10.5772/intechopen.102613",signatures:"Adane Atara Debessa, Degefa Tolossa and Berhanu Denu",slug:"analysis-of-the-nexus-between-coping-strategies-and-resilience-to-food-insecurity-shocks-the-case-of",totalDownloads:45,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Food Systems Resilience",coverURL:"https://cdn.intechopen.com/books/images_new/10897.jpg",subseries:{id:"91",title:"Sustainable Economy and Fair Society"}}},{id:"80753",title:"Toward Safe Food Systems: Analyses of Mycotoxin Contaminants in Food and Preventive Strategies Thereof for Their Formation and Toxicity",doi:"10.5772/intechopen.101461",signatures:"Dikabo Mogopodi, Mesha Mbisana, Samuel Raditloko, Inonge Chibua and Banyaladzi Paphane",slug:"toward-safe-food-systems-analyses-of-mycotoxin-contaminants-in-food-and-preventive-strategies-thereo",totalDownloads:57,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Food Systems Resilience",coverURL:"https://cdn.intechopen.com/books/images_new/10897.jpg",subseries:{id:"91",title:"Sustainable Economy and Fair Society"}}},{id:"80388",title:"Social Resilience in Local Food Systems: A Foundation for Food Security during a Crisis",doi:"10.5772/intechopen.101998",signatures:"Tanya Zerbian, Mags Adams and Neil Wilson",slug:"social-resilience-in-local-food-systems-a-foundation-for-food-security-during-a-crisis",totalDownloads:52,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Food Systems Resilience",coverURL:"https://cdn.intechopen.com/books/images_new/10897.jpg",subseries:{id:"91",title:"Sustainable Economy and Fair Society"}}},{id:"80098",title:"Bundling Weather Index Insurance with Microfinance: Trekking the Long Road between Expectations and Reality. A Study on Sub-Saharan Africa",doi:"10.5772/intechopen.101742",signatures:"Dorcas Stella Shumba",slug:"bundling-weather-index-insurance-with-microfinance-trekking-the-long-road-between-expectations-and-r",totalDownloads:67,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Food Systems Resilience",coverURL:"https://cdn.intechopen.com/books/images_new/10897.jpg",subseries:{id:"91",title:"Sustainable Economy and Fair Society"}}},{id:"79696",title:"How to Build Food Safety Resilience in Commercial Restaurants?",doi:"10.5772/intechopen.101481",signatures:"Rayane Stephanie Gomes De Freitas and Elke Stedefeldt",slug:"how-to-build-food-safety-resilience-in-commercial-restaurants",totalDownloads:107,totalCrossrefCites:1,totalDimensionsCites:1,authors:null,book:{title:"Food Systems Resilience",coverURL:"https://cdn.intechopen.com/books/images_new/10897.jpg",subseries:{id:"91",title:"Sustainable Economy and Fair Society"}}},{id:"79604",title:"Perspective Chapter: Food System Resilience - Towards a Joint Understanding and Implications for Policy",doi:"10.5772/intechopen.99899",signatures:"Bart de Steenhuijsen Piters, Emma Termeer, Deborah Bakker, Hubert Fonteijn and Herman Brouwer",slug:"perspective-chapter-food-system-resilience-towards-a-joint-understanding-and-implications-for-policy",totalDownloads:121,totalCrossrefCites:1,totalDimensionsCites:2,authors:null,book:{title:"Food Systems Resilience",coverURL:"https://cdn.intechopen.com/books/images_new/10897.jpg",subseries:{id:"91",title:"Sustainable Economy and Fair Society"}}}]},publishedBooks:{paginationCount:10,paginationItems:[{type:"book",id:"10799",title:"Phenolic Compounds",subtitle:"Chemistry, Synthesis, Diversity, Non-Conventional Industrial, Pharmaceutical and Therapeutic Applications",coverURL:"https://cdn.intechopen.com/books/images_new/10799.jpg",slug:"phenolic-compounds-chemistry-synthesis-diversity-non-conventional-industrial-pharmaceutical-and-therapeutic-applications",publishedDate:"February 23rd 2022",editedByType:"Edited by",bookSignature:"Farid A. Badria",hash:"339199f254d2987ef3167eef74fb8a38",volumeInSeries:26,fullTitle:"Phenolic Compounds - Chemistry, Synthesis, Diversity, Non-Conventional Industrial, Pharmaceutical and Therapeutic Applications",editors:[{id:"41865",title:"Prof.",name:"Farid A.",middleName:null,surname:"Badria",slug:"farid-a.-badria",fullName:"Farid A. Badria",profilePictureURL:"https://mts.intechopen.com/storage/users/41865/images/system/41865.jpg",institutionString:"Mansoura University",institution:{name:"Mansoura University",institutionURL:null,country:{name:"Egypt"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9753",title:"Terpenes and Terpenoids",subtitle:"Recent Advances",coverURL:"https://cdn.intechopen.com/books/images_new/9753.jpg",slug:"terpenes-and-terpenoids-recent-advances",publishedDate:"July 28th 2021",editedByType:"Edited by",bookSignature:"Shagufta Perveen and Areej Mohammad Al-Taweel",hash:"575689df13c78bf0e6c1be40804cd010",volumeInSeries:21,fullTitle:"Terpenes and Terpenoids - Recent Advances",editors:[{id:"192992",title:"Prof.",name:"Shagufta",middleName:null,surname:"Perveen",slug:"shagufta-perveen",fullName:"Shagufta Perveen",profilePictureURL:"https://mts.intechopen.com/storage/users/192992/images/system/192992.png",institutionString:"King Saud University",institution:{name:"King Saud University",institutionURL:null,country:{name:"Saudi Arabia"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9731",title:"Oxidoreductase",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/9731.jpg",slug:"oxidoreductase",publishedDate:"February 17th 2021",editedByType:"Edited by",bookSignature:"Mahmoud Ahmed Mansour",hash:"852e6f862c85fc3adecdbaf822e64e6e",volumeInSeries:19,fullTitle:"Oxidoreductase",editors:[{id:"224662",title:"Prof.",name:"Mahmoud Ahmed",middleName:null,surname:"Mansour",slug:"mahmoud-ahmed-mansour",fullName:"Mahmoud Ahmed Mansour",profilePictureURL:"https://mts.intechopen.com/storage/users/224662/images/system/224662.jpg",institutionString:"King Saud bin Abdulaziz University for Health Sciences",institution:{name:"King Saud bin Abdulaziz University for Health Sciences",institutionURL:null,country:{name:"Saudi Arabia"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"8094",title:"Aflatoxin B1 Occurrence, Detection and Toxicological Effects",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/8094.jpg",slug:"aflatoxin-b1-occurrence-detection-and-toxicological-effects",publishedDate:"June 3rd 2020",editedByType:"Edited by",bookSignature:"Xi-Dai Long",hash:"44f4ad52d8a8cbb22ef3d505d6b18027",volumeInSeries:14,fullTitle:"Aflatoxin B1 Occurrence, Detection and Toxicological Effects",editors:[{id:"202142",title:"Prof.",name:"Xi-Dai",middleName:null,surname:"Long",slug:"xi-dai-long",fullName:"Xi-Dai Long",profilePictureURL:"https://mts.intechopen.com/storage/users/202142/images/system/202142.jpeg",institutionString:"Youjiang Medical University for Nationalities",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"8004",title:"Nitrogen Fixation",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/8004.jpg",slug:"nitrogen-fixation",publishedDate:"April 8th 2020",editedByType:"Edited by",bookSignature:"Everlon Cid Rigobelo and Ademar Pereira Serra",hash:"02f39c8365ba155d1c520184c2f26976",volumeInSeries:11,fullTitle:"Nitrogen Fixation",editors:[{id:"39553",title:"Prof.",name:"Everlon",middleName:"Cid",surname:"Rigobelo",slug:"everlon-rigobelo",fullName:"Everlon Rigobelo",profilePictureURL:"https://mts.intechopen.com/storage/users/39553/images/system/39553.jpg",institutionString:"São Paulo State University",institution:{name:"Sao Paulo State University",institutionURL:null,country:{name:"Brazil"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"8028",title:"Flavonoids",subtitle:"A Coloring Model for Cheering up Life",coverURL:"https://cdn.intechopen.com/books/images_new/8028.jpg",slug:"flavonoids-a-coloring-model-for-cheering-up-life",publishedDate:"March 11th 2020",editedByType:"Edited by",bookSignature:"Farid A. Badria and Anthony Ananga",hash:"6c33178a5c7d2b276d2c6af4255def64",volumeInSeries:10,fullTitle:"Flavonoids - A Coloring Model for Cheering up Life",editors:[{id:"41865",title:"Prof.",name:"Farid A.",middleName:null,surname:"Badria",slug:"farid-a.-badria",fullName:"Farid A. Badria",profilePictureURL:"https://mts.intechopen.com/storage/users/41865/images/system/41865.jpg",institutionString:"Mansoura University",institution:{name:"Mansoura University",institutionURL:null,country:{name:"Egypt"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"8170",title:"Chemical Properties of Starch",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/8170.jpg",slug:"chemical-properties-of-starch",publishedDate:"March 11th 2020",editedByType:"Edited by",bookSignature:"Martins Emeje",hash:"0aedfdb374631bb3a33870c4ed16559a",volumeInSeries:9,fullTitle:"Chemical Properties of Starch",editors:[{id:"94311",title:"Prof.",name:"Martins",middleName:"Ochubiojo",surname:"Emeje",slug:"martins-emeje",fullName:"Martins Emeje",profilePictureURL:"https://mts.intechopen.com/storage/users/94311/images/system/94311.jpeg",institutionString:"National Institute for Pharmaceutical Research and Development",institution:{name:"National Institute for Pharmaceutical Research and Development",institutionURL:null,country:{name:"Nigeria"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"8019",title:"Alginates",subtitle:"Recent Uses of This Natural Polymer",coverURL:"https://cdn.intechopen.com/books/images_new/8019.jpg",slug:"alginates-recent-uses-of-this-natural-polymer",publishedDate:"February 5th 2020",editedByType:"Edited by",bookSignature:"Leonel Pereira",hash:"61ea5c1aef462684a3b2215631b7dbf2",volumeInSeries:7,fullTitle:"Alginates - Recent Uses of This Natural Polymer",editors:[{id:"279788",title:"Dr.",name:"Leonel",middleName:null,surname:"Pereira",slug:"leonel-pereira",fullName:"Leonel Pereira",profilePictureURL:"https://mts.intechopen.com/storage/users/279788/images/system/279788.jpg",institutionString:"University of Coimbra",institution:{name:"University of Coimbra",institutionURL:null,country:{name:"Portugal"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"8504",title:"Pectins",subtitle:"Extraction, Purification, Characterization and Applications",coverURL:"https://cdn.intechopen.com/books/images_new/8504.jpg",slug:"pectins-extraction-purification-characterization-and-applications",publishedDate:"January 22nd 2020",editedByType:"Edited by",bookSignature:"Martin Masuelli",hash:"ff1acef627b277c575a10b3259dd331b",volumeInSeries:6,fullTitle:"Pectins - Extraction, Purification, Characterization and Applications",editors:[{id:"99994",title:"Dr.",name:"Martin",middleName:"Alberto",surname:"Masuelli",slug:"martin-masuelli",fullName:"Martin Masuelli",profilePictureURL:"https://mts.intechopen.com/storage/users/99994/images/system/99994.jpg",institutionString:"National University of San Luis",institution:{name:"National University of San Luis",institutionURL:null,country:{name:"Argentina"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"7953",title:"Bioluminescence",subtitle:"Analytical Applications and Basic Biolo